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Interrogating the Mechanistic Basis for Cytokine-Mediated Glucocorticoid Resistance in 
Lymphoid-Driven Diseases 
 
Lauren Kimberly Meyer 
 
Abstract 
 Glucocorticoids (GCs) are potently immunosuppressive due to their pro-apoptotic effects 
on lymphoid cells, leading to their utility in a wide range of clinical contexts including 
autoimmune diseases, hyperinflammatory conditions, and lymphoid malignancies. In addition, 
GCs are endogenously produced hormones that mediate a wide range of physiologic functions 
that are essential for life. As a result, cells of the immune system face constant exposure to GCs 
and therefore require intrinsic mechanisms by which to resist their pro-apoptotic effects under 
certain developmental and environmental conditions. The retention of these resistance 
mechanisms in lymphoid-driven diseases thereby poses a challenge to the clinical use of GCs 
in these contexts. Common g-chain cytokines, through activation of the JAK/STAT signal 
transduction pathway, play essential roles in the differentiation, survival, and function of 
lymphoid cells. Here, we assess the interplay between GC activity and cytokine-mediated pro-
survival signaling in two lymphoid-driven diseases, acute lymphoblastic leukemia and 
hemophagocytic lymphohistiocytosis, and demonstrate that cytokines are potent mediators of 
GC resistance. Mechanistically, we show that activation of STAT5 downstream of cytokine 
receptor signaling is necessary for cytokine-induced GC resistance. STAT5 functions as a 
transcription factor to upregulate expression of anti-apoptotic mediators, thereby reducing the 
apoptotic potential and promoting the survival of lymphoid cells. Through both genetic and 
pharmacologic approaches, we demonstrate that targeted inhibition of cytokine receptor 
signaling effectively restores GC sensitivity, and we establish the feasibility of this therapeutic 
approach in two in vivo models of disease.   
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Chapter 1: Introduction 
1.1: Glucocorticoids 
 
 Glucocorticoids (GCs) are one of the most commonly used classes of drugs in clinical 
medicine. Owing to their potent immunosuppressive properties, GCs are central to the treatment 
of many acute and chronic inflammatory conditions, autoimmune diseases, and lymphoid 
malignancies. GCs are small lipophilic molecules capable of diffusing through plasma 
membranes into cytoplasm, where they encounter the cytoplasmic GC receptor (GR). In its 
inactive state, GR is maintained in the cytoplasm via its association with cytoplasmic chaperone 
proteins. Upon ligand binding, GR undergoes a conformational change that facilitates its 
translocation into the nucleus, where it associates with DNA sequences known as GC response 
elements (GREs). GC/GR binding to these GREs facilitates their function as transcriptional 
enhancers, regulating the expression of a wide range of GR target genes (1) (Figure 1-1). While 
the GR-induced transcriptome varies widely by cell type, in cells of the lymphoid lineage this 
transcriptional activity is pro-apoptotic, thereby underlying the lymphotoxic effects of GCs (2).  
 Unlike many other drug classes used in clinical medicine, GCs are unique in that, in 
addition to being used therapeutically, they are endogenously produced hormones that exert a 
multitude of critical physiologic functions. Cortisol, an endogenous GC, is produced by the 
adrenal glands under regulation by the hypothalamic-pituitary-adrenal axis (HPA axis), and 
mediates essential homeostatic functions and physiologic stress responses (3). Of relevance to 
their therapeutic use as immunosuppressive agents, endogenous GCs are also crucial for 
shaping the development of the immune cell repertoire.  
 In particular, GCs have been implicated as important regulators of normal thymopoiesis. 
Thymopoiesis begins with the migration of bone marrow-derived stem cells to the thymus. 
Differentiation of these T-cell precursors progresses from a CD4/CD8 double negative (DN) 
stage through a CD4/CD8 double positive (DP) stage prior to differentiation into either CD4 or 
 3 
CD8 single positive (SP) T-cells (4) (Figure 1-2). During the early stages of this process, 
developing T-cells undergo RAG-mediated recombination of T-cell receptor (TCR) loci, leading 
to the expression of a fully-rearranged TCR by the DP stage. Given the extraordinary number of 
possible TCR rearrangements, of which only a small number are both productive and non-
autoreactive, these DP thymocytes are subjected to a selection checkpoint prior to further 
differentiation. At this checkpoint, thymocytes are exposed to self-peptides expressed by thymic 
epithelial cells. These early thymocytes then undergo cell death unless they are rescued by a 
low-affinity interaction with these peptides in a process called positive selection, which leads to 
a pro-survival signal downstream of the activated TCR. At the opposite extreme, those 
thymocytes expressing TCRs engaging in high affinity interactions with self-peptides are deleted 
through a process known as negative selection, which functions as a safeguard against the 
development of autoreactive T-cells (4). 
 Early evidence for the importance of endogenous GCs in the regulation of thymopoiesis 
stemmed from the observation that adrenalectomized mice develop thymic hyperplasia (5,6), 
suggesting that GCs may play a role in the modulation of the selection checkpoint. Intriguingly, 
studies in T-cell hybridoma systems revealed that both TCR engagement and exposure to GCs 
independently induced cell death, however simultaneous exposure to both stimuli was 
protective (7). This seemingly paradoxical finding is reconciled through a model known as 
mutual antagonism. Though the molecular details of this model remain to be elucidated, it 
implies the existence of cross-talk between the TCR and GR signaling pathways and suggests 
that endogenous GC activity plays a role in establishing the window of acceptable TCR signal 
strength between the positive and negative selection thresholds (8).  
 One important corollary to the fact that GCs are endogenous hormones with lymphotoxic 
potential is that lymphoid cells, either by virtue of their differentiation state or by exposure to cell 
extrinsic stimuli, such as the cytokines described below, resist these lymphotoxic effects under 
certain developmental or environmental conditions. This poses a challenge for the therapeutic 
 4 
application of GCs, as it suggests that lymphoid cell populations possess innate and physiologic 
mechanisms of resisting cell death in response to GC exposure, whether endogenous or 
pharmacologic. The following chapters describe novel insights into the ways in which lymphoid 
cells in two disease contexts, acute lymphoblastic leukemia (ALL) and hemophagocytic 
lymphohistiocytosis (HLH), exploit these innate processes to resist the pro-apoptotic effects of 
therapeutic GCs.  
 
1.2: Apoptosis 
 
 Cell death is a critical cell biologic process that is required for normal tissue development 
and homeostasis. Dysregulation of cell death pathways underlies a number of disease states, 
including cancer, where the rate of cellular proliferation outpaces the rate of cell death, and 
neurologic diseases such as Alzheimer’s disease, which is characterized by excessive 
activation of cell death pathways (9). In cancer and other conditions associated with aberrant 
cellular proliferation, including hyperinflammation, activation of cell death pathways is a common 
goal of therapy. Specifically, many therapeutic agents promote cell death via activation of 
apoptosis, a tightly regulated program of controlled cell death that spares surrounding tissues 
from the damage associated with necrosis, an alternative and poorly controlled process of cell 
death arising following tissue injury (9). 
 In apoptosis, cell death is carried out by the activity of a family of cysteine-aspartic 
proteases known as caspases, which cleave cellular macromolecules and promote the 
recruitment of phagocytic cells. Depending on the initiating trigger, apoptosis may proceed via 
the extrinsic or intrinsic pathway. Extrinsic apoptosis is initiated in response to activation of cell 
surface death receptors, and is most well-characterized in the context of immune cell 
interactions. Intrinsic, or mitochondrial, apoptosis is instead triggered by a complex network of 
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intracellular processes that converge upon the regulation of the BCL-2 family of proteins 
localized in the outer mitochondrial membrane (9).  
 The BCL-2 family constitutes a complex class of proteins that can be broadly subdivided 
into pro- and anti-apoptotic proteins on the basis of their respective roles in regulating the 
permeabilization of the mitochondrial membrane. Specifically, two pro-apoptotic family 
members, BAX and BAK, oligomerize to form pores in the mitochondria, allowing for the release 
of cytochrome c, a protein that then functions in the cytoplasm to trigger caspase activation and 
the subsequent progression of apoptosis. The pore-forming capacity of BAX and BAK is in turn 
regulated by the relative balance between pro- and anti-apoptotic BCL-2 family members. For 
example, the proteins BID and BIM, which consist only of a BCL-2 homology 3 (BH3) protein 
domain, function as activator proteins, directly engaging with BAX and BAK to promote pore 
formation. The multi-domain anti-apoptotic family members, including BCL-2, BCL-XL, and 
MCL-1, function to antagonize both BAX and BAK as well as BID and BIM, and are themselves 
inhibited by the sensitizer class of BH3-only pro-apoptotic proteins, which includes BAD, PUMA, 
and NOXA (10). 
 The complexity and redundancy of this protein network poses significant challenges with 
respect to experimental interrogation of the intrinsic apoptotic pathway. Specifically, measuring 
expression levels of individual proteins is insufficient to appreciate the overall apoptotic potential 
of a cell in a given state, as that apoptotic potential is dictated both by the relative balance 
between the expression of pro- and anti-apoptotic family members and the nature of their 
respective protein-protein interactions. As an additional layer of complexity, many of these 
proteins also undergo a multitude of post-translational modifications that further affect their 
function (11). Taken together, this necessitates the use of functional assays to facilitate an 
integrated understanding of cellular apoptotic potential.   
 BH3 profiling is one such functional assay that was developed in the laboratory of Dr. 
Anthony Letai at the Dana Farber Cancer Institute. Likened to “poking cells with a stick” (12), 
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BH3 profiling relies on exposing cells to synthetic BH3 domains corresponding to endogenous 
BH3-only proteins or to synthetic small molecule BH3 mimetics and measuring the subsequent 
release of cytochrome c. A cell with increased apoptotic potential, read as one that releases 
more cytochrome c in response to exposure to BH3 domains, is said to be more “primed” for 
apoptosis (13). Taking advantage of the differing affinities of the BH3-only sensitizer proteins for 
the multi-domain anti-apoptotic proteins, this technique is also powered to interrogate the 
relative anti-apoptotic dependencies of a given cell on the basis of the response patterns 
produced by exposure to different BH3 domains. As these dependencies have been shown to 
change as a function of factors such as developmental stage (14), this has particular therapeutic 
relevance in light of the increasing number of BH3 mimetics currently in preclinical development 
or clinical use (15).  
 By performing BH3 profiling on cells in their basal state and in response to pro-apoptotic 
stimuli, including therapeutic agents, it is possible to understand at a molecular level how these 
stimuli promote cell death. Of particular relevance to the following chapters, mounting evidence 
suggests that activation of the intrinsic apoptotic pathway is required for GC-induced lymphoid 
cell death, with GR acting either directly or indirectly to promote the upregulation of BIM and the 
downregulation of BCL2, thereby promoting a pro-apoptotic state (16–18). As described in the 
following chapters, the BH3 profiling technique can be further extended to understand how cell 
extrinsic factors that promote drug resistance modulate the apoptotic potential of a cell to 
interfere with drug-induced cell death.  
 
1.3: Common g-Chain Cytokines  
 
 The vague definition of cytokines as “proteins that exert effects on cells” reflects the 
considerable diversity of cytokines and their ubiquitous roles in nearly all cellular processes. 
Most cytokines are soluble factors, produced by a cell to act in an autocrine, paracrine, or 
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endocrine manner to influence cellular function. The importance of cytokines is best understood 
in the field of immunology, where they have well-described effects to modulate immune cell 
differentiation, survival, and proliferation and to regulate inflammatory responses (19). 
 In particular, the common g-chain family of cytokines, united by their shared use of the 
cytokine receptor g-chain as a component of their heterodimeric or -trimeric receptor complexes, 
play an essential role in the differentiation, function, and survival of lymphoid cells. As evidence 
of their essentiality, inherited mutations in IL2RG, the gene encoding the g-chain, underlie X-
linked severe combined immunodeficiency (SCID), characterized by loss of T-cell, NK cell, and 
B-cell function (20). The receptors for the common g-chain cytokines lack intrinsic kinase 
activity, and instead signal via their intracellular associations with the Janus kinases (JAKs). 
Specifically, JAK1 associates with the cytokine-specific receptor chains, while JAK3 associates 
with the g-chain. Following ligand binding and subsequent receptor activation, these JAK 
proteins mediate phosphorylation of the intracellular domains of the cytokine receptor chains, 
which in turn creates phosphotyrosine binding sites for the SH2 domains of downstream effector 
proteins known as signal transducer and activator of transcription (STAT) proteins. Upon 
binding to these phosphotyrosine sites, the STAT proteins themselves become phosphorylated, 
facilitating their dimerization and translocation to the nucleus where they function as 
transcription factors to modulate target gene expression (21) (Figure 1-3). 
 Despite the multitude of cytokine ligands that activate JAK/STAT signaling, the 
remarkable diversity of the resulting downstream effector functions is carried out by only seven 
mammalian STAT proteins, namely STAT1-4, STAT5a, STAT5b, and STAT6. While all cytokine 
receptors contain tyrosine residues capable of serving as docking sites for STAT proteins, the 
amino acid sequence surrounding these docking sites on individual receptor chains dictates the 
specific STAT proteins activated in response to receptor engagement (22). However, this alone 
is insufficient to explain the diverse and sometimes opposing functions of cytokine receptors 
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that activate shared STAT proteins, necessitating additional mechanisms of specificity. Some of 
this specificity may arise from the fact that individual cytokine receptors retain the capacity to 
activate multiple STAT proteins, and the relative degree of activation may differ between 
STATs, creating a receptor-specific constellation of activated STAT proteins that cooperate to 
execute a cytokine-specific transcriptional program (23). Additionally, there have been 
measured differences in the relative duration of STAT protein responses elicited downstream of 
cytokine receptor activation, suggesting that qualitative features of this response may similarly 
contribute to specificity (24).  
 STAT protein activation downstream of the g-chain cytokine receptors mediates a 
diversity of immune cell functions, summarized in Table 1-1. The following chapters describe the 
mechanisms by which g-chain cytokines function as mediators of GC resistance in lymphoid-
driven diseases, with particular emphasis on interleukin-2 (IL-2) and IL-7. Importantly, the 
receptors for both of these cytokines have been shown to predominantly activate STAT5 (25). 
Consistent with these findings, we demonstrate through a series of genetic and biochemical 
approaches that STAT5 is a key effector of GC resistance via its effect to activate an anti-
apoptotic transcriptional program in T-cells.  
 
1.4: Acute Lymphoblastic Leukemia 
 
 Acute lymphoblastic leukemia (ALL) is a malignancy arising from immature cells of the 
lymphoid lineage, and as such can be broadly subdivided into B-cell ALL (B-ALL) and T-cell ALL 
(T-ALL). ALL is the most common malignancy of childhood, and remains the leading cause of 
cancer-related mortality in children (26). However, owing to large-scale clinical trials conducted 
through national and international consortia, survival rates for children diagnosed with ALL have 
improved considerably over the last half-century, with aggregate survival rates now up to 90% 
on many trials (27). The rapid development of “-omics” technologies in recent years has led to 
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increasing appreciation of the molecular heterogeneity of ALL, facilitating the identification of 
distinct molecular subtypes of disease. This in turn has prompted efforts to improve risk 
stratification tools and to more effectively tailor therapy to the unique molecular features of these 
subtypes (28).  
 First recognized for their utility in the treatment of lymphoid malignancies in the 1950s 
(29), GCs remain central to all therapeutic regimens for ALL. In particular, the intrinsic sensitivity 
of ALL cells to GCs at diagnosis is one of the strongest known predictors of future relapse. On 
European treatment protocols, patients receive a one week prophase of GC monotherapy 
following diagnosis. Patients who respond poorly to GCs during this upfront window have 
significantly inferior long-term outcomes (30). Analogously, the induction phase of therapy in the 
United States, which comprises the first month of therapy, consists primarily of GCs. Patients 
who are minimal residual disease (MRD) positive at the end of induction, largely reflecting 
intrinsic GC resistance (31), face significantly higher rates of relapse (32). Despite decades of 
clinical use of GCs and the known prognostic significance of the GC response, there are 
currently no rationally designed therapeutic strategies aimed at enhancing GC sensitivity in 
patients who are at risk for a poor GC response. 
 Despite their profound efficacy however, GCs are associated with significant acute and 
chronic adverse effects, which can be particularly detrimental given the young average age of 
children diagnosed with ALL and the lengthy treatment duration, resulting in considerable 
cumulative GC exposure (33). These data, combined with the outstanding survival rates for 
many of the molecular subtypes of ALL, warrant studies focused on improving our 
understanding of the mechanisms of GC response and resistance in order to better inform the 
use of GCs in ALL therapy and to suggest cooperative therapeutic approaches to optimize their 
efficacy. The following chapters will describe studies in two subtypes of ALL, Philadelphia 
chromosome-like B-cell ALL and T-cell ALL, that seek to understand mechanisms of intrinsic 
GC resistance and to identify therapeutic strategies to overcome them.  
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1.5: Hemophagocytic Lymphohistiocytosis 
 
 A key feature of a healthy immune response is that it is self-limiting. In response to an 
initiating stimulus, the immune system triggers the activation of immune cells, the release of 
inflammatory cytokines, and the engagement of cytolytic processes that collectively result in 
destruction of the stimulus. Following clearance of this stimulus, the immune system re-
establishes homeostasis, with associated reductions in the number of activated immune cells 
and in the production of inflammatory cytokines (Figure 1-4). In contrast, hemophagocytic 
lymphohistiocytosis (HLH) is a rare hyperinflammatory condition in which, due to inherited or 
acquired defects in immune cell function, immune responses are initiated but fail to be 
appropriately terminated. In response to an immune trigger, including infection, autoimmunity, or 
malignancy, this results in excessive activation of immune cells and release of inflammatory 
cytokines that mediate severe and often life-threatening tissue injury (34) (Figure 1-5).  
 As opposed to secondary HLH, which arises in the absence of an apparent causal 
mutation, primary HLH occurs due to inherited loss-of-function mutations in genes required for 
the cytolytic functions of CD8 T-cells or NK cells, most commonly in PRF1, the gene encoding 
perforin. Perforin is a key protein component of the cytotoxic granules released from CD8 T-
cells and NK cells and is required for the entry of cytolytic proteins into target cells, which 
ultimately mediates target cell destruction (34). As evidence for the central role of perforin in this 
process, it was found that Prf1-/- mice fail to effectively clear infections with lymphocytic 
choriomeningitis virus (LCMV) (35). As a result, following exposure to LCMV these mice 
develop an HLH-like syndrome that recapitulates many of the key features of human disease, 
including fever, splenomegaly, pancytopenia, hypercytokinemia, and hemophagocytosis (36). 
These features have made the Prf1-/- mouse one the best-studied and most accurate murine 
models of HLH, and this model was employed for the studies described in Chapter 8. 
 While HLH is defined by the occurrence of excessive immune activation and failed 
immune resolution, the considerable diversity with respect both to causal mutations and 
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underlying etiologies poses a number of diagnostic and therapeutic challenges (37). For the 
past decades, most patients meeting the diagnostic criteria for HLH were treated according to 
the protocols established by the HLH-94 and HLH-2004 trials, which consist primarily of the GC 
dexamethasone and the chemotherapeutic agent etoposide. Even with these protocols, clinical 
outcomes for HLH remain poor, with a 5-year survival of only 62% on HLH-2004 (38). 
Encouragingly however, continued improvements in the understanding of disease 
pathophysiology are beginning to drive the emergence of rationally-designed therapeutic 
strategies. In particular, the hypercytokinemia of HLH is increasingly being recognized both as a 
driver of disease, necessary for stimulating the persistent activation of CD8 T-cells and innate 
immune cells, as well as a contributor to the clinical manifestations of disease, with these 
cytokines known to directly mediate much of the end-organ damage (39). Consistent with this 
central role for cytokines in the disease process, it was first recognized that selective 
neutralization of the inflammatory cytokine interferon-g (IFN-g) was protective against disease in 
the Prf1-/- model (36), thereby establishing proof-of-concept for a therapeutic strategy involving 
direct targeting of inflammatory cytokines. These preclinical studies stimulated clinical 
development of a human antibody against IFN-g, known as emapalumab, which in 2018 
received accelerated approval for the treatment of refractory, recurrent, or progressive HLH in 
both pediatric and adult patient populations (40). 
 The importance of IFN-g is well-established in murine models and early trials have 
demonstrated the efficacy of emapalumab in a subset of patients (41), thereby clinically 
validating the results of those preclinical studies. Biochemically however, consideration of the 
signal transduction pathways activated by IFN-g as well as a multitude of other disease-
associated cytokines suggests additional candidate therapeutic targets. Specifically, the vast 
majority of these cytokines, including IFN-g, activate signaling via the JAK/STAT pathway 
(Figure 1-3), suggesting that JAK is a central signaling node shared by these cytokines, and that 
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inhibition of JAK has the potential to mitigate the downstream consequences of both excessive 
IFN-g signaling as well as signaling induced by many other cytokines. Consistent with this idea, 
it was recently demonstrated in both the Prf1-/- model as well as a murine model of secondary 
HLH that inhibition of JAK signaling with the JAK1/2 inhibitor ruxolitinib is superior to IFN-g 
blockade with respect to attenuation of many disease parameters (42). The work described in 
Chapter 8 extends these studies of ruxolitinib to examine the cooperative potential of combining 
ruxolitinib with the GC dexamethasone, a key component of the current standard of care for the 
treatment of HLH.   
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1.6: Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1: Mechanisms of GC action. GCs bind to a cytoplasmic GR (1), which induces 
translocation of the GC/GR complex to the nucleus (2). This complex binds to GREs to induce 
or repress transcription (3). In cells of the lymphoid lineage, this transcriptional activity alters the 
expression of components of the intrinsic apoptotic pathway, resulting in apoptosis (4). 
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Figure 1-2: Schematic of early T-cell differentiation. T-cells progenitors in the thymus 
progress through a CD4/CD8 double negative (DN) stage, followed by a CD4/CD8 double 
positive (DP) stage, prior to differentiation into CD4 or CD8 single positive (SP) thymocytes. 
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Figure 1-3: Schematic of cytokine receptor signaling. The common g-chain family of 
cytokine receptors lack intrinsic kinase activity, and instead signal via intracellular associations 
with JAK proteins. Specifically, the cytokine-specific receptor chain associates with JAK1, and 
the common g-chain associates with JAK3. JAKs catalyze the phosphorylation of tyrosine 
residues on the intracellular domains of the cytokine receptors, creating docking sites for STAT 
proteins, of which STAT5 is most essential to common g-chain cytokine receptor signaling. 
These STAT proteins then become phosphorylated, promoting their dimerization and 
translocation to the nucleus, where they function as transcription factors to modulate target 
gene expression.  
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Figure 1-4: Schematic of a healthy immune response. In a healthy immune response, the 
immune system becomes activated in response to a trigger such as malignancy, autoimmunity, 
or infection. This results in activation and expansion of immune cells that secrete inflammatory 
cytokines to promote further immune cell activation. Due to the cytotoxic activity of immune 
cells, the initiating stimulus is then cleared, ultimately leading to resolution of the immune 
response and the return to a homeostatic state.  
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Figure 1-5: Schematic of HLH pathogenesis. Due to the impaired cytotoxic function of CD8 T-
cells or NK cells in HLH, the immune system becomes appropriately activated in response to a 
stimulus, but is unable to effectively clear that stimulus. This results in persistent activation of 
immune cells, which continue to proliferate and release large amounts of inflammatory cytokines 
that mediate devastating tissue damage.  
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1.7: Table 
 
Table 1-1: Cellular sources and functions of g-chain cytokines (43) 
Cytokine Cellular Source(s) Major Function(s) 
IL2 Primarily CD4 T-cells, with some 
production by CD8 T-cells, NK cells, 
and NKT cells 
T-cell growth, T helper cell 
differentiation, B-cell growth and 
differentiation, and NK cell proliferation 
IL4 T-cells B-cell differentiation, M2 macrophage 
production, and Th2 responses  
IL7 Stroma T-cell development and survival, pre-B-
cell growth  
IL9 T-cells Mast cell growth, IgE and IgG 
production, innate lymphoid-cell survival 
IL15 Dendritic cells and monocytes T-cell growth, maintenance of memory 
CD8 T-cells 
IL21 T helper cells and NKT cells  B cell differentiation and 
immunoglobulin production 
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Chapter 2: Mechanisms of Glucocorticoid Response and Resistance in  
Lymphoid Malignancies 
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2.1: Abstract 
 Glucocorticoids are an integral component of multi-agent therapy regimens for a wide 
variety of lymphoid malignancies due to their potent effects to induce apoptosis in cells of the 
lymphoid lineage. Despite their clinical utility, de novo and acquired resistance to GCs is a 
significant clinical problem that contributes to inferior outcomes for many of these diseases. This 
review summarizes what is currently known about mechanisms of GC resistance in lymphoid 
malignancies, with a particular focus on novel therapeutic strategies currently in preclinical or 
clinical development that are rationally-designed to overcome GC resistance and improve 
clinical outcomes.   
 
2.2: Introduction 
 For decades, glucocorticoids (GCs) have been a key component of therapy for the 
treatment of lymphoid malignancies and are widely used in both frontline and salvage therapy 
regimens (44)(45). In many of these cancers, the response to GC therapy is a strong prognostic 
indicator that is related to both overall and event-free survival (EFS) rates (44)(46)(47). In 
particular, patients with acute lymphoblastic leukemia (ALL) treated on Berlin-Frankfurt-Münster 
(BFM) protocols can be classified as having a prednisone good response (PGR) or a 
prednisone poor response (PPR), defined based on the response to an upfront one-week 
window of monotherapy consisting of the GC prednisone. In early ALL-BFM protocols, patients 
with a PPR had significantly inferior outcomes relative to patients with a PGR (44). These data 
indicate that therapeutic strategies to overcome GC resistance may significantly improve patient 
outcomes. The objective of this review is to highlight key concepts regarding GC resistance in 
lymphoid malignancies, with a specific focus on therapeutic strategies designed to overcome 
GC resistance.   
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2.3: Mechanisms of Glucocorticoid Action 
 GCs are a class of steroid hormones that bind to the GC receptor (GR). In the absence 
of endogenous or exogenous GC ligand, GR is largely retained in the cytoplasm through its 
association with a variety of molecular chaperone proteins, including HSP70 and HSP90 (48). 
Upon ligand binding, GR undergoes a conformational change that promotes translocation of the 
GC-GR complex to the nucleus, where it associates with DNA sequences known as GC 
response elements (GREs). These GREs function as enhancer elements to modulate the 
activity of associated gene promoters, which in turn mediate the activation or repression of 
target gene expression (1). The effects of GCs are highly tissue-specific due to differences in 
GRE binding patterns and transcriptional activities in different cell types. Importantly, while GCs 
exert pro-survival effects in many tissues, they potently induce cell death in cells of the lymphoid 
lineage (49), underlying their importance in the treatment of lymphoid malignancies.  
 While there is little overall consensus regarding the specific components of the GR-
associated transcriptome that mediate the effects of GCs on lymphoid cells, many groups have 
demonstrated that activation of the intrinsic apoptotic pathway is required for GC-induced cell 
death (49). Consistent with this idea, the concept of a “BCL2 rheostat” has been proposed, 
whereby modulation of both the pro- and anti-apoptotic components of the intrinsic apoptotic 
pathway results in an altered apoptotic threshold that leads to cell death. Through an analysis of 
both basal and GC-induced expression of components of the intrinsic apoptotic pathway in 
primary ALL cells, Ploner et al. identified key expression patterns that are associated with GC-
induced apoptosis. Specifically, they noted potent induction of the pro-apoptotic family members 
BIM and BMF, and demonstrated that loss of expression of either of these proteins is sufficient 
to decrease GC sensitivity. Conversely, they demonstrated that overexpression of anti-apoptotic 
family members, including BCL2, BCL-XL, and MCL1, impairs GC-induced apoptosis, an effect 
that is reversed upon experimental silencing of these genes (50). Taken together, these data 
suggest that coordinate modulation of both pro- and anti-apoptotic family members contributes 
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to GC-induced apoptosis. Jing et al. further elucidated the importance of such a BCL2 rheostat 
through an analysis of ALL patient derived xenografts (PDXs). Using chromatin 
immunoprecipitation with sequencing (ChIP-seq), this group identified a novel GR binding site 
within an intronic region of the BIM gene. When this region was mutated to abolish GR binding, 
GC-induced upregulation of BIM expression was lost and GC sensitivity was significantly 
decreased, providing further evidence that GR-mediated upregulation of BIM is required for GC 
sensitivity. Furthermore, this study elucidated a series of GR-mediated transcriptional events 
that lead to downregulation of BCL2 expression, and found that these events were also required 
for effective GC-induced apoptosis (18). Given the importance of the intrinsic apoptotic pathway 
in mediating GC sensitivity in lymphoid cells, it is not surprising that while diverse mechanisms 
of GC resistance have been elucidated in lymphoid malignancies, these mechanisms largely 
converge on a failure to appropriately modulate the intrinsic apoptotic pathway.    
 
2.4: Mechanisms of Glucocorticoid Resistance 
2.4.1: GR Intrinsic Mechanisms of GC Resistance  
NR3C1 Mutations 
 The GR protein, which is encoded by the NR3C1 gene, is comprised of three major 
functional domains: the ligand binding domain (LBD), the DNA binding domain (DBD), and the 
N-terminal transactivation domain (NTD), which interacts with the transcriptional machinery and 
with transcriptional coregulators to mediate the effects of GR on gene expression (48). 
Mutations in each of these domains have been identified in the context of familial and sporadic 
generalized GC resistance, where they lead to complete or partial insensitivity of target tissues 
to both endogenous and exogenous GCs (51). In addition to generalized GC resistance, 
localized GC resistance that is attributable to NR3C1 mutations has been reported in a number 
of disease contexts, including asthma and autoimmune diseases (52). Given this precedent for 
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GC resistance mediated by GR mutations, many groups have hypothesized that pre-existing 
mutations in the GR gene, or mutations acquired over the course of GC therapy, may contribute 
to de novo or acquired GC resistance in lymphoid malignancies. Much of this work has focused 
on CCRF-CEM cells, a cell line model of human T-cell ALL (T-ALL) that has been studied 
extensively in the context of GC sensitivity and resistance. Early studies involving CCRF-CEM 
cells identified considerable heterogeneity in the clonal composition of the cell line, leading to 
the subsequent isolation and characterization of a number of subclonal cell lines with varying 
degrees of GC sensitivity (53). In an analysis of the parental CCRF-CEM cell line, a 
heterozygous point mutation was identified in the LBD, and functional studies demonstrated 
impaired functionality of this mutant allele (54)(55)(56)(57). However, this same heterozygous 
mutation has since been identified in both GC sensitive and GC resistant subclones derived 
from the parental CCRF-CEM cell line, suggesting that additional events are required to confer 
GC resistance. Consistent with this idea, it has been shown that the GC resistant subclones 
derived from the GC sensitive parental cell line express this mutant allele in the absence of a 
wild-type allele, resulting in complete impairment of GR activity (54). Interestingly, this LBD point 
mutation was identified in biopsy tissue taken after the initiation of treatment from the patient 
from whom CCRF-CEM cells were derived, suggesting that it was acquired in vivo and was 
likely selected for over the course of GC treatment (58). Similar to CCRF-CEM cells, Jurkat 
cells, another human T-ALL cell line, are heterozygous for a mutation that impairs GR 
transcriptional activity. Unlike CCRF-CEM cells however, Jurkat cells also express low basal 
levels of GR and fail to induce expression of GR upon GC exposure, resulting in profound GC 
resistance (59).  
 Based on this evidence supporting a role for NR3C1 mutations as a cause of GC 
resistance in cultured cell lines, multiple groups have conducted studies to determine whether 
such mutations cause clinically relevant GC resistance in patients receiving GC therapy for the 
treatment of lymphoid malignancies. In an analysis of a panel of cell lines derived from paired 
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diagnostic and relapse samples taken from pediatric patients with ALL, Beesley et al. identified 
significant variability in GC sensitivity. Upon sequencing the NR3C1 gene in these cell lines, this 
group identified a number of polymorphisms, all of which had previously been shown to have a 
negligible effect on GC sensitivity (52), but no deleterious mutations. This finding led them to 
conclude that NR3C1 mutations are not a common mechanism of naturally-acquired GC 
resistance (60). Consistent with these findings, sequencing of NR3C1 in a larger cohort of 
diagnostic pediatric ALL samples revealed a similar distribution of polymorphisms, but these 
polymorphisms failed to correlate with the clinical response to prednisone therapy and did not 
occur at a significantly higher rate than previously reported in the general population (61), 
supporting the conclusion that NR3C1 mutations are not a common cause of de novo GC 
resistance. However, there have been a number of reports demonstrating the presence of 
deleterious NR3C1 mutations that are undetectable at diagnosis but are significantly enriched at 
the time of disease relapse, suggesting that the acquisition of such mutations may confer 
acquired GC resistance (62)(63)(64). Taken together, the existing data suggest that NR3C1 
mutations are a relatively minor cause of GC resistance in human lymphoid malignancies, 
particularly at the time of diagnosis, but may be more important in the context of relapsed 
disease following the selective pressure of exposure to GC therapy.  
 
Modulation of GR Expression and Function 
 
 In addition to GR mutations, expression levels of GR have been evaluated as a potential 
biomarker for GC sensitivity and resistance. Using large cohorts of diagnostic ALL samples, 
early clinical data suggested that the absolute number of GRs in lymphoblasts is positively 
correlated with the clinical response to GC monotherapy (65), the likelihood of disease 
remission (66), and with five-year EFS rates (67). More recently, GR expression has been 
shown to carry prognostic significance specifically in the context of pediatric B-cell ALL (B-ALL) 
harboring the ETV6/RUNX1 fusion oncogene. In these patients, deletions of NR3C1 resulting in 
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loss of GR protein expression are associated with increased minimal residual disease (MRD) 
and with risk of relapse (68). Despite these findings, other studies have failed to identify a 
clinically meaningful relationship between basal GR expression at diagnosis and the clinical 
response to GC therapy. In an analysis of GR protein expression in diagnostic samples taken 
from patients treated on ALL-BFM protocols, there was no significant difference in GR 
expression between PPR and PGR patient groups (69), suggesting that basal GR expression 
may be an unsuitable biomarker for predicting GC sensitivity. However, it has been shown that 
in lymphoid cells, exposure to GCs results in autoinduction of GR expression mediated by a 
direct transcriptional effect of GR (70), and multiple studies have demonstrated that expression 
levels of GR after autoinduction, rather than basal expression levels, are required for a GC 
response and may be a better predictor of GC sensitivity. Using a titratable expression system 
in a human T-ALL cell line, Ramdas et al. demonstrated that basal levels of GR may be 
insufficient to confer GC sensitivity, but that levels comparable to those achieved following GC 
exposure and subsequent autoinduction of GR expression are sufficient to mediate GC-induced 
apoptosis (71). Consistent with these data, a failure to autoinduce GR expression upon GC 
exposure has been implicated in GC resistance in Jurkat T-ALL cells (59) and in multiple 
myeloma cell lines (72).  
 Several studies have also identified other genetic and epigenetic events that lead to 
altered GR expression levels, and may therefore contribute to GC resistance. For example, 
loss-of-function mutations in the E3 ubiquitin ligase FBXW7 have been associated with a 
favorable prognosis and an early response to GC therapy in ALL (73)(74). A later study 
demonstrated that FBXW7 mediates the ubiquitination and subsequent proteasomal 
degradation of GR, leading to insufficient GR levels to mediate GC-induced apoptosis. This 
same study found that inactivation of FBXW7 in an in vitro system was sufficient to restore GR 
expression and consequently, GC sensitivity (75). The NALP3 inflammasome has also been 
implicated as a modulator of cellular GR levels. In an analysis of GC resistant primary ALL 
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samples, it was found that decreased promoter methylation of CASP1 and NLRP3 resulted in 
increased expression of the NALP3 inflammasome, and that the associated increase in caspase 
1 activity caused increased cleavage of GR protein, leading to an attenuated GC response 
mediated by a loss of GR protein expression (76). Therefore, while basal GR expression has 
not proven to be a tractable biomarker with clinical utility for predicting GC sensitivity, altered 
levels of GR expression may nonetheless contribute to a poor GC response. 
 In addition to GR expression levels, post-transcriptional processing of the GR mRNA 
results in multiple GR isoforms, which may also play a role in dictating GC sensitivity. GRa is 
the most abundant GR isoform and has been shown to mediate the pro-apoptotic effects of GCs 
in lymphocytes. Exon 9 of NR3C1 encodes a portion of the LBD, and alternative splicing of this 
exon distinguishes the GRa isoform from the GRb isoform (48). The GRb isoform does not bind 
GCs, does not have transcriptional activity, and has been shown to exert a dominant negative 
effect on the GRa protein, thereby impeding its pro-apoptotic activity (77). Additionally, 
alternative splicing involving the intron between exons 3 and 4 gives rise to the GRg isoform, 
which has an altered DBD. Therefore, GRg retains ligand binding capacity but has limited 
transcriptional activity (48). Finally, alternative splicing involving the LBD results in the 
production of the GR-A and GR-P isoforms, both of which fail to bind ligand (48). As a result of 
the impaired activity of multiple GR isoforms, many groups have studied the relationship 
between GC sensitivity and the relative expression and distribution of these isoforms in a variety 
of lymphoid malignancies. One of the earliest such studies focused on a patient with chronic 
lymphocytic leukemia (CLL) who was found to have generalized GC resistance. An analysis of 
the expression pattern of GR isoforms in cells taken from this patient demonstrated decreased 
GRa expression and increased GRb expression, resulting in an altered ratio between the two 
isoforms (78). Given the dominant negative effect of GRb on GRa, this group concluded that the 
altered ratio may contribute to the generalized GC resistance observed in this patient. 
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Consistent with these findings, an analysis of 23 diagnostic ALL samples revealed an inverse 
correlation between the GRb/GRa ratio and the number of apoptotic cells following in vitro 
exposure to prednisolone, further indicating that high expression of GRb impairs GC sensitivity 
(79). Relative to diagnostic samples, relapsed ALL samples have also been shown to have a 
decreased mRNA to protein ratio of GRa (80). Similarly, GRg expression has been shown to be 
increased in PPR patients relative to PGR patients, which is consistent with the idea that GRg 
expression might impair the transcriptional activity of GRa, leading to an inferior GC response 
(81).  
 Further regulation of GR activity is mediated by the chaperone protein systems that 
interact with GR, the two most important of which are the HSP70 and HSP90 systems. These 
chaperones assist with maintaining GR in a conformation in which it is competent for ligand 
binding and they facilitate the subsequent nuclear translocation of ligand-bound GR (82). Given 
the central role of chaperone proteins in modifying GR activity, several groups have 
hypothesized that aberrant expression or activity of these chaperone systems could contribute 
to GC resistance in lymphoid malignancies. However, in an analysis of PPR and PGR patients 
treated on ALL-BFM trials, there was no correlation between in vivo GC sensitivity and HSP90 
expression (83). In a more in-depth analysis looking at mRNA expression of key chaperone 
proteins in GC sensitive versus GC resistant ALL cells, there were also no meaningful 
differences in transcript expression (84). While this finding does not exclude the possibility that 
differences in protein expression of these chaperones may underlie differences in GC 
sensitivity, these studies suggest that chaperone proteins likely do not play a significant role in 
clinical GC resistance in lymphoid malignancies.   
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2.4.2: GR Extrinsic Mechanisms of GC Resistance 
Epigenetic Regulation of GR Activity 
 
 Changes in GR target gene expression require the association of ligand-bound GR with 
a GRE (1). Some of the cell- and tissue-specificity of GCs may be mediated by differences in 
chromatin accessibility, as GR binding has been shown to occur predominantly at accessible 
chromatin sites (85). Given this requirement for pre-existing chromatin accessibility, a number of 
groups have assessed the role for an altered epigenetic landscape as a mediator of GC 
resistance. Chromatin accessibility is maintained in part through the activity of the SWI/SNF 
complex (85), and decreased expression of core components of this complex correlate with the 
occurrence of GC resistance in ALL cells (86). In an analysis of gene expression and DNA 
methylation patterns in matched pairs of pediatric B-ALL samples obtained at the time of 
diagnosis and at relapse, Hogan et al. identified a distinct pattern of gene expression associated 
with relapse and found that this gene expression pattern co-occurred with increased promoter 
methylation (87). With the addition of the DNA methyltransferase inhibitor decitabine, this 
relapse-specific gene expression pattern could be reverted, allowing for re-expression of 
hypermethylated genes. Exposure to decitabine, along with the histone deacetylase (HDAC) 
inhibitor vorinostat, resulted in significant potentiation of GC-induced apoptosis (88), suggesting 
that modification of the epigenetic landscape may facilitate GR-mediated changes in gene 
expression that lead to apoptosis. Similarly, it was shown that elevated expression of a number 
of HDAC genes is common in patients who have a PPR (89). Consistent with these findings, 
Jones et al. reported a high frequency of deletions of TBL1XR1, a component of the nuclear 
receptor corepressor (NCoR) complex, in patients with B-ALL. These deletions stabilize NCoR, 
which represses GR activity by decreasing its recruitment to target gene loci and by recruiting 
HDAC3 to further promote inhibition of target gene expression. Treating these cells with an 
HDAC inhibitor was sufficient to restore GC sensitivity (90). Collectively, these data suggest that 
GC sensitivity is mediated in part by a permissive epigenetic landscape, and that the use of 
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epigenetic modulators may represent a therapeutic strategy to enhance GC sensitivity in 
lymphoid malignancies that are associated with an altered epigenetic landscape. 
 
Signal Transduction 
 
 Dysregulated signal transduction is a hallmark feature of many lymphoid malignancies 
including T-ALL (91), B-ALL (92), and non-Hodgkin lymphoma (NHL) (93). Importantly, the 
downstream effectors of these signal transduction pathways exhibit known cross-talk with GR 
signaling and transcriptional activity (94). As a result of these interactions, aberrant regulation of 
these signal transduction pathways is an important cause of GC resistance in lymphoid 
malignancies and significant attention has been devoted to the use of targeted signal 
transduction inhibitors as a strategy to overcome GC resistance. 
 Cyclic Adenosine Monophosphate (cAMP) Signaling. cAMP is a second messenger 
molecule that initiates signaling cascades responsible for mediating a variety of immune cell 
functions. cAMP is generated through the catalytic activity of adenylate cyclases and is 
degraded by a family of enzymes called phosphodiesterases (PDEs) (95). It has long been 
known that in addition to GCs, activation of cAMP decreases lymphoid cell proliferation and 
induces apoptosis (96). Furthermore, it has been shown in T-cell lines that stimulation of cAMP 
signaling has a synergistic effect to induce cell death when combined with the GC 
dexamethasone (DEX) (97), and that cAMP and GCs likely converge to promote the 
upregulation of BIM expression (98)(99), thereby facilitating the induction of apoptosis. Given 
the pro-apoptotic effects of cAMP and the effects of PDEs to decrease the cellular pool of 
cAMP, significant attention has been devoted to the development of PDE inhibitors (100), and a 
number of groups have evaluated the efficacy of PDE inhibitors as a means of overcoming GC 
resistance in lymphoid malignancies. In the CCRF-CEM cell line, both a non-specific PDE 
inhibitor and rolipram, a PDE4-specific inhibitor, significantly potentiated DEX-induced apoptosis 
(101). In primary CLL cells, rolipram synergized with GCs to induce apoptosis, and this effect 
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was associated with increased GR-mediated transcriptional activity (102). Furthermore, in these 
same cells, it was found that rolipram exposure resulted in an increase in both transcript and 
protein expression of GRa (103). In patients, PDE4 overexpression has been observed in a 
cohort of primary diffuse large B-cell lymphoma (DLBCL) samples. Consistent with the data in 
leukemia cell lines, inhibition of PDE4 in DLBCL cells was sufficient to restore GC sensitivity 
(104). Finally, in a large-scale gene expression analysis of primary DLBCL samples obtained 
from patients who received treatment with cyclophosphamide, adriamycin, vincristine, and 
prednisone (CHOP), elevation of PDE4 expression was enriched in patients with fatal or 
refractory disease relative to patients who were cured with CHOP therapy (105). Taken 
together, these data suggest that alterations in cAMP pathway signaling may contribute to GC 
resistance in lymphoid malignancies and that therapeutic targeting of this pathway may have 
clinical utility. 
 Mitogen Activated Protein Kinase (MAPK) Signaling. The three best studied MAPKs are 
p38, ERK, and JNK, all of which become activated downstream of a signaling cascade induced 
by cellular exposure to mitogenic stimuli (106). Each of these MAPKs has been shown to 
modulate GC sensitivity, resulting in a considerable number of studies devoted to investigating 
the therapeutic potential of MAPK pathway signaling modulators as a means of enhancing GC 
sensitivity. In GC resistant clones derived from the parental CCRF-CEM cells, inhibition of p38 
MAPK decreased DEX sensitivity, while inhibition of ERK activity increased sensitivity. These 
data implicate p38 as a positive regulator of GC activity and ERK as a negative regulator of GC 
activity (107), suggesting that distinct arms of the MAPK signaling cascade interact differently 
with the GR pathway. Consistent with these findings, it has been shown that exposing CCRF-
CEM cells to DEX results in increased phosphorylation and activation of p38, one substrate of 
which is GR itself. Specifically, this study demonstrated that p38 mediates Ser-211 
phosphorylation of GR (108), which has been shown to increase the transcriptional activity of 
GR (48), thereby providing a mechanistic explanation for the positive effect of p38 activity on 
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GC sensitivity. Another study demonstrated that inhibition of p38 in CCRF-CEM cells resulted in 
decreased induction of BIM expression upon DEX exposure, leading to an attenuated apoptotic 
response and suggesting that p38 might further contribute to GC sensitivity by enabling the 
upregulation of BIM expression (109).  
 Other studies have focused on elucidating the molecular basis for the inhibitory effect of 
ERK signaling on GC sensitivity. Importantly, ERK has been shown to phosphorylate BIM, 
preventing it from interacting with other members of the intrinsic apoptotic pathway to induce 
apoptosis (110). To determine whether this mechanism contributes to ERK-mediated GC 
resistance, Rambal et al. demonstrated in ALL cell lines and primary patient samples a 
synergistic interaction between a MEK inhibitor and DEX, with simultaneous exposure to both 
agents resulting in increased BIM expression due to a reduction in ERK-mediated BIM 
phosphorylation (111). In addition to ERK, JNK activation has previously been implicated as a 
negative regulator of GC sensitivity. In contrast to p38, JNK is known to catalyze an inhibitory 
phosphorylation of GR, resulting in decreased transcriptional activity (112). Jones et al. further 
established the role of ERK and JNK as negative regulators of GC sensitivity through an shRNA 
screen designed to identify genes that modify prednisolone sensitivity in B-ALL cell lines. 
Interestingly, this screen identified MEK2, which activates ERK, and MEK4, which activates 
JNK, as important candidate GC resistance genes. Through a variety of functional studies, the 
authors demonstrated that loss of MEK2 expression induced generalized chemosensitivity, 
including to GCs, through a p53-dependent mechanism and that loss of MEK4 increased 
expression of GR, leading to improved GC sensitivity. Furthermore, they demonstrated the 
clinical relevance of these findings by assessing ERK activity in paired diagnostic and relapse 
samples from patients with B-ALL and found increased levels of phosphorylated ERK in the 
relapsed samples (113), consistent with the idea that aberrant activation of ERK signaling may 
contribute to GC resistance. Given the large number of past and current clinical trials conducted 
in a wide variety of malignancies (114), the addition of small molecules that modulate MAPK 
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pathway activity may be a feasible strategy for overcoming GC resistance in some lymphoid 
malignancies. 
 PI3K/AKT/mTOR Signaling. The PI3K/AKT/mTOR pathway is another signal 
transduction pathway that is commonly dysregulated in lymphoid malignancies and represents a 
potential therapeutic target for strategies aimed at overcoming GC resistance. In a recent study 
involving a large cohort of pediatric T-ALL samples, AKT1 and PTEN mutations were two of only 
several genetic lesions that had a univariable association with relapse (91), suggesting that 
mutational activation of this pathway may play a role in therapy resistance, including to GCs. In 
another analysis of primary B-ALL samples, patients with increased phosphorylated AKT at 
diagnosis had a significantly inferior response to steroid-containing induction therapy and had 
decreased overall and relapse-free survival (115). These studies provide correlative evidence 
for the role of aberrant PI3K/AKT/mTOR pathway activity in GC resistance. To more directly 
assess a mechanistic basis for this relationship, Piovan et al. demonstrated using co-
immunoprecipitation that AKT1 binds to and phosphorylates GR on Ser-134, a phosphorylation 
event that impairs nuclear translocation of ligand-activated GR. Using the PTEN-null CCRF-
CEM cell line, the authors demonstrated through both in vitro and in vivo studies that combined 
treatment with GCs and the AKT inhibitor MK2206 is sufficient to reverse GC resistance (116). 
One class of proteins that has been found to cooperate with AKT to modulate GC activity is the 
14-3-3 class of phospho-serine/threonine binding proteins, which regulate the subcellular 
localization of proteins with phosphorylated serine or threonine residues, including 
phosphorylated GR (117). Consistent with this function, the 14-3-3s protein interacts with GR 
upon AKT1-mediated Ser-134 phosphorylation, resulting in impaired nuclear translocation of 
ligand-bound GR and leading to reduced transcriptional activity in the presence of GCs 
(117)(118). Similarly, it has been shown that more proximal inhibition of this pathway with a 
PI3K inhibitor results in synergy when combined with GCs, both in vitro and in an in vivo 
xenograft model (119). In B-ALL cell lines and primary diagnostic patient samples, PI3K 
 33 
inhibition augmented nuclear translocation of ligand-activated GR through a reduction in Ser-
134 phosphorylation (120), further confirming the effect of aberrant PI3K/AKT pathway inhibition 
to promote cytoplasmic retention of GR and prevent transcriptional activation.  
 One important downstream effector of PI3K/AKT pathway activation is mTOR (121), and 
many groups have studied the role of aberrant mTOR activation as a mediator of GC resistance 
in lymphoid malignancies. Using a chemical genomics approach, Wei et al. compared a large 
number of drug-associated gene expression profiles with the gene expression signature of GC 
sensitive and resistant ALL cells. Through this analysis, they determined that the changes in 
gene expression associated with exposure to the mTOR inhibitor rapamycin matched that 
associated with GC sensitive cells, suggesting that rapamycin may show efficacy by altering the 
gene expression pattern in GC resistant cells to better mimic that of GC sensitive cells. They 
further demonstrated that exposure to rapamycin sensitized cells to GCs through a mechanism 
involving downregulation of expression of the anti-apoptotic protein MCL1 (122). Similarly, Gu et 
al. demonstrated a synergistic relationship between rapamycin and DEX in a panel of T-ALL 
cells, and further elucidated the mechanistic basis for this interaction by identifying a synergistic 
induction of expression of the pro-apoptotic BAX and BIM proteins in conjunction with 
downregulation of MCL1 (123). In addition, it has been shown that simultaneous exposure to an 
mTOR inhibitor and GCs results in a synergistic induction of the cyclin-dependent kinase (CDK) 
inhibitor proteins p21 and p27 (123)(124), suggesting that mTOR inhibitors and GCs converge 
both to induce cell cycle arrest and activation of the intrinsic apoptotic pathway. This effect was 
further demonstrated in vivo using PDXs derived from primary patient T- and B-ALL samples, 
and the combinatorial effect of mTOR inhibition and GCs was found to be particularly effective 
in T-ALL samples with loss of PTEN expression (125), providing further evidence that aberrant 
regulation of upstream PI3K/AKT pathway activity results in altered mTOR activity that can be 
targeted therapeutically to augment the GC response. Finally, given the direct effects of both 
AKT and mTOR on GC sensitivity, several groups have investigated the efficacy of the dual 
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PI3K and mTOR inhibitor BEZ235, reasoning that dual inhibition at two critical points in this 
pathway may have a more profound effect to induce GC sensitivity. Indeed, in ALL cell lines and 
primary patient samples both in vitro and in vivo, synergy has been demonstrated between 
BEZ235 and DEX (126)(127), suggesting that multiple nodes within this pathway are viable 
therapeutic targets for augmenting GC sensitivity. 
 JAK/STAT Signaling. The JAK/STAT signaling pathway is the critical effector pathway of 
cytokine receptor signaling, which plays a crucial role in mediating survival, proliferation, and 
differentiation of lymphoid cells (128). Not surprisingly, aberrant activation of this pathway is 
common in lymphoid malignancies (91)(129), and significant attention has been devoted to 
assessing the role of JAK/STAT pathway inhibition as a novel treatment modality. Activation of 
cytokine receptors recruits JAK proteins to intracellular domains of cytokine receptors, and 
these activated JAK proteins recruit and phosphorylate STAT proteins, which translocate to the 
nucleus and function as transcription factors (128). Interestingly, GR and one of these STAT 
proteins, STAT5, have been shown to physically interact at certain genomic loci. Specifically, 
STAT5 is known to inhibit the action of GR on GR target genes (130). Consistent with this 
inhibitory role of JAK/STAT signaling on GR activity, inhibition of this pathway has been shown 
to overcome GC resistance in a number of lymphoid malignancies. In Philadelphia 
chromosome-like B-ALL, which is associated with aberrant JAK/STAT pathway activation, the 
combination of a JAK2 specific inhibitor and DEX demonstrated in vitro synergy and showed 
improved survival in an in vivo xenograft model (131). Similarly, in primary diagnostic T-ALL 
samples, exposure to the cytokine interleukin-7 resulted in increased JAK/STAT pathway 
activity that induced GC resistance and could be overcome with the addition of the JAK1/2 
inhibitor ruxolitinib (132). Finally, in CLL cells, GC resistance was found to be associated with 
autocrine activation of another STAT protein, STAT3, and inhibition of STAT3 activation with 
ruxolitinib resulted in increased sensitivity to DEX in vitro (133).  
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 NOTCH Signaling. NOTCH receptors are transmembrane receptors that, upon ligand 
binding, undergo a series of cleavage events to release the activated intracellular component of 
NOTCH from the membrane, allowing it to translocate to the nucleus and function as a 
transcription factor. The g-secretase complex mediates the final step in this processing (134). 
Due to the important role of NOTCH signaling in the pathogenesis of T-cell malignancies, 
inhibitors of this g-secretase complex have been evaluated as potential therapeutic agents for 
the treatment of these diseases in combination with GCs. Specifically, in T-ALL cell lines, g-
secretase inhibitors have been shown to sensitize cells to the cytotoxic effects of DEX (135). 
Several groups have demonstrated that the combination of g-secretase inhibitors and GCs 
facilitates autoinduction of GR and potentiates the induction of BIM expression, leading to 
increased cell death in both in vitro and in vivo model systems (136)(137). Despite these 
promising preclinical findings, the clinical utility of g-secretase inhibitors has been limited by 
severe gastrointestinal toxicity (138). However, in an elegant study conducted in a T-ALL 
xenograft model, it was shown that simultaneous exposure to a g-secretase inhibitor and DEX 
not only overcame GC resistance, but also attenuated the toxicities associated with the g-
secretase inhibitor (136), suggesting that the combination of g-secretase inhibitors and GCs may 
be a viable therapeutic strategy to enhance GC sensitivity. Finally, at least one study has 
evaluated the efficacy of an anti-NOTCH1 monoclonal antibody in a T-ALL PDX model and 
demonstrated potentiation of GC activity when given in combination (139).  
 Src Family Kinase Signaling. In T-cells, the Src family kinases Lck and Fyn mediate 
critical signal transduction events downstream of the T-cell receptor (TCR) (140). Through the 
use of reverse-phase protein arrays applied to PPR and PGR T-ALL samples, Lck was found to 
be aberrantly activated in PPR patients relative to PGR patients (141). Consistent with these 
findings, inhibition of Lck with the Src family kinase inhibitor dasatinib has demonstrated in vitro 
 36 
efficacy to enhance GC sensitivity (142) and has been shown to impair the engraftment of T-
ALL cells in vivo relative to treatment with either agent alone (141). 
 
Metabolism 
 
 In addition to studies demonstrating the importance of GR expression levels as a 
mediator of GC sensitivity, many groups have demonstrated that metabolic processes that limit 
the availability of GC ligand can similarly contribute to GC resistance. In normal physiology, the 
11b-hydroxysteroid dehydrogenase (HSD) class of enzymes mediates the conversion between 
cortisol, the active endogenous hormone, and cortisone, the inert form of the hormone. 
Specifically, 11b-HSD1 regenerates cortisol from cortisone while 11b-HSD2 inactivates cortisol 
(143). In an analysis of primary patient ALL samples, basal 11b-HSD1 expression was found to 
be higher in GC sensitive samples relative to GC resistant samples. Furthermore, 11b-HSD1 
expression was upregulated in response to DEX exposure specifically in the GC sensitive 
samples but not in the GC resistant samples, suggesting that 11b-HSD1 may participate in a 
GC-regulated feedback loop to maintain the availability of ligand for GR binding (144). The 
same group similarly analyzed 11b-HSD2 expression in the GC resistant T-ALL cell line 
MOLT4F and the GC sensitive CCRF-CEM cell line and demonstrated that 11b-HSD2 
expression was higher in the setting of GC resistance. They further demonstrated that 
pharmacologic inhibition of 11b-HSD2 was sufficient to potentiate GC-induced apoptosis (145). 
Consistent with these findings, 11b-HSD2 expression was compared between GC resistant T-
ALL cell lines, GC sensitive NHL cell lines, and normal peripheral T-cells. In the GC resistant 
cell lines, 11b-HSD2 expression was found to be significantly elevated relative to the GC 
sensitive cell lines or normal T-cells (146). To determine how 11b-HSD2 is dynamically 
regulated in the presence of GCs, transcript and protein expression as well as enzymatic activity 
were assessed in the GC sensitive CEM-C7 cell line after exposure to DEX. This analysis 
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demonstrated a reduction in expression and enzymatic activity upon DEX exposure, suggesting 
that, in contrast to 11b-HSD1, GC-induced downregulation of 11b-HSD2 may be important for 
maintaining GC sensitivity (147).  
 In addition to HSDs, glutathione S-transferases (GSTs) are a class of enzymes involved 
in the metabolism of a wide variety of drugs, including steroids (148). In an analysis of PGR and 
PPR patient samples from children treated on an ALL-BFM protocol, deletion of the GST family 
member GSTT1 was enriched in the PPR patient group and was associated with an increased 
risk of relapse (149). These data suggest that genetic lesions involving GST genes might 
contribute to differences in clinical GC response, though further studies are needed to 
determine whether aberrant GST activity plays a significant role in altering the availability of GC 
ligand and whether this contributes to GC resistance. 
 While metabolism of GCs themselves may play a role in modulating GC sensitivity, GC 
resistance has also been attributed to the aberrant activity of key bioenergetic metabolic 
pathways. Specifically, it has been shown in both ALL cell lines and in primary patient ALL 
samples that GC resistance is associated with increased rates of glycolysis, oxidative 
phosphorylation, and cholesterol biosynthesis. In a gene expression profiling study using ALL 
cell lines, pathways involved in these metabolic processes emerged as the top biological 
pathways associated with GC resistance. Furthermore, when these gene sets were studied in 
the context of primary patient samples, enrichment for these gene sets was a strong predictor of 
relapse (150), suggesting that activation of these bioenergetic pathways may promote 
chemoresistance. The same group went on to demonstrate that inhibition of glycolysis, oxidative 
phosphorylation, or cholesterol biosynthesis was sufficient to sensitize GC resistant T-ALL cells 
to GCs (151), further supporting the idea that aberrant activation of cellular metabolic processes 
may confer GC resistance.  
 Based on these findings, significant attention has been devoted to studying the role of 
glucose metabolism as a modulator of GC sensitivity. In an analysis of a large cohort of primary 
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B-ALL samples with varying degrees of in vitro prednisolone sensitivity, genes associated with 
carbohydrate metabolism were found to be differentially expressed between GC sensitive and 
GC resistant samples (152). Furthermore, in ALL cell lines and primary patient samples, 
prednisolone resistance was found to correlate with increased glucose consumption, and 
inhibition of glycolysis with the metabolite 2-deoxy-D-glucose (2-DG) sensitized cells to GCs, 
supporting the idea that excessive metabolic activity may impair GC-induced apoptosis (153). 
To further assess the relationship between glucose consumption and GC sensitivity, GC 
sensitive ALL cell lines and primary patient samples were exposed to DEX, which was found to 
inhibit glycolysis, leading to decreased glucose consumption that was mediated by a reduction 
in the expression of the glucose transporter GLUT1. This group went on to demonstrate that 
culturing cells in low glucose conditions resulted in increased DEX-induced apoptosis (154). 
Taken together, these data suggest that a reduction in glucose metabolism may be required for 
optimal GC-induced apoptosis. Consistent with this idea, it was shown that in prednisolone 
sensitive primary B-ALL samples, MCL1 expression decreased upon exposure to prednisolone, 
while it did not decrease in prednisolone resistant samples. Genetic silencing of MCL1 was 
found to be associated with an increase in glucose consumption, and simultaneous inhibition of 
glycolysis and silencing of MCL1 resulted in further sensitization to prednisolone (155). The 
importance of excessive glucose metabolism as a mediator of GC resistance has also been 
studied in the context of NHL cell lines and primary patient samples. In these cells, inhibition of 
glycolysis was found to synergize with methylprednisolone to induce cell cycle arrest and 
apoptosis (156). Providing a genetic explanation for the relationship between altered glucose 
metabolism and GC sensitivity, Chan et al. recently performed ChIP-seq to assess the binding 
pattern of transcription factors that are commonly inactivated in B-ALL, including PAX5 and 
IKZF1. They demonstrated that in B-ALL, these transcription factors are recruited to genetic loci 
that encode positive and negative regulators of glucose uptake. Re-expression of PAX5 and 
IKZF1 in B-ALL cells resulted in decreased glucose uptake and was sufficient to overcome 
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prednisolone resistance (157). The authors speculated that the hypermetabolic state associated 
with the deletion of these transcription factors facilitates leukemogenesis and simultaneously 
facilitates resistance to GC therapy. 
 In addition to glucose metabolism, aberrant lipid metabolism has also been shown to 
contribute to GC resistance. Specifically, lymphoid cells have been shown to have a unique 
dependency on exogenously synthesized cholesterol, and similar to glycolysis, GCs may exert 
their pro-apoptotic effects in part through inhibiting this cholesterol synthesis pathway. Indeed, 
in GC sensitive CEM-C7 cells, DEX was found to inhibit cholesterol synthesis, while this did not 
occur effectively in GC resistant CEM-C1 cells. Furthermore, exposure of CEM-C7 cells to 
exogenous cholesterol decreased DEX sensitivity, suggesting that DEX resistance may be 
mediated in part by increased cholesterol metabolism (158). Further supporting these data, T-
ALL PDXs treated with a GC-containing four-drug induction regimen that acquired in vivo drug 
resistance were found to have altered cholesterol metabolism. In these samples, exposure to 
DEX and simvastatin, an inhibitor of cholesterol biosynthesis, demonstrated ex vivo synergy 
(159). These data suggest that additional preclinical studies may be warranted to evaluate the 
use of drugs that modulate bioenergetic pathways as a means of overcoming GC resistance. 
 
MicroRNAs 
 
 MicroRNAs (miRNAs) are short non-coding RNAs that are most commonly contained 
within introns. Once transcribed, they bind to complementary sequences within the 3' 
untranslated region (3'UTR) of target gene mRNAs. Through this activity, miRNAs function 
primarily as negative regulators of translation, though they may have other repressive and 
activating roles (160). Dysfunctional expression of miRNAs is a common feature of many 
cancers, including hematologic malignancies. In ALL samples, a miRNA microarray analysis of 
paired diagnostic and relapse samples identified a distinct miRNA profile in the relapse samples 
relative to the diagnostic samples (161). Similarly, in a study involving miRNA sequencing of 
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samples from patients with Burkitt lymphoma, DLBCL, and follicular lymphoma, many miRNAs 
were found to be aberrantly expressed in lymphoma cells relative to normal lymphoid cells. 
Functionally, these miRNAs were found to be associated with altered regulation of key signal 
transduction pathways, including the Ras/MAPK and PI3K/AKT signaling pathways, suggesting 
that these miRNAs may play a role both in lymphomagenesis and in chemoresistance, including 
GC resistance (162).  
 MiR-17. In B-ALL cell lines, DEX exposure downregulated expression of miR-17 in GC 
sensitive but not in GC resistant cells. ChIP-seq analysis demonstrated that this is mediated by 
direct GR binding to the miR-17 locus specifically in GC sensitive cells. Functionally, miR-17 
was found to target the BIM transcript for silencing, and pharmacologic inhibition of miR-17 
increased DEX sensitivity with an associated increase in BIM expression (163).  
 MiR-100/99a. The miRNA species miR-100/99a has also been implicated in GC 
resistance and is known to be downregulated in samples from ALL patients with clinically high 
risk features. Specifically, low expression has been associated with inferior leukemia-free and 
overall survival (164). In cell lines, ectopic expression of miR-100/99a promoted DEX-induced 
apoptosis through a reduction in expression of the miR-100/99a target FKBP51. The reduction 
in FKBP51 expression was associated with increased nuclear localization of ligand-bound GR 
and decreased expression of mTOR, subsequently leading to a reduction in MCL1 expression 
which further potentiated apoptosis (164).  
 MiR-124. The role of MiR-124 as a mediator of GC resistance was first appreciated in 
the context of sepsis, where it was found that miR-24 represses the GRa transcript (165), 
suggesting that its overexpression might mediate GC resistance by decreasing the availability of 
GR protein for ligand binding. Indeed, miR-124 expression was found to be increased in 
prednisolone resistant ALL cell lines and in PPR patient samples and overexpression of miR-
124 in ALL cells was associated with a reduction in GR protein expression (166). However, at 
least one study has suggested the opposite effect of miR-124 in GC sensitivity. In DLBCL cells, 
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miR-124 expression was found to decrease expression of PDE4B, thereby relieving the 
inhibitory effect on cAMP signaling and increasing GC sensitivity (167). Further studies are 
therefore needed to elucidate the role of miR-124 in modulating GC sensitivity in distinct 
lymphoid malignancies. 
 MiR-128b and miR-221. In MLL-AF4 ALL, miR-128b and miR-221 were found to be 
downregulated relative to other types of ALL. Overexpression of these miRNAs in MLL-AF4 ALL 
cell lines resulted in increased sensitivity to GCs, which was accompanied by downregulation of 
MLL, AF4, and their associated fusion genes (168). Further implicating low miR-128b as a 
mediator of GC resistance in MLL-AF4 ALL, miR-128b mutations found in both cell lines and 
primary patient samples were shown to impair the appropriate processing of miR-128b. This 
resulted in GC resistance mediated by a failure to downregulate the expression of fusion 
oncogenes involving MLL and AF4, though the mechanisms by which MLL and AF4 themselves 
contribute to GC resistance are currently unknown (169). 
 MiR-142-3p. MiR-142-3p was initially shown in T-regulatory cells to target adenylyl 
cyclase 9 mRNA for silencing, resulting in a reduction in the cellular pool of cAMP due to the 
loss of adenylyl cyclase enzymatic activity (170). Elevated expression of miR-142-3p in primary 
T-ALL samples was found to be associated with an increased risk of relapse and decreased 
leukemia-free survival relative to patients with lower miR-142-3p expression. Consistent with its 
known effects on the adenylyl cyclase 9 transcript, high miR-142-3p expression was associated 
with increased cAMP pathway activity. Furthermore, miR-142-3p was found to target the GRa 
transcript for repression via direct binding to the 3'UTR. In this context, inhibition of miR-142-3p 
overcame GC resistance both by facilitating an increase in cAMP pathway activity and an 
increase in GRa expression (171).  
 MiR-182. In an analysis of variety of murine and human malignant lymphoid cell lines, 
miR-182 expression was higher in GC resistant cells relative to GC sensitive cells, and high 
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expression was associated with decreased FOXO3A expression. One important downstream 
target of FOXO3A is BIM, and high expression of miR-182 was also associated with a reduction 
in BIM expression. Consistent with this activity, overexpression of miR-182 restored BIM 
expression, thereby overcoming GC resistance (172).  
 MiR-185-5p. Finally, miR-185-5p was found to be overexpressed in GC sensitive ALL 
cell lines. One target of miR-185-5p is the mTORC2 mRNA. Forced overexpression of miR-185-
5p in GC resistant ALL cells restored GC sensitivity with a concomitant reduction in mTORC2 
activity (173).   
 
2.5: Conclusion 
 
 Given the pleiotropic effects of GCs and the innumerable interactions between GR and a 
wide variety of cellular processes, it is not surprising that the mechanisms of GC resistance are 
complex and that our understanding of these mechanisms is constantly evolving (Figure 2-1). 
However, despite a well-justified concern for GC resistance and its associated clinical 
implications, GCs are profoundly efficacious in the treatment of lymphoid malignancies and will 
undoubtedly remain an integral component of therapy. Therefore, there is an urgent need to 
translate the findings from the numerous preclinical and clinical studies highlighted in this review 
into standard clinical practice for the treatment of these diseases. With the application of large-
scale sequencing and epigenetic profiling technologies, the development of small molecule and 
biologic therapeutics, and increasing access to patient-derived tissue samples, there is 
significant potential for the elucidation of additional causes of GC resistance and the 
identification and implementation of novel therapeutic strategies to overcome them.  
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2.7: Figures 
 
Figure 2-1: Mechanisms of GC Resistance. GC resistance may arise due to processes that 
impact any component of normal GR signaling, including the availability of GC ligand or GR (A), 
nuclear translocation of the activated GC/GR complex (B), transcriptional activity of ligand-
bound GR (C), or the induction of apoptosis (D). 
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Chapter 3: The Bone Marrow Microenvironment as a Mediator of Chemoresistance in 
Acute Lymphoblastic Leukemia 
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3.1: Abstract  
 
 Acute lymphoblastic leukemia (ALL) is a malignancy of immature lymphoid cells that 
arises due to clonal expansion of cells that undergo developmental arrest and acquisition of 
pathogenic mutations. With the introduction of intensive multi-agent chemotherapeutic 
regimens, survival rates for ALL have improved dramatically over the past several decades, 
though survival rates for adult ALL continue to lag behind those of pediatric ALL. Resistance to 
chemotherapy remains a significant obstacle in the treatment of ALL, and chemoresistance due 
to molecular alterations within ALL cells have been described. In addition to these cell-intrinsic 
factors, the bone marrow microenvironment has more recently been appreciated as a cell-
extrinsic mediator of chemoresistance, and it is now known that stromal cells within the bone 
marrow microenvironment, through direct cell-cell interactions and through the release of 
lymphoid-acting soluble factors, contribute to ALL pathogenesis and chemoresistance. This 
review discusses mechanisms of chemoresistance mediated by factors within the bone marrow 
microenvironment and highlights novel therapeutic strategies that have been investigated to 
overcome chemoresistance in this context. 
 
3.2: Introduction 
 
 Acute lymphoblastic leukemia (ALL) is a malignancy of immature lymphoid cells of either 
the B-cell (B-ALL) or T-cell (T-ALL) lineage. ALL is the most common malignancy of childhood, 
and survival rates for children with ALL now approach 90% on modern treatment protocols, with 
even better survival rates for some molecular subtypes (174). In contrast, survival rates for adult 
ALL remain lower at 30-40% (175). In both contexts, improvements in survival were achieved in 
recent decades due in large part to the continued optimization of intensive multi-agent 
chemotherapy. The agents most commonly utilized in the treatment of ALL and their 
mechanisms of action are outlined in Table 3-1. Despite these improvements, patients with 
relapsed or refractory ALL continue to face inferior outcomes, underscoring the importance of 
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studies aimed at understanding the drivers of chemoresistance and identifying novel therapeutic 
strategies to restore chemosensitivity.  
 The genomic landscapes of both pediatric and adult ALL have been extensively 
characterized (176–178), and in many cases the presence of specific molecular or cytogenetic 
alterations can be correlated with prognosis or with resistance to a particular chemotherapeutic 
agent (116,179–182). These genetic factors therefore represent cell-intrinsic drivers of 
chemoresistance, and there have been considerable efforts to target these resistance 
mechanisms through the use of biologic and small molecule therapeutic agents. Equally 
important however are the complex and diverse cell-extrinsic factors that similarly modulate 
response to chemotherapy and clinical outcomes in ALL.  
 Specifically, both normal hematopoietic progenitor cells and ALL cells residing in the 
bone marrow receive key survival, proliferative, and homing signals from the bone marrow 
microenvironment. This microenvironment is classically subdivided into two distinct niches 
comprised of the endosteal niche and the vascular niche. In the endosteal niche, hematopoietic 
cells maintain direct cell-cell interactions with osteoblasts, which support hematopoietic cell 
survival and proliferation. The vascular niche consists of small sinusoidal blood vessels within 
the marrow cavity, which ensure the movement of oxygen, nutrients, and cellular homing factors 
in and out of the bone marrow, thereby supporting hematopoietic cell function and maintaining 
communication with other tissue types (183). Given these abundant interactions between the 
bone marrow microenvironment and ALL cells, there is significant interest in elucidating the 
microenvironmental drivers of chemoresistance in ALL and in identifying novel therapeutic 
strategies to overcome these cell-extrinsic mechanisms of chemoresistance (184–186). 
 
3.3: Cell-Cell Interactions in the Bone Marrow Microenvironment  
 
 A number of model systems of have been investigated for their ability to facilitate the ex 
vivo analysis of primary patient ALL cells, which demonstrate a high rate of spontaneous 
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apoptosis under standard cell culture conditions. In particular, it has been shown that co-culture 
with bone marrow stromal cells (BMSCs) significantly enhances the survival of leukemic blasts 
ex vivo (187). Specifically, this survival effect is often dependent upon direct contact with 
BMSCs, as BMSC conditioned media is insufficient to mediate the same improvement in cell 
survival (188). These studies highlight the importance of cell-cell interactions with BMSCs for 
the survival and proliferation of ALL cells, and a number of studies, many of which are described 
below, have demonstrated that these cell-cell interactions mediate chemoresistance.  
 
3.3.1: Integrins 
 
 Integrins are a class of transmembrane cell adhesion receptors that make up a critical 
component of the extracellular matrix (ECM). Integrins are comprised of heterodimers of a 
number of distinct a and b subunits and each have specific ligand-binding capabilities, 
determined predominantly by the identity of the a subunit. Upon engagement by extracellular 
stimuli, activated integrins mediate a variety of signal transduction events leading to modulation 
of a wide range of cellular processes, including cell survival, gene expression, and cell motility 
(189).  
  Despite the ubiquitous expression of this class of cell adhesion receptors throughout all 
tissue types, distinct integrin heterodimers demonstrate tissue-specific expression patterns. The 
b1-containing integrins, collectively known as very-late activation antigens (VLAs), 
heterodimerize with a4 subunits (CD49b) to form VLA-4. VLA-4 is highly expressed on 
hematopoietic progenitors and more mature blood cells, including healthy leukocytes and 
leukemic blasts, and functions to mediate trafficking of these cells within and out of the bone 
marrow (189). Importantly, aberrant expression of VLA-4 in leukemic blasts has been 
associated with chemoresistance and poor clinical outcomes. For example, amongst patients 
enrolled on the Children’s Oncology Group (COG) B-ALL trial P9906 who were minimal residual 
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disease (MRD) positive following one month of induction chemotherapy, those with low a4 
integrin expression had significantly improved overall survival (OS) relative to those with high a4 
integrin expression (190). Another analysis of samples from children with relapsed B-ALL 
enrolled on the ALL-REZ BFM 2002 trial from the Berlin-Frankfurt-Münster (BFM) study group 
demonstrated that patients with increased VLA4 expression at the time of first relapse had a 
significantly impaired response to chemotherapy and inferior event-free survival (EFS) and OS 
(191). The authors of this study went on to demonstrate that VLA-4 blocking antibodies 
attenuated the adhesion of B-ALL cells to BMSCs in vitro, and that this was sufficient to 
decrease cellular proliferation and overcome the cytarabine resistance conferred by co-culture 
with BMSCs (191). 
 In healthy hematopoietic cells, VLA-4 demonstrates high affinity for vascular cell 
adhesion molecule-1 (VCAM-1), a cell surface protein that is highly expressed on the vascular 
endothelium, as well as the ECM glycoproteins fibronectin and osteopontin (192). In particular, it 
is this affinity for VCAM-1 that is thought to play the predominant role in hematopoietic cell 
trafficking, as antibodies against VCAM-1 are sufficient to reduce progenitor cell adhesion to 
BMSCs both in vitro (193) and in vivo (194), while anti-fibronectin antibodies are not (195). In 
the context of leukemia, the VLA-4/VCAM-1 interaction is similarly thought to be the primary 
mediator of chemoresistance. Co-culture of ALL cell lines with BMSCs, but not with BMSC 
conditioned media, significantly reduced sensitivity to cytarabine and etoposide, an effect that 
was abrogated in the presence of VCAM-1 blocking antibodies (196).   
 Mechanistically, engagement of the VLA-4/VCAM-1 axis has been shown to activate 
pro-survival signaling pathways in ALL cells that in turn mediate chemoresistance. For example, 
in vitro stimulation of VLA-4 was shown to activate the PI3K/Akt signaling pathway in a B-ALL 
cell line, concomitant with the induction of adriamycin resistance, and inhibition of PI3K was 
sufficient to restore adriamycin sensitivity (197). Furthermore, Astier et al. analyzed global gene 
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expression changes in ALL cells following in vitro engagement of VLA-4 and found that a 
number of apoptotic regulators, including members of the caspase family, are significantly 
downregulated following VLA-4 activation while pro-survival factors, such as XIAP and survivin, 
are upregulated, together contributing to a chemoresistant state (198). Interestingly, there is 
also evidence to suggest that chemoresistance is mediated by reciprocal signaling through the 
VLA-4/VCAM-1 axis. Jacamo et al. demonstrated that co-culture of BMSCs with leukemic blasts 
resulted in an upregulation of NFkB signaling in the BMSCs themselves, and that this was 
attenuated in the presence of a VLA-4 blocking antibody. Furthermore, genetic or chemical 
inhibition of NFkB signaling in BMSCs restored sensitivity to vincristine in ALL cells both in vitro 
and in vivo. The authors speculate that the paracrine effects of many NFkB target genes, 
including cytokines, that are induced in the presence of ALL cells may in turn facilitate the 
protective microenvironment provided by the BMSCs (199). Finally, VLA-4 may promote 
chemoresistance via its interactions with ion channels present at the leukemic cell surface. In 
particular, the potassium channel KV11.1 has been shown to be overexpressed in ALL cell lines 
and patient samples (200). Intriguingly, VLA-4 can form cell surface signaling complexes 
involving KV11.1, that in turn lead to activation of ERK and PI3K/Akt signaling with the 
concomitant induction of chemoresistance (201).   
 Given the well-established role of VLA-4 as a mediator of chemoresistance in ALL cells, 
there has been increasing interest in augmenting chemosensitivity through the use of anti-VLA-
4 therapeutics, many of which have been used successfully in a number of autoimmune and 
inflammatory conditions due to their ability to modulate leukocyte activity. Natalizumab is a 
humanized monoclonal antibody that targets the a4 integrin subunit, thereby inhibiting VLA-4 
and the closely related a4b7 integrin, which similarly binds VCAM-1 (202). Hsieh et al. 
demonstrated that natalizumab significantly prolonged survival in a xenograft model of B-ALL 
when combined with multi-agent chemotherapy consisting of vincristine, dexamethasone, and L-
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asparaginase relative to chemotherapy alone (190). Other therapeutic approaches involve 
peptide or non-peptide ligands that compete with VCAM-1 for VLA-4 binding. One such small 
molecule, TBC3486, has significantly increased affinity for VLA-4 relative to a4b7 and has been 
shown to enhance chemosensitivity in vitro in B-ALL cells co-cultured with BMSCs and in vivo in 
a xenograft model of B-ALL (203). 
 In addition to VLA-4, several other integrins have been implicated in chemoresistance in 
ALL. For example, CD11b is an a integrin that is typically expressed on myeloid cells and plays 
an important role in cellular migration and extravasation during an immune response (204). 
While expression in lymphoid cells is usually restricted to memory B-cells, Rhein et al. 
investigated the significance of aberrant CD11b expression on pre-B-ALL blasts. In this 
analysis, the authors demonstrated that high CD11b expression at diagnosis was an 
independent poor prognostic factor, with the CD11b-high patients demonstrating significantly 
higher rates of post-induction MRD relative to the CD11b-low patients. Furthermore, they 
demonstrated that the blasts remaining at the end of induction therapy had significantly higher 
CD11b expression relative to the cells analyzed prior to the initiation of therapy (205). Further 
studies are needed to assess the functional significance of increased CD11b expression on B-
ALL cells. Finally, in T-ALL cell lines and patient samples, the collagen-binding a2b1 integrin 
has been shown to confer resistance to doxorubicin. Engagement of the a2b1 integrin with 
collagen resulted in increased activity of the MAPK signaling pathway and sustained expression 
of the anti-apoptotic protein Mcl-1. Consistent with these findings, doxorubicin sensitivity could 
be restored with MEK inhibition (206). 
 
3.3.2: Cadherins 
 
 First described for their role in regulating epithelial-to-mesenchymal transitions during 
normal embryonic development, cadherins have since been recognized as a structurally and 
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functionally diverse superfamily of transmembrane proteins that play important roles in normal 
cellular processes and in the development and progression of cancer (207). The intracellular 
domains of cadherin proteins interact with a multitude of signal transduction effectors to carry 
out a variety of cellular processes. One crucial class of intracellular effectors is the catenin 
family of proteins, which provide a physical link between the intracellular domains of cadherin 
proteins and the actin cytoskeleton, thereby facilitating the role of cadherins in maintaining cell 
adhesion. In immune cells, the b-catenin protein, through its involvement in canonical Wnt 
pathway signaling, plays a critical role in the regulation of immune processes (208).  
 Canonical Wnt signaling involves the binding of Wnt1 ligands to their receptor, known as 
Frizzled (Frz). In the absence of ligand binding, the intracellular b-catenin destruction complex is 
stabilized, resulting in low levels of intracellular b-catenin. Upon ligand binding, this complex 
becomes destabilized, allowing for an increase in levels of b-catenin protein in the cytoplasm. 
This b-catenin protein then translocates to the nucleus and associates with the TCF/LEF 
transcription factor complex, converting it from a repressive complex to an activating complex, 
which in turn activates a transcriptional program that mediates processes such as cell 
proliferation and differentiation (209).  
 Of the cadherin subfamilies, the Fat cadherins are the most commonly mutated in ALL, 
and many reports have demonstrated their tumor suppressive activity. In an analysis of primary 
T-ALL samples from adult patients, Neumann et al. determined that 12% of the samples in their 
cohort had missense or nonsense mutations in FAT1, leading to loss of expression (210). 
Similar FAT1 mutations have subsequently been reported in pediatric T-ALL (177). Interestingly, 
loss of function mutations in FAT1 have been associated with augmented Wnt pathway 
signaling. Specifically, Morris et al. demonstrated that the tumor suppressive effects of wild-type 
FAT1 protein derive from its ability to bind b-catenin at the periphery of the cell, thereby 
sequestering it in the cytoplasm and preventing its localization to the nucleus and activation of 
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TCF/LEF complex (211). This aberrant activation of Wnt/b-catenin signaling has been 
implicated as a mediator of chemoresistance in ALL. Upon exposure of ALL cell lines and 
primary patient samples to BMSCs, Yang et al. found that the resulting cytarabine resistance 
was associated with inactivation of the b-catenin destruction complex and upregulation of 
members of the Wnt signaling pathway. Inhibition of b-catenin was sufficient to restore 
chemosensitivity both in vitro and in vivo (212). An integrated analysis of pairs of diagnostic and 
relapsed pediatric ALL samples incorporating gene expression, copy number alterations, and 
DNA methylation analyses revealed that dysregulation of this pathway was enriched at the time 
of disease relapse (213), providing correlative evidence that altered Wnt/b-catenin signaling 
may be a clinically relevant mediator of resistance to chemotherapy. This same group went on 
to functionally test this interaction by demonstrating that, in contrast to their corresponding 
diagnostic samples, relapsed samples had significant overactivation of Wnt/b-catenin signaling 
and were highly refractory to the glucocorticoid prednisolone. In this context, the Wnt inhibitor 
iCRT14 synergized with prednisolone to induce apoptosis in relapsed patient samples (214).  
 Intriguingly, other reports suggest that Fat cadherins may instead function as 
oncogenes, where they contribute to disease progression and chemoresistance. For example, 
de Bock, et al. demonstrated that ALL cell lines express higher levels of Fat1 relative to healthy 
blood or bone marrow cells. The authors also demonstrated in two cohorts of pediatric patients 
with B-ALL that high FAT1 expression was associated with inferior relapse-free and overall 
survival (215). The same authors subsequently found that some T-ALL cell lines and patient 
samples express a truncated version of the FAT1 transcript, which in turn results in expression 
of a truncated protein that lacks the extracellular domain. Furthermore, this protein was found to 
cooperate with the Notch signaling pathway, described below, thereby serving an oncogenic 
function (216). 
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3.3.3: Galectins 
 
 The lectin family of cell surface proteins recognizes and binds to carbohydrates, leading 
to downstream signal transduction events that play crucial roles in normal physiology and in a 
variety of disease states (217). The galectins represent a subclass of lectins with binding 
specificity for b-galactoside epitopes, commonly found in association with proteins that undergo 
glycosylation during their trafficking through the secretory pathway. As a result of their distinct 
affinities for specific glycoproteins, galectins provide a means of interpreting the information 
contained within these glycosylation events and converting that information into intracellular 
signal transduction processes. The ability of galectins to bind their glycoprotein ligands is 
facilitated in part by their ability to form higher order multimeric structures, thereby increasing 
their binding capacity (218). In particular, galectin-3, which is commonly overexpressed in 
cancer, has extensive oligomerization capabilities, allowing it to form dynamic lattice structures 
at the cell surface that modulate the movement and activity of its glycoprotein binding partners 
(219).  
 Galectin-3 was first identified as a potential mediator of chemoresistance in ALL cells 
through an analysis of gene expression changes following co-culture of ALL cells with BMSCs. 
Jurkat T-ALL cells were rendered resistant to doxorubicin upon co-culture with BMSCs, 
concomitant with upregulation of galectin-3. Forced overexpression of galectin-3 in these cells 
was sufficient to confer chemoresistance in the absence of BMSCs (220). Consistent with these 
findings, Fei et al. found that in vitro, patient-derived B-ALL cells harvested from underneath a 
BMSC feeder cell layer, where they maintained direct cell-cell contact with feeder cells, had 
more galectin-3 on their cell surface relative to cells found in suspension above the cell layer or 
cells cultured in the absence of BMSCs (221). These same authors went on to assess secreted 
galectin-3 levels in the growth medium from BMSCs cultured in the absence or presence of ALL 
cells, and found that BMSCs secreted more galectin-3 in the context of ALL cell co-culture 
relative to culture of BMSCs alone, while ALL cells alone did not secrete galectin-3 under any 
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conditions. These results suggested that the elevated galectin-3 found on the cell surface of 
ALL cells had a stromal origin. The authors further confirmed this by demonstrating that 
exosomes derived from BMSCs, but not from ALL cells, contained galectin-3 and that these 
exosomes were secreted by BMSCs and subsequently taken up by ALL cells (222). Hu et al. 
similarly demonstrated that co-culture of ALL cells with BMSCs resulted in increased cell 
surface galectin-3 and chemoresistance, and extended this finding to demonstrate that 
transcriptional targets of the Wnt/b-catenin signaling pathway, previously implicated in 
chemoresistance (212,214), were upregulated in wild-type ALL cells co-cultured with BMSCs 
but not in galectin-3 knockout cells, suggesting that activation of this pathway is galectin-3-
dependent (223). Interestingly, galectin-3 inhibitors have demonstrated efficacy in acute myeloid 
leukemia (224), diffuse large B-cell lymphoma (225), and multiple myeloma (226,227). 
Additional studies are necessary to determine whether such inhibitors may similarly augment 
chemosensitivity in the context of ALL. 
 
3.3.4: Notch Signaling 
 
 The Notch signal transduction pathway is unique in several ways. First, its activation is 
dependent upon direct cell-cell contact between a ligand-expressing cell, such as a T-cell, and a 
receptor-expressing cell, such as a BMSC. Second, unlike other non-enzymatic transmembrane 
receptors, upon engagement of the Notch receptor by its ligands Delta-like or Jagged, the 
receptor itself undergoes proteolytic cleavage. Specifically, the extracellular domain of the 
receptor is shed first, followed by cleavage within the transmembrane domain by the g-secretase 
complex. This allows the intracellular domain of the receptor (NICD) to translocate to the 
nucleus and function as a transcriptional regulator (228). 
 In normal physiology, Notch signaling plays a critical role in T- and B-cell development. 
In T-cells, Notch activity is required for cell survival and proliferation during the double negative 
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(DN) stages of thymocyte development, and is important for b selection during the production of 
a fully rearranged ab T-cell receptor (TCR) (229). Further highlighting the importance of Notch 
signaling for thymocyte development, ectopic expression of Delta-like 1 in the OP9 stromal cell 
line is sufficient to support early T-cell differentiation ex vivo (230). Importantly, aberrant Notch 
signaling is a common feature of T-ALL. In pediatric T-ALL, activating mutations in components 
of the Notch signaling pathway, including in NOTCH1 itself, are found in nearly 80% of 
diagnostic samples (177). Though not found to be mutationally activated in B-ALL, Notch 
signaling does also play an important role in B-cell development where it promotes the 
differentiation of marginal zone and follicular zone B-cells (231).  
 Interestingly, within the bone marrow microenvironment, Notch signaling has been 
shown to mediate chemoresistance in the setting of hypoxia. Specifically, the bone marrow is a 
highly hypoxic environment, with a reported oxygen saturation of only 87.5% in healthy subjects, 
compared to 99% in peripheral blood (232). Upon exposure to a hypoxic environment, cells 
upregulate expression of the transcription factor hypoxia-inducible factor-1a (HIF-1a), which 
mediates a variety of tissue-specific transcriptional programs (233). In solid tumor cells, it has 
been shown that Notch signaling is induced in response to hypoxia and functions to promote 
cellular motility and invasiveness (234). Zou et al. similarly demonstrated that in the setting of 
hypoxia, T-ALL cells undergo HIF-1a-dependent Notch activation. In T-ALL cell lines, exposure 
to hypoxia was sufficient to confer chemoresistance, and this could be overcome with Notch 
silencing (235). 
 Due to the role for Notch signaling as a mediator of chemoresistance, there is interest in 
pharmacologically targeting the Notch signaling pathway. In addition to monoclonal antibodies 
targeting Notch receptors or ligands (236), significant attention has been devoted to the 
preclinical and clinical development of g secretase inhibitors (GSIs). Interestingly, numerous 
preclinical studies have demonstrated the ability of GSIs to augment chemosensitivity (237–
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239). Unfortunately, early single agent clinical trials involving GSIs were limited by severe 
gastrointestinal toxicity (240). However, Real et al. demonstrated through a series of elegant in 
vivo experiments that GSIs effectively overcome glucocorticoid resistance in T-ALL, and that 
concomitant exposure to glucocorticoids and GSIs abrogates the gastrointestinal toxicity 
associated with GSIs, thereby restoring the potential for the use of GSIs to modulate response 
to chemotherapy in T-ALL (241). This strategy was employed in a clinical trial involving relapsed 
or refractory pediatric solid tumors and T-cell leukemia (NCT01088763). 
 
3.4: Soluble Factors 
 
 In addition to direct cell-cell interactions, a number of secretory products made by cells 
within the bone marrow microenvironment engage with receptors on lymphoid cells to mediate 
functions such as cell proliferation and survival. Like the factors described above, many of these 
soluble products have similarly been shown to mediate chemoresistance. 
 
3.4.1: TNFa 
 
 TNFa is a pro-inflammatory cytokine that is responsible for normal immune system 
homeostasis and plays numerous well-established roles in the development and maintenance of 
malignancy (242). Produced by macrophages, natural killer cells, and T-cells, TNFa normally 
functions as a regulator of hematopoiesis when present in conjunction with other growth factors 
that similarly act to maintain the appropriate size and function of the hematopoietic compartment 
(243). Interestingly, a polymorphism in the TNF gene itself, which results in higher plasma levels 
of TNFa, has been shown to corelate with poor outcomes in a number of hematologic 
malignancies, including Hodgkin’s (244) and non-Hodgkin’s lymphoma (245). Consistent with 
these findings, Lauten et al. demonstrated in a cohort of children treated on BFM protocols that 
amongst patients with a prednisone poor response, those with TNF gene polymorphisms had a 
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higher rate of relapse (246). Mechanistically, TNFRII signaling has been shown to activate the 
PI3K/Akt signal transduction pathway, leading to downstream pro-survival signaling. Activation 
of this pathway has been associated with the induction of doxorubicin resistance in ALL cell 
lines (247), though further studies are needed to fully elucidate the relationship between altered 
TNFa expression and signaling and clinical outcomes for patients with ALL. 
 
3.4.2: g Chain Cytokines 
 
 Consisting of interleukin (IL)-2, 4, 7, 9, 15, and 21, the common g chain family of 
cytokines exert their effects on immune cells via a receptor that contains one or more cytokine-
specific receptor chains as well as the common cytokine receptor g chain. These multimeric 
receptor complexes lack intrinsic enzymatic activity and instead recruit downstream effectors via 
their cytoplasmic domains. Specifically, the cytokine-specific receptor chains most commonly 
recruit the kinase JAK1, while the g chain recruits JAK3. Activation of these JAK proteins results 
in phosphorylation of the cytoplasmic domains of the receptor subunits, which in turn creates 
docking sites for the STAT family of transcription factors, with STAT protein binding specificity 
determined by the identity of the specific receptor docking sites. Upon recruitment to activated 
cytokine receptors, these STAT proteins undergo JAK-mediated phosphorylation, leading to 
their translocation to the nucleus where they function as transcription factors to mediate target 
gene expression (43). Due to their central roles in regulating the differentiation, survival, and 
proliferation of healthy lymphoid cells, it is not surprising that g chain cytokine receptors play an 
important role in mediating chemoresistance in ALL. 
 Produced by T-cells, IL-4 acts on a multitude of immune cell subtypes leading to a wide 
range of downstream effects. For example, IL-4 is a signature cytokine in the differentiation of 
naïve CD4+ T-cells into the Th2 subtype of T helper cells. In the B-cell lineage, IL-4 functions as 
a B-cell differentiation factor, promoting immunoglobulin isotype switching, and in the myeloid 
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lineage, IL-4 is important for the development of M2 macrophages (43). Importantly, IL-4 has 
been implicated in glucocorticoid resistance in both non-malignant (248,249) and malignant T-
cells. Serafin et al. discovered that in T-ALL patients with a poor initial response to the 
glucocorticoid prednisone, the IL4 gene was upregulated downstream of aberrant activation of 
LCK, a Src family non-receptor tyrosine kinase that is important for lymphocyte development 
and activation. The authors demonstrated that culturing glucocorticoid sensitive T-ALL cell lines 
in the presence of IL-4 was sufficient to confer glucocorticoid resistance (250). Interestingly, in 
conjunction with TNFa, IL-4 is also a potent inducer of VCAM-1 expression (251), with TNFa 
and IL-4 exposure promoting the adhesion of ALL cells to bone marrow fibroblasts in culture 
(193,252). As described above, the VLA-4/VCAM-1 axis has been implicated in 
chemoresistance in a variety of model systems. 
 IL-7 is produced by the stromal cells of the bone marrow and thymus and plays a crucial 
nonredundant role in lymphoid cell development and survival. Activation of the IL-7 receptor (IL-
7R) primarily recruits the STAT5 transcription factors, which induce expression of antiapoptotic 
proteins such as BCL-2. Interestingly, many studies of early thymocyte development have 
demonstrated an interaction between IL-7R signaling, T-cell receptor (TCR) signaling, and 
endogenous glucocorticoid exposure that is critical for the appropriate development of the T-cell 
repertoire. Specifically, in normal T-cell development, IL-7R is expressed at high levels in the 
early DN thymocyte population, thereby maintaining cell survival prior to rearrangement of the 
T-cell receptor (TCR) (43). Upon induction of TCR rearrangement during the late DN and early 
double positive (DP) stage of development, IL-7R is transiently downregulated, thereby 
abrogating its strong pro-survival signal (253). At this stage, exposure to endogenous 
glucocorticoids is sufficient to induce cell death unless the cell is rescued by pro-survival 
signaling following successful TCR rearrangement (8). In this model, loss of IL-7R-mediated 
pro-survival signaling is required to enable an apoptotic response to endogenous 
glucocorticoids in the absence of an appropriately rearranged TCR. In the context of T-ALL, 
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signaling through the IL-7R/JAK/STAT5 pathway has been shown to confer resistance to 
pharmacologic concentrations of glucocorticoids, suggesting that this normal developmental 
process is co-opted in this malignant state to promote chemotherapy resistance. 
 Specifically, gain-of-function mutations in the IL-7R/JAK/STAT5 pathway occur in 25% of 
pediatric and young adult T-ALLs (177), underscoring the strong selective pressure for 
activation of this pathway as a mediator of T-cell survival. Both mutational and non-mutational 
activation of this pathway have been implicated in glucocorticoid resistance in T-ALL. For 
example, Li et al. demonstrated in diagnostic samples from children with T-ALL that mutations in 
the IL-7R/JAK/STAT5 pathway were associated with decreased ex vivo prednisolone sensitivity 
and with inferior relapse free survival. The authors went on to express mutant alleles of IL-7R 
pathway genes in glucocorticoid sensitive T-ALL cell lines and found that many of these 
mutations were sufficient to confer resistance to glucocorticoids, but not to other 
chemotherapies (182). Consistent with this idea, we previously demonstrated that IL-7-induced 
glucocorticoid resistance most commonly occurs in T-ALLs that lack activating mutations in the 
IL-7R/JAK/STAT5 pathway, and that this resistance phenotype is enriched in T-ALLs of the 
early T-cell precursor (ETP) subset, which correspond to the early DN stages of thymocyte 
development. Like Li et al., we similarly found that IL-7-mediated effects on chemoresistance 
are specific to glucocorticoids (132). We later showed that glucocorticoid resistance is mediated 
specifically by induction of the anti-apoptotic protein BCL-2 downstream of STAT5, and can be 
overcome with inhibition of JAK. Interestingly, we further demonstrated that this mechanism of 
IL-7-induced glucocorticoid resistance occurs in distinct subpopulations of healthy developing 
thymocytes both in vivo and ex vivo, and that T-ALLs with gene expression signatures 
resembling early stages of thymocyte development are enriched for this resistance phenotype 
(254). Taken together, these data provide strong evidence for a developmentally-retained 
mechanism by which T-ALLs, arising from stages of thymocyte development that rely on IL-7R 
 61 
signaling, can utilize this pathway to resist apoptosis in response to glucocorticoid therapy even 
in the absence of activating pathway mutations. 
 While not a g chain cytokine receptor, the thymic stromal lymphopoietin (TSLP) receptor 
(TSLP-R) consists of a heterodimer of the IL-7Ra chain and cytokine receptor-like factor 2 
(CRLF2), and plays a role in normal B-cell development (255). Aberrant signaling through 
TSLP-R, most commonly mediated by chromosomal rearrangements of CRLF2 and/or 
mutational activation of its downstream effector, JAK2, is a hallmark feature of Philadelphia 
chromosome-like (Ph-like) B-ALL. These leukemias demonstrate a gene expression signature 
that is similar to that of Ph-positive B-ALL but lack the BCR-ABL1 translocation (129). 
Importantly, CRLF2 rearrangements and JAK2 mutations, collectively leading to increased 
TSLP-R signaling capacity, have been associated with poor outcomes in patients with Ph-like 
ALL (256). Similar to T-ALL, we previously demonstrated that CRLF2-rearranged Ph-like B-ALL 
samples uniformly demonstrate in vitro glucocorticoid resistance (257). 
 Given the role of cytokine-mediated JAK/STAT signaling in the pathogenesis and 
chemoresistance of ALL cells, there has been considerable interest in targeting this pathway as 
a means of improving clinical outcomes. While several approaches have been studied, including 
the use of reducing agents to disrupt disulfide bond formation within IL-7R, blocking antibodies 
against IL-7R, and IL-7R-directed chimeric antigen receptor (CAR) T-cells (258), small molecule 
inhibitors of JAK are currently furthest along in clinical development. Ruxolitinib is a JAK1/2 
inhibitor that has shown efficacy as a single agent in xenograft models of ETP T-ALL (259) and 
Ph-like ALL (260), and has been shown to sensitize ALL cells to glucocorticoids in vitro 
(132,254,257). Consistent with these promising results, clinical trials have been initiated to 
investigate the efficacy of ruxolitinib in ALL (NCT03571321 and NCT02723994). 
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3.4.3: Chemokines 
 
 Chemokines are a subclass of cytokines that are specifically responsible for the export 
of immune cells from the bone marrow and for the homing of these cells to sites of infection and 
inflammation. Chemokine ligands characteristically contain one or more cysteine residues, 
enabling their division into the XC, CC, CXC, CX3C subgroups on the basis of the location of 
their cysteine residues within their amino acid sequences. Upon secretion, chemokines bind to 
G-protein-coupled receptors (GPCRs), with some receptors showing specificity for a single 
ligand and others capable of binding multiple distinct ligands (261). In particular, CXCR4 
signaling has been implicated in the initiation and progression of ALL, and has further been 
shown to mediate chemoresistance. 
 CXCL12, also called stromal derived factor 1 (SDF-1) is the chemokine ligand for the 
CXCR4 receptor and is expressed ubiquitously at all stages of development, where it plays an 
important role in tissue homeostatic functions, including within the hematopoietic compartment 
(262). Importantly, aberrant CXCL12/CXCR4 signaling has been functionally implicated in 
leukemogenesis and associated with poor clinical outcomes. For example, it has been shown 
that the protein phosphatase calcineurin is aberrantly activated in T-ALL and is required for the 
activity of leukemia initiating cells (263). Passaro et al. further demonstrated that cell surface 
expression of CXCR4 is regulated by calcineurin activity, and the presence of CXCR4 at the cell 
surface is required for the migratory capability of T-ALL cells. The authors further showed that 
silencing of CXCR4 was associated with the induction of apoptosis in a T-ALL cell line and in a 
patient-derived xenograft model of T-ALL (264). In pediatric B-ALL, high CXCR4 expression 
was associated with inferior relapse free survival (265), and in adult B-ALL, phosphorylated 
CXCR4, corresponding to an active form of the receptor, was associated with reduced OS 
(266).  
 To assess the relationship between CXCR4 expression and chemosensitivity in ALL, 
Sison et al. utilized primary samples from infants with mixed lineage leukemia (MLL)-rearranged 
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ALL, a high-risk molecular subtype of B-ALL that is associated with poor outcomes. Consistent 
with other reports, the authors found that exposure to BMSCs conferred chemoresistance and 
that co-treatment with the CXCR4 antagonist plerixafor was sufficient to restore 
chemosensitivity (267). The same group went on to demonstrate that in response to 
chemotherapy, ALL cells upregulate expression of CXCR4, priming them to respond to BMSC-
secreted CXCL12. In light of these findings, the authors demonstrated the efficacy of a 
combinatorial therapeutic strategy involving plerixafor in an in vivo xenograft model and found 
that co-treatment with plerixafor abrogated the protective effect of the bone marrow 
microenvironment on the response to chemotherapy (268). As a result of these promising 
results in preclinical models, the Pediatric Oncology Experimental Therapeutics Investigators’ 
Consortium conducted a phase 1 study to evaluate the potential for combining plerixafor with 
the chemotherapies cytarabine and etoposide in children with relapsed or refractory acute 
leukemia (NCT01319864). While the only clinical responses observed in this cohort occurred in 
children with AML, the number of patients with ALL was small (269). Based on these results, the 
role of plerixafor in augmenting chemosensitivity remains to be studied in additional patient 
cohorts in conjunction with other chemotherapy backbones. 
 
3.4.4: Asparagine 
 
 The introduction of L-asparaginase into modern treatment regimens has dramatically 
improved outcomes for patients with ALL (270). The efficacy of L-asparaginase relies upon the 
unique requirement for asparagine in leukemia cells. In healthy cells, asparagine is a non-
essential amino acid, synthesized intracellularly through the activity of asparagine synthetase. In 
contrast, ALL cells lack sufficient expression of asparagine synthetase to meet their requirement 
for asparagine, thereby relying instead on exogenous sources. The use of L-asparaginase 
exploits this dependency by hydrolyzing asparagine, thus depriving ALL cells of this exogenous 
supply (271). BMSCs have been shown to contribute to L-asparaginase resistance through 
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upregulation of asparagine synthetase. Specifically, Iwamoto et al. demonstrated that 
expression of the gene encoding asparagine synthetase, ASNS, was significantly higher in 
BMSCs than in ALL cells themselves, and that co-culture of ALL cells with BMSCs conferred 
resistance to L-asparaginase, suggesting that BMSCs function as an exogenous source of 
asparagine for ALL cells (272). 
 
3.5: Conclusion 
 
 Comprehensive analyses of the genomic and transcriptomic landscape of ALL have 
revealed many factors that contribute to chemoresistance and poor clinical outcomes for 
patients with ALL. In contrast to these cell-intrinsic drivers of chemoresistance, cell-extrinsic 
factors are less well-appreciated for their role in modulating clinical outcomes. As described 
here, the bone marrow microenvironment, through direct cell-cell interactions and the production 
of soluble factors, plays a complex and multifactorial role in determining the response of ALL 
cells to chemotherapy. This review highlights a number of efforts to target the microenvironment 
as a means of augmenting the efficacy of chemotherapy. While many of the preclinical studies 
described here present promising results, further studies are needed to validate these 
therapeutic strategies in other preclinical model systems and to facilitate their eventual clinical 
implementation. 
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3.7: Table 
 
Table 3-1: Mechanisms of action of chemotherapeutic agents used in the treatment of 
acute lymphoblastic leukemia. 
 
Drug Mechanism of Action 
Asparaginase • Cleaves exogenous asparagine to deprive ALL cells of this amino 
acid 
Clofarabine • Purine nucleoside analog that inhibits synthesis and repair of 
DNA  
Corticosteroids 
(prednisone or 
dexamethasone) 
• Glucocorticoid receptor agonists that induce pro-apoptotic effects 
in lymphoid cells  
Daunorubicin and 
Doxorubicin 
• Anthracyclines that inhibit topoisomerases  
Etoposide • Topoisomerase II inhibitor  
Methotrexate • Antimetabolite that inhibits dihydrofolate reductase to inhibit 
synthesis of purine nucleotides  
Vincristine • Microtubule-destabilizing agent 
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Chapter 4: CRLF2 Rearrangement in Ph-Like Acute Lymphoblastic Leukemia Predicts 
Glucocorticoid Resistance that is Overcome with MEK or Akt Inhibition 
 67 
4.1: Abstract 
 
 Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a 
genetically heterogeneous subtype of B-cell ALL characterized by chromosomal 
rearrangements and mutations that result in aberrant cytokine receptor and kinase signaling. In 
particular, chromosomal rearrangements resulting in the overexpression of cytokine receptor-
like factor 2 (CRLF2) occur in 50% of Ph-like ALL cases. CRLF2 overexpression is associated 
with particularly poor clinical outcomes, though the molecular basis for this is currently unknown. 
Glucocorticoids (GCs) are integral to the treatment of ALL and GC resistance at diagnosis is an 
important negative prognostic factor. Given the importance of GCs in ALL therapy and the poor 
outcomes for patients with CRLF2 overexpression, we hypothesized that the aberrant signal 
transduction associated with CRLF2 overexpression might mediate intrinsic GC insensitivity. To 
test this hypothesis, we exposed Ph-like ALL cells from patient-derived xenografts to GCs and 
found that CRLF2 rearranged (CRLF2R) leukemias uniformly demonstrated reduced GC 
sensitivity in vitro. Furthermore, targeted inhibition of signal transduction with the MEK inhibitor 
trametinib and the Akt inhibitor MK2206, but not the JAK inhibitor ruxolitinib, was sufficient to 
augment GC sensitivity. These data suggest that suboptimal GC responses may in part underlie 
the poor clinical outcomes for patients with CRLF2 overexpression and provide rationale for 
combination therapy involving GCs and signal transduction inhibitors as a means of enhancing 
GC efficacy. 
 
4.2: Introduction 
 
 Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a subtype 
of B-cell ALL that displays a gene expression profile resembling that of BCR-ABL1-positive ALL 
but lacks the BCR-ABL1 translocation. Instead, Ph-like ALL is characterized by genetic 
alterations that result in aberrant cytokine receptor and kinase signaling (273). In particular, 50% 
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of Ph-like ALL cases harbor chromosomal rearrangements that result in overexpression of 
cytokine receptor-like factor 2 (CRLF2), which heterodimerizes with the interleukin-7 receptor 
alpha chain to form the thymic stromal lymphopoietin receptor (TSLPR) (256). Upon activation 
by TSLP ligand, TSLPR signals through the JAK/STAT, Ras/MAPK, and PI3K/Akt/mTOR 
pathways (274). Importantly, overexpression of CRLF2 is associated with a particularly poor 
prognosis, with these patients demonstrating significantly worse relapse-free survival relative to 
patients without CRLF2 overexpression (256,275). While the molecular basis for this clinical 
observation is currently unknown, this suggests that these patients may have intrinsic resistance 
to conventional chemotherapy. 
Glucocorticoids (GCs) are an integral component of therapy for patients with ALL (30). 
GCs act by binding to a cytoplasmic GC receptor (GR), which promotes translocation of the 
GC/GR complex to the nucleus and induction of a transcriptional program that results in 
apoptosis in lymphoid cells (1). Downstream effectors of signal transduction pathways have 
been shown to inhibit several of these processes, including nuclear translocation of ligand-
activated GR (116,276) and induction of the GR transcriptional program (113). Furthermore, 
cytokines present in the microenvironment have been shown to promote GC resistance in 
lymphoblasts by activating these signal transduction pathways (132,249,277).  
Given the importance of GC resistance in ALL and the comparatively poor clinical 
outcomes for patients with CRLF2 overexpression, we hypothesized that the aberrant signal 
transduction associated with CRLF2 overexpression might contribute to suboptimal responses 
to GC therapy. We tested this hypothesis by assessing in vitro drug responses in CRLF2-
rearranged (CRLF2R) and -non-rearranged (CRLF2NR) cells from patient-derived xenografts of 
Ph-like ALL, and found that CRLF2R samples were uniformly less sensitive to GCs relative to 
many CRLF2NR samples. Furthermore, we demonstrated that GC sensitivity could be 
significantly enhanced with concomitant signal transduction inhibition, providing rationale for 
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further evaluation of a combination therapy strategy as a means of augmenting GC sensitivity in 
patients with CRLF2 overexpression. 
 
4.3: Results 
 
Eleven of the 19 Ph-like leukemias were positive for CRLF2 rearrangements. Of these, 
nine expressed transcripts corresponding to the IGH@-CRLF2 rearrangement and two were 
positive for the P2RY8-CRLF2 rearrangement. Seven of these CRLF2R leukemias had 
concomitant activating mutations in JAK2. All eight CRLF2NR Ph-like leukemias had point 
mutations or rearrangements involving other kinases previously implicated in Ph-like ALL (278) 
(Supplemental Table 4-1).  
Both IGH@-CRLF2 and P2RY8-CRLF2 translocations have been reported to result in 
CRLF2 overexpression (279). Consistent with these data, the CRLF2R leukemias analyzed in 
the current study exhibited higher cell surface TSLPR protein expression relative to CRLF2NR 
leukemias (p=0.0003; Figure 4-1A). We next assessed the induction of phosphorylated (p) 
STAT5, ERK, and Akt in response to short-term TSLP stimulation in CRLF2R and CRLF2NR 
leukemias. Four of 10 CRLF2R leukemias, including two that lacked a concomitant JAK2 
mutation, markedly induced pSTAT5 in response to short-term TSLP stimulation, while 
CRLF2NR leukemias did not (Figure 4-1B). CRLF2R leukemias also induced pERK and pAkt in 
response to TSLP, with no induction in the CRLF2NR leukemias (p=0.001 and p=0.002 versus 
CRLF2NR leukemias, respectively; Figures 4-1C-D). There were no differences in basal levels of 
pSTAT5, pERK, or pAkt between CRLF2R and CRLF2NR leukemias (Supplemental Figure 4-1). 
To test the hypothesis that aberrant signal transduction might impair GC sensitivity in 
CRLF2R leukemias, we assessed the response to DEX in vitro. In the presence of DEX, all 11 
CRLF2R leukemias retained greater than 50% survival at 48 hours, in contrast to only four 
CRLF2NR leukemias (p=0.006 versus CRLF2NR leukemias; Figure 4-2A). Importantly, this 
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difference in DEX sensitivity was not explained by differences in GR expression (Supplemental 
Figure 4-2A). Given the uniform DEX insensitivity in the CRLF2R leukemias, we asked whether 
inhibition of one or more signal transduction pathways downstream of TSLPR might augment 
DEX-induced cell death in these samples. We treated these leukemias with the combination of 
DEX and inhibitors of JAK1/2 (ruxolitinib), MEK (trametinib), or Akt (MK2206) at concentrations 
that attenuated TSLP-induced signaling in the CRLF2R Ph-like ALL cell line Mutz-5 
(Supplemental Figures 4-2B-D) and that did not demonstrate toxicity in healthy PBMCs 
(Supplemental Figure 4-2E). In the CRLF2R samples, ruxolitinib had no significant single agent 
effect when assessed across the entire cohort, but it showed increased efficacy in samples with 
a JAK2 mutation relative to those without (p=0.03; Supplemental Figure 4-3A). Furthermore, the 
combination of DEX and ruxolitinib was not more effective than either agent alone (Figure 4-2B). 
In contrast, trametinib and MK2206, which showed moderate single-agent activity (p=0.005 and 
p=0.04 versus vehicle, respectively), were significantly more effective in combination with DEX 
relative to either single agent alone (p=0.005 and p<0.0001 versus DEX alone, respectively; 
Figures 4-2C-D). Bliss independence analysis confirmed these findings, demonstrating no 
interaction between DEX and RUX but cooperativity between DEX and trametinib and DEX and 
MK2206 (Figures 4-2E-G). In the CRLF2NR samples, these signal transduction inhibitors 
demonstrated variable effects, with some modulation of DEX sensitivity in several samples that 
demonstrated relative insensitivity to DEX as a single agent (Supplemental Figures 4-3B-D).  
 
4.4: Discussion 
 
Taken together, these data demonstrate that Ph-like ALL samples with CRLF2 
rearrangements uniformly demonstrate limited GC sensitivity in vitro. Furthermore, these data 
suggest a model whereby dysregulated signal transduction in the context of CRLF2 
overexpression contributes to relative GC resistance. This provides rationale for a clinical 
strategy involving combination therapy with GCs and signal transduction inhibitors as a means 
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of enhancing GC efficacy. A precedent for this type of combination therapy approach includes 
the addition of ABL kinase inhibitors to standard chemotherapy regimens for children with Ph-
positive ALL, which has dramatically improved clinical outcomes for these patients (280). 
Together with the known prognostic value of GC sensitivity, our findings suggest that the inferior 
survival rates for patients with CRLF2 overexpression may be driven at least in part by 
suboptimal responses to GC therapy. These data support further evaluation of CRLF2 
rearrangement status as a clinical biomarker for relatively poor sensitivity to GCs, thereby 
enabling the identification of patients who may benefit from the addition of molecularly targeted 
therapy to conventional anti-leukemia chemotherapy.  
 
4.5: Methods 
 
To assess GC sensitivity in Ph-like ALL cells, cryopreserved splenocytes were obtained 
from 19 patient-derived xenografts of high-risk Ph-like ALL established from treatment-naïve 
diagnostic samples banked in the Children’s Hospital of Philadelphia leukemia biorepositories. 
Written informed consent for the use of diagnostic specimens for future research was obtained 
from patients or their guardians at the time of sample collection, according to the Declaration of 
Helsinki and the National Cancer Institute and the institutional review board of Children’s 
Hospital of Philadelphia, which approved this study. As a control to assess for in vitro drug 
toxicity, peripheral blood mononuclear cells (PBMCs) from healthy donors were obtained from 
Vitalant. Rearrangements involving the CRLF2 locus were detected as previously described 
(256). Cells were thawed, allowed to rest for 1 hour at 37˚C, then cultured at 37˚C in media 
supplemented with 25 ng/mL recombinant human TSLP (Peprotech, Rocky Hill, NJ, USA). 
Ruxolitinib (Selleckchem, Houston, TX, USA), a JAK1/2 inhibitor, was used at 500nM while 
dexamethasone (DEX; Sigma-Aldrich, St. Louis, MO, USA), a synthetic GC, trametinib 
(Selleckchem), a MEK1/2 inhibitor, and MK2206 (Selleckchem), a pan-Akt inhibitor, were used 
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at 1µM. Cells were harvested at 48 hours and flow cytometry was performed as previously 
described using a FACSVerse flow cytometer (BD Biosciences, San Jose, CA, USA) (259). 
Antisera included anti-human CD45, anti-cleaved caspase-3, anti-TSLPR, anti-STAT5 (pY694), 
anti-ERK1/2 (pT202/pY204), anti-Akt (pS473) (BD Biosciences), and anti-GR (Cell Signaling, 
Danvers, MA, USA). Signal strength was quantified as the median fluorescence intensity (MFI) 
of cells negative for cleaved caspase-3 within the human CD45-positive gate. Viability assays 
were performed via calculation of the frequency of Hoechst (ThermoFisher, Waltham, MA, USA) 
negative cells in the human CD45-positive gate. All viability data are presented as the 
percentage of viable cells in the drug-treated condition relative to the percentage of viable cells 
in the corresponding vehicle control condition for each individual sample.  The average viability 
across all samples in the vehicle control condition at 48 hours was 39% +/- 23%. Statistical 
analyses were performed using Prism 8 (GraphPad, San Diego, CA, USA). All tests were two-
sided and the threshold for significance was p≤0.05. Specifically, comparisons between groups 
were made using t-tests, with one-way ANOVA and Tukey’s method for multiple comparisons 
adjustment used for comparisons of three or more groups. Drug-drug interactions were 
assessed using the Bliss independence model of synergy (281). 
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4.7: Figures 
 
 
 
Figure 4-1: CRLF2R leukemias demonstrate TSLPR overexpression and increased signal 
transduction activity relative to CRLF2NR leukemias. (A) MFI of TSLPR cell surface protein 
expression as determined by antibody staining and flow cytometry in cells from CRLF2R and 
CRLF2NR samples. Individual patient samples are shown in the same color in all figures and in 
Supplemental Table 4-1. (B-D) Induction of (B) pSTAT5, (C) pERK, and (D) pAkt in CRLF2R 
and CRLF2NR samples in response to a 30-minute stimulation with 25ng/mL TSLP, presented 
as the fold change in MFI following TSLP stimulation relative to the basal condition. Samples 
JH721 and NL432 were not included in this analysis due to limitations in cell number. Error bars 
represent the standard error of the mean. Statistical significance was assessed using a two-
sample t-test. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Figure 4-2: CRLF2R leukemias are uniformly DEX resistant and can be sensitized to DEX 
with targeted inhibition of MEK or Akt. (A) Cell viability in response to 1µM DEX, presented 
as the percentage of viable cells in the DEX treated condition relative to the vehicle control 
condition in CRLF2R and CRLF2NR samples. (B-D) Cell viability of CRLF2R samples following 
exposure to 1µM DEX, (B) 500nM ruxolitinib, (C) 1µM trametinib, (D) 1µM MK2206, or a 
combination of DEX and a targeted inhibitor presented as the percentage of viable cells in the 
drug treated conditions relative to the vehicle control condition. (E-G) Bliss independence 
scores for the combination of DEX and ruxolitinib (E), trametinib (F), or MK2206 (G) in CRLF2R 
samples, in which positive values indicate a synergistic interaction between the two agents. 
Error bars represent the standard error of the mean. Statistical significance was assessed using 
a two-sample t-test (A) or one-way ANOVA with Tukey’s method for multiple comparisons 
adjustment (B-D). ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Supplemental Figure 4-1: Basal pathway activity is not different between CRFL2R and 
CRLF2NR samples. MFI of basal (A) pSTAT5, (B) pERK, and (C) pAkt in CRLF2R and CRLF2NR 
leukemias. Error bars represent the standard error of the mean. Statistical significance was 
assessed using a two-sample t-test. 
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Supplemental Figure 4-2: Signal transduction inhibitors effectively inhibit pathway 
activity and are not toxic to PBMCs. (A) MFI of intracellular GR protein expression as 
determined by flow cytometry in CRLF2R and CRLF2NR samples. (B-D) Histograms indicating 
levels of (B) pSTAT5, (C) pERK, or (D) pAkt following TSLP stimulation with or without one hour 
pre-treatment with 500nM ruxolitinib, 1µM trametinib, or 1µM MK2206, respectively, in the 
CRLF2R Ph-like ALL cell line Mutz-5. (E) Viability of PBMCs from three healthy donors following 
exposure to 500nM ruxolitinib, 1µM trametinib, or 1µM MK2206. Error bars represent the 
standard error of the mean. Statistical significance was assessed using a two-sample t-test (A) 
or one-way ANOVA with Tukey’s method for multiple comparisons adjustment (E).  
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Supplemental Figure 4-3: Effects of signal transduction inhibitors on CRLF2NR samples. 
(A) Cell viability of CRLF2R samples with JAK2 mutations versus those without JAK2 mutations 
following exposure to 500nM ruxolitinib. (B-D) Cell viability of CRLF2NR samples following 
exposure to 1µM DEX, (B) 500nM ruxolitinib, (C) 1µM trametinib, (D) 1µM MK2206, or a 
combination of DEX and a targeted inhibitor presented as the percentage of viable cells in the 
drug treated conditions relative to the vehicle control condition. Error bars represent the 
standard error of the mean. Statistical significance was assessed using a paired t-test (A) or 
one-way ANOVA with Tukey’s method for multiple comparisons adjustment (B-D). ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05. 
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4.8: Table 
 
Supplemental Table 4-1: Characteristics of Ph-like ALL Samples 
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Chapter 5: Glucocorticoids Paradoxically Facilitate Steroid Resistance in T-Cell Acute 
Lymphoblastic Leukemias and Thymocytes 
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5.1: Abstract 
 
 Glucocorticoids (GCs) are a central component of therapy for patients with T-cell acute 
lymphoblastic leukemia (T-ALL) and while resistance to GCs is a strong negative prognostic 
indicator in T-ALL, mechanisms of GC resistance remain poorly understood. Using diagnostic 
samples from patients enrolled on the frontline Children’s Oncology Group (COG) T-ALL clinical 
trial AALL1231, we demonstrated that one-third of primary T-ALLs were resistant to GCs when 
cultured in the presence of interleukin-7 (IL7), a cytokine that is critical for normal T-cell function 
and that plays a well-established role in leukemogenesis. We demonstrated that in these T-
ALLs and in distinct populations of normal developing thymocytes, GCs paradoxically induced 
their own resistance by promoting upregulation of IL7 receptor (IL7R) expression. In the 
presence of IL7, this augmented downstream signal transduction resulting in increased STAT5 
transcriptional output and upregulation of the pro-survival protein BCL-2. Taken together, we 
demonstrated that IL7 mediates an intrinsic and physiologic mechanism of GC resistance in 
normal thymocyte development that is retained during leukemogenesis in a subset of T-ALLs 
and is reversible with targeted inhibition of the IL7R/JAK/STAT5/BCL-2 axis.  
 
5.2: Introduction 
 
 T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease 
characterized by a range of alterations involving transcription factors, cell cycle regulators, and 
signal transduction effectors (282). Unlike B-cell ALL (B-ALL), where genetic factors are widely 
used to inform risk stratification and subsequent intensification of therapy (283), few genetic 
lesions in T-ALL have independent prognostic significance (282). As a result, efforts to 
implement risk-adapted therapeutic strategies have been limited by a lack of genetic 
biomarkers, highlighting the need for functional studies aimed instead at elucidating recurrent 
patterns of drug response and resistance across the spectrum of T-ALL.   
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 While outcomes for children with T-ALL have improved dramatically over the past 
several decades, children with relapsed T-ALL continue to face poor survival rates (284), 
suggesting that novel strategies are needed to improve the upfront efficacy of therapy in order 
to induce deeper remissions and decrease the likelihood of disease relapse. Glucocorticoids 
(GCs) are a central component of T-ALL therapy, and the initial response to GC therapy is an 
important predictor of long-term outcomes (285). For example, on the ALL-BFM 95 trial, patients 
were stratified into those who had a prednisone good response (PGR) and those who had a 
prednisone poor response (PPR) following seven days of prednisone monotherapy. Patients 
with a PGR had an eight-year event free survival rate of 81.3%, as opposed to only 55.1% for 
patients with a PPR (30). These data demonstrate that intrinsic differences in GC sensitivity 
exist at the time of disease diagnosis and that these differences can have long-term prognostic 
significance. Despite decades of clinical use, a comprehensive understanding of the 
mechanistic basis for differential intrinsic GC sensitivity is lacking. GCs act by binding to a 
cytoplasmic GC receptor (GR), which promotes translocation of GR to the nucleus where it 
binds to target gene loci and induces a transcriptional program that results in apoptosis in 
lymphoid cells (49). Unlike other agents used in the treatment of T-ALL, GCs are unique in that 
they also exist as endogenous hormones that play critical roles in normal T-cell physiology. For 
example, endogenous GC activity has been shown to interact with T-cell receptor (TCR) 
signaling to shape the developing T-cell repertoire (286,287) and to promote T-cell homeostasis 
in the periphery following an immune response (288). Given these frequent encounters with 
GCs in normal physiology and the fact that GCs are potent inducers of apoptosis in both normal 
and transformed lymphoid cells, we reasoned that T-cells must possess intrinsic mechanisms 
that allow them to resist GC-induced apoptosis under certain developmental and environmental 
conditions. Furthermore, we hypothesized that these mechanisms may be retained during 
leukemogenesis and exploited to confer resistance to GC therapy in T-ALL.  
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 One critical endogenous factor in the T-ALL microenvironment is the cytokine 
interleukin-7 (IL7). In addition to promoting the survival and differentiation of developing 
thymocytes (4), the IL7 receptor (IL7R)/JAK/STAT5 signaling pathway contributes to T-ALL 
pathogenesis and disease maintenance (289–291). We previously demonstrated that over half 
of primary treatment-naïve T-ALL patient samples are intrinsically resistant to the glucocorticoid 
dexamethasone (DEX) when cultured in the presence of IL7. Of these DEX resistant samples, 
half could be sensitized to DEX with inhibition of JAK signaling (132). Interestingly, the majority 
of samples with JAK/STAT5-mediated DEX resistance lacked activating mutations in 
components of the IL7R/JAK/STAT5 pathway. In the present study, we analyzed a larger cohort 
of fresh diagnostic samples obtained from pediatric patients enrolled on the COG frontline T-
ALL clinical trial AALL1231, with the goal of establishing the mechanistic basis for this DEX 
resistance phenotype. In this cohort, we demonstrated that one-third of primary diagnostic 
samples are resistant to DEX specifically when cultured in the presence of IL7. Furthermore, we 
found that subsets of normal developing thymocytes similarly demonstrate this IL7-induced DEX 
resistance phenotype. Through functional analyses, we elucidated a mechanism by which GCs 
paradoxically induce their own resistance by augmenting the pro-survival activity of the 
IL7R/JAK/STAT5 pathway in distinct subsets of developing thymocytes and T-ALLs. Taken 
together, these data suggest that IL7 facilitates GC resistance in developing thymocyte 
populations, and that subsets of T-ALL cells retain this capacity to utilize IL7 as a means of 
resisting GC-induced apoptosis. These findings have significant therapeutic implications, as 
they suggest that inhibiting the IL7R/JAK/STAT5 pathway or its transcriptional targets may 
enhance GC efficacy in patients who exhibit a poor initial response to GC therapy. 
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5.3: Results 
 
JAK signaling mediates dexamethasone resistance in a subset of T-ALLs   
 
 In a large independent cohort consisting of 73 samples from patients enrolled on COG 
AALL1231, we validated our previous finding that in vitro DEX sensitivity is highly variable 
across T-ALL (Figure 5-1A) (132). Importantly, these differences in DEX sensitivity are not 
dose-dependent, but persist at saturating concentrations of DEX (Supplemental Figure 5-1A). 
Defining “DEX resistant” as samples that retain greater than 50% cell viability following DEX 
exposure, we found that 63% of primary diagnostic samples are intrinsically DEX resistant when 
cultured in the presence of IL7 (Figure 5-1A). Binding of IL7 to IL7R results in the recruitment of 
JAK1 and JAK3, which subsequently become phosphorylated to create docking sites for STAT5 
(253). Consistent with our previous findings (132), inhibition of JAK signaling with the JAK1/2 
inhibitor ruxolitinib (RUX) was sufficient to overcome DEX resistance in 54% of these DEX 
resistant samples (p<0.0001 for DEX versus DEX+RUX and for RUX versus DEX+RUX; Figure 
5-1B).  
 To facilitate further studies aimed at investigating the mechanistic basis for DEX 
resistance mediated by JAK signaling, we next evaluated the human T-ALL cell line CCRF-CEM 
for its utility as a model system in which to study the DEX resistance phenotype observed in 
these primary patient T-ALL samples. This analysis revealed a dose-dependent reduction in 
DEX sensitivity with increasing concentrations of IL7 (Figure 5-1C and Supplemental Figure 5-
1B). Consistent with the primary patient samples, RUX was sufficient to completely restore DEX 
sensitivity in CCRF-CEM cells in the presence of IL7 (Figure 5-1D). Furthermore, Bliss 
independence analysis indicated a synergistic interaction between DEX and RUX (Figure 5-1E). 
To ensure that this sensitization effect was due specifically to JAK1 inhibition by RUX and not to 
off-target effects, we also utilized the JAK3 inhibitor tofacitinib, which should similarly inhibit 
IL7R signaling, and the JAK2 inhibitor CHZ868, which should not inhibit IL7R signaling. In this 
analysis, tofacitinib phenocopied the effects of RUX to overcome IL7-induced DEX resistance 
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while CHZ868 had no effect on cell viability (Supplemental Figure 5-1C), suggesting that on-
target inhibition of JAK1 or JAK3 is sufficient to abrogate IL7-induced DEX resistance. 
 
Dexamethasone exposure augments IL7R/JAK/STAT5 pathway activity 
 
 To confirm that IL7 induces DEX resistance in CCRF-CEM cells via signaling through 
IL7R, we first used CRISPR/Cas9 genome editing to generate clonal populations of scramble 
control and IL7Ra knockout (KO) CCRF-CEM cells (Supplemental Figure 5-2A). In the KO 
clones, loss of IL7Ra expression was sufficient to restore DEX sensitivity in the presence of IL7 
(Figure 5-2A). We next asked whether IL7R signaling interferes with the activation and/or 
function of GR. First, to determine whether exposure to IL7 alters the availability of GR for DEX 
binding, we assessed GR protein expression in CCRF-CEM cells treated with DEX with or 
without IL7. Under these conditions, DEX exposure effectively induced GR expression to 
comparable levels regardless of the presence of IL7 (Supplemental Figure 5-2B). Furthermore, 
upon exposure to DEX both in the absence and presence of IL7, GR effectively translocated to 
the nucleus and became phosphorylated on Ser211 (Supplemental Figure 5-2C), a modification 
that has been shown to correlate with the capacity to activate or repress transcription (292). 
Finally, to determine whether IL7 interferes with induction of the GR transcriptional program, we 
performed RNA sequencing (RNA-seq) on four scramble control CCRF-CEM cell clones 
exposed to vehicle control or DEX with or without IL7 for four hours to elucidate primary GR 
target genes. Under these conditions, IL7 did not interfere with GR-mediated transcript induction 
or repression (Supplemental Figure 5-2D and Supplemental Table 5-1). Taken together, these 
data suggest that GR activity remains intact in the presence of IL7.   
 In some mature T-cell populations, GCs have been shown to induce expression of 
IL7Ra (293–296). Specifically, chromatin immunoprecipitation (ChIP) studies in both murine 
(297) and human (298) lymphocytes have demonstrated that GR is recruited to a GR binding 
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motif in a noncoding sequence upstream of the IL7Ra promoter, and deletion of this region is 
sufficient to abrogate GR-induced upregulation of IL7Ra (293), suggesting that IL7Ra 
upregulation occurs as a direct transcriptional effect of activated GR. To determine if DEX 
modulates IL7Ra expression in CCRF-CEM cells, we measured IL7RA transcript before and 
after DEX exposure and found a time-dependent increase in IL7RA transcript expression 
(Figure 5-2B) that occurred both in the absence and presence of IL7 (Supplemental Figure 5-
2E). DEX exposure also increased IL7Ra protein expression at the cell surface relative to 
untreated cells (p<0.0001). This increase was inhibited in the presence of the translation 
inhibitor cycloheximide (CHX), suggesting that the increase in cell surface IL7Ra reflects de 
novo protein synthesis rather than re-localization of existing protein (Figure 5-2C). Given our 
finding that inhibition of JAK signaling is sufficient to sensitize cells to DEX in the presence of 
IL7, we next asked whether the increase in cell surface IL7Ra expression is associated with an 
increased capacity for JAK signaling downstream of IL7R. We first exposed CCRF-CEM cells to 
DEX for 24 hours, then stimulated them with IL7 and measured the induction of phosphorylated 
STAT5 (pSTAT5) as a downstream effector of JAK signaling (Supplemental Figure 5-2F). Under 
these conditions, DEX exposure resulted in significantly more robust pSTAT5 induction in 
response to IL7 stimulation relative to untreated cells (p=0.0002). Furthermore, pre-treating 
these cells with RUX for one hour prior to IL7 stimulation was sufficient to abrogate the 
increased JAK/STAT5 signaling following DEX exposure (Figure 5-2D and Supplemental Figure 
5-2G). Importantly, IL7 stimulation, either with or without DEX pre-treatment, did not induce 
phosphorylation of other STAT proteins that are activated downstream of other g chain cytokine 
receptors (Supplemental Figure 5-2H). Given this specific increase in STAT5 activation upon 
IL7 stimulation following DEX exposure, we then asked whether the increase in IL7Ra 
expression is associated with a sustained increase in STAT5 transcriptional activity. To test this, 
we transiently transfected CCRF-CEM cells with a STAT5-luciferase reporter construct and 
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assessed STAT5-induced luciferase activity in cells exposed to DEX in the presence or absence 
of IL7 for 36 hours. This analysis revealed a significant induction of STAT5 transcriptional 
activity in cells exposed to the combination of DEX and IL7 relative to either DEX or IL7 alone 
(p<0.0001 versus both DEX alone and IL7 alone). Furthermore, the addition of RUX was 
sufficient to overcome this increase in transcriptional activity (Figure 5-2E). To further confirm 
this increase in STAT5 transcriptional output, we performed RNA-seq on scramble control 
CCRF-CEM cell clones treated with DEX with or without IL7 for four hours. Using gene set 
enrichment analysis (GSEA) with gene sets derived from published STAT5 ChIP with 
sequencing (ChIP-seq) data in human CD4+ T-cells (299), we found enrichment for 
transcriptional targets of STAT5A and STAT5B (p<0.0001; FDR<0.0001), STAT5A alone 
(p=0.002; false discovery rate (FDR)=0.001), and STAT5B alone (p<0.0001; FDR=0.001) in 
cells exposed to DEX plus IL7 relative to IL7 alone (Figure 5-2F and Supplemental Table 5-2), 
further supporting the finding that, in the presence of IL7, DEX exposure augments activation of 
the STAT5 transcriptional program. 
 
BCL-2 is a critical mediator of IL7-induced dexamethasone resistance 
 
 Based on these findings, we hypothesized that STAT5 may be an important downstream 
mediator of DEX resistance in the presence of IL7. To directly interrogate the role of STAT5 in 
this context, we used CRISPR/Cas9 genome editing to generate clonal populations of STAT5A 
KO, STAT5B KO, and STAT5A/B double KO CCRF-CEM cells (Figure 5-3A). Importantly, 
deletion of one or both STAT5 isoforms did not affect expression of GR relative to scramble 
control clones (Supplemental Figure 5-3A). Exposure of STAT5 KO cells to DEX in the 
presence or absence of IL7 revealed that deletion of STAT5B, but not of STAT5A, was sufficient 
to significantly attenuate DEX resistance in the presence of IL7 (Figure 5-3B and Supplemental 
Figure 5-3B). These data suggest that transcriptional targets of STAT5B represent candidate 
DEX resistance genes. To identify these candidate genes, we performed RNA-seq on scramble 
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control and STAT5A/B KO CCRF-CEM cell clones treated with DEX with or without IL7 for 
sixteen hours. Using these data, we found that deletion of STAT5A/B did not affect the capacity 
for DEX-induced upregulation of IL7RA (Supplemental Figure 5-3C), further confirming that 
IL7R upregulation is a GR-dependent but STAT5-independent transcriptional event. Using 
differential expression analysis, we identified the top differentially expressed genes between 
scramble control cells treated with DEX alone or with the combination of DEX and IL7 
(Supplemental Table 5-3). We then compared this gene list to the core enrichment genes from 
the STAT5B gene set (Figure 5-2F and Supplemental Table 5-2) to identify STAT5B target 
genes that are differentially expressed in cells exposed to DEX relative to the combination of 
DEX and IL7. This analysis identified the anti-apoptotic family member BCL2 (log fold change = 
1.48 for DEX+IL7 relative to DEX alone) and the Rho guanine nucleotide exchange factor 
ARHGEF3 (log fold change = 1.64) as two candidate mediators of DEX resistance in the 
presence of IL7 (Figure 5-3C). Consistent with their presence on both of these gene lists, 
targeted analysis of the RNA-seq data revealed that these genes were induced by the 
combination of DEX and IL7 relative to DEX or IL7 alone only in the scramble control clones and 
not in the STAT5A/B KO clones (Figures 5-3D-E).   
 Given the anti-apoptotic function of BCL-2 and the importance of downregulation of BCL-
2 for DEX-induced apoptosis in T-ALL cells (18), we focused subsequent analyses on BCL-2 
expression and function. Interestingly, other anti-apoptotic BCL-2 family members were not 
regulated in a similar manner in response to DEX and IL7 (Supplemental Figure 5-3D), 
suggesting a BCL-2-specific effect. To determine whether the induction of BCL-2 expression 
upon exposure to DEX and IL7 is mediated specifically by STAT5B, we assessed BCL-2 protein 
expression in scramble control and STAT5 single and double KO CCRF-CEM cell clones. This 
analysis revealed upregulation of BCL-2 with the combination of DEX and IL7 in scramble 
control and STAT5A single KO clones, but not in either the STAT5B single KO or STAT5A/B 
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double KO clones, consistent with a central role for STAT5B in the regulation of BCL-2 
expression (Figure 5-3F and Supplemental Figure 5-3E).  
 Given that this increased STAT5 transcriptional activity depends first on the upregulation 
of IL7Ra as a primary transcriptional target of GR, we reasoned that STAT5-mediated 
upregulation of BCL-2 must occur as a secondary transcriptional effect following exposure to 
DEX and IL7. To test this, we performed qPCR to measure the changes in expression over time 
of BCL2 and of primary GR target genes in CCRF-CEM cells cultured in the presence of DEX 
and IL7. This analysis revealed that while primary GR transcriptional targets are upregulated as 
early as two hours following DEX treatment, BCL2 is not significantly upregulated until the eight-
hour time point (Supplemental Figure 5-3F). To further confirm that BCL2 is upregulated as a 
secondary transcriptional target, we exposed CCRF-CEM cells to DEX with or without IL7 in the 
presence or absence of CHX and measured transcript and protein expression of BCL2 and of 
the primary GR transcriptional target BCL2L11 (BIM) (18). CHX was sufficient to inhibit the 
upregulation of BIM and BCL-2 protein expression, suggesting effective inhibition of translation 
and de novo protein synthesis (Supplemental Figure 5-3G). BCL2L11 transcript expression was 
induced by DEX both in the absence and presence of CHX, consistent with this being a primary 
transcriptional target of GR, the upregulation of which is not dependent on intermediary de novo 
protein synthesis. In contrast, BCL2 transcript expression was upregulated only in the absence 
of CHX, suggesting a dependence on de novo protein synthesis, consistent with this being a 
secondary transcriptional event (Figure 5-3G).  
 To establish the functional significance of BCL-2 upregulation, we first performed BH3 
profiling with the BCL-2 inhibitor ABT-199 in CCRF-CEM cells treated with DEX with or without 
IL7. Under these conditions, DEX alone produced a significant increase in apoptotic priming 
(p=0.0007). This effect was attenuated in the presence of IL7 (p=0.64), suggesting that the 
increase in BCL-2 expression with the combination of DEX and IL7 is sufficient to oppose the 
induction of the apoptotic program (Figure 5-4A). To determine whether ABT-199 may have a 
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therapeutic role to enhance DEX sensitivity in the presence of IL7, we exposed CCRF-CEM 
cells to DEX in the presence of IL7 and increasing concentrations of ABT-199. This analysis 
demonstrated that ABT-199 potently sensitizes cells to DEX in the presence of IL7 in a 
synergistic manner (Figures 5-4B-C). In addition, we utilized a series of short hairpin RNAs 
(shRNAs) to knock down BCL-2 expression in CCRF-CEM cells and found that loss of BCL-2 
expression increases sensitivity to DEX in the presence of IL7 in a manner that correlates with 
the degree of BCL-2 knockdown (Supplemental Figure 5-4A and Figures 5-4D-E). To assess 
the importance of high BCL-2 expression in a patient cohort for which clinical outcome data are 
available, we next analyzed published gene expression data from 265 diagnostic T-ALL 
samples obtained from patients enrolled on the prior COG T-ALL trial AALL0434 (282). 
Consistent with our in vitro findings, we found that patients who were minimal residual disease 
(MRD) positive at the end of induction therapy had significantly higher BCL-2 expression relative 
to patients who were MRD negative (p=0.0009 for patients with MRD <1% and p<0.0001 for 
patients with MRD >1%; Figure 5-4F), suggesting a relationship between high BCL-2 
expression and relative GC resistance. In contrast, shRNA-mediated knockdown of the other 
candidate resistance gene, ARHGEF3, had no effect to overcome IL7-induced DEX resistance 
(Supplemental Figures 5-4B-C) and ARHGEF3 expression did not differ according to MRD 
status in the AALL0434 patient cohort (Supplemental Figure 5-4D). Taken together, these data 
support a model (Figure 5-4G) whereby DEX (i), through upregulating IL7Ra expression (ii), 
paradoxically induces its own resistance by augmenting JAK/STAT5 signaling (iii) and activation 
of STAT5B target genes (iv), including BCL2. This upregulation of BCL-2 in turn is sufficient to 
antagonize the pro-apoptotic effects of DEX. 
 
IL7 induces dexamethasone resistance in subsets of developing thymocytes   
 
 We next sought to determine why IL7-mediated DEX resistance occurs only in a subset 
of primary patient T-ALL samples. In our previous patient cohort, we demonstrated that 64% of 
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samples with IL7-mediated DEX resistance did not have activating mutations in the 
IL7R/JAK/STAT5 pathway (132), suggesting that this phenotype is not dictated by the 
mutational status of a T-ALL sample. Given these findings, an alternative hypothesis is that IL7-
mediated DEX resistance might reflect a physiologic mechanism of GC resistance that occurs in 
normal populations of developing thymocytes, as both GC sensitivity and IL7R expression are 
known to vary throughout development (4,300). To test this hypothesis, we evaluated normal 
murine thymocytes to determine if IL7R/JAK/STAT5 signaling modulates DEX sensitivity. We 
first exposed mice to DEX in vivo and assessed the relative sensitivity of the major thymocyte 
subpopulations. In this analysis, DEX induced a significant reduction in overall thymic cellularity 
(p=0.02; Supplemental Figure 5-5A) and resulted in a dramatic shift in the distribution of the 
major thymocyte subpopulations. Consistent with previous reports (300), we found that DEX 
induced a significant reduction in the proportion of CD4/CD8 double positive (DP) thymocytes 
(p<0.0001), with a compensatory increase in the percentage of the earlier double negative (DN) 
thymocytes (p=0.005) and later single positive (SP) thymocytes (p<0.0001 for both CD4 and 
CD8 SP thymocytes; Figure 5-5A and Supplemental Figures 5-5B-C). Importantly, we 
recapitulated the findings by other investigators (301) that GR expression is paradoxically 
lowest at the DP stage of development despite these cells being highly DEX sensitive, 
suggesting that GR expression is insufficient to explain this pattern of differential sensitivity 
(Supplemental Figure 5-5D). To determine if this differential DEX sensitivity reflects differences 
in the apoptotic potential of these thymocyte subpopulations in their basal state, we performed 
BH3 profiling on freshly harvested thymocytes. We found that DP thymocytes have significantly 
higher apoptotic potential relative to DN or SP thymocytes (p=0.002, p=0.0004, and p=0.01 
versus DN, CD4 SP, and CD8 SP thymocytes, respectively; Figure 5-5B), consistent with the 
pattern of DEX sensitivity observed in vivo.  
 We next evaluated basal IL7Ra expression and signaling capacity across the major 
thymocyte subpopulations. Consistent with previous reports (4), we found a reduction in IL7Ra 
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expression and IL7-induced pSTAT5 in the DP thymocytes relative to the DN and SP 
thymocytes (Figures 5-5C-D). Based on these findings and the pattern of DEX sensitivity we 
observed in vivo, we hypothesized that the presence of IL7 in the in vivo microenvironment 
might activate JAK/STAT5 signaling in DN and SP thymocytes, which could in turn confer 
protection against the GC surges that occur during a physiologic stress response (302) and 
against pharmacologic concentrations of GCs. To test this hypothesis, we first exposed 
thymocytes to vehicle or DEX ex vivo in the absence or presence of increasing concentrations 
of IL7. DN and SP thymocytes demonstrated profound DEX resistance specifically in the 
presence of IL7, while DP thymocytes remained highly sensitive to DEX regardless of IL7 
(Figure 5-5E), consistent with their reduced IL7Ra expression (Figure 5-5C). To determine 
whether the mechanism of JAK/STAT5-mediated DEX resistance that we elucidated in CCRF-
CEM cells is applicable in these thymocyte subpopulations, we exposed thymocytes to DEX ex 
vivo and assessed cell surface IL7Ra expression and BCL-2 expression. Consistent with the 
observed pattern of DEX resistance in the presence of IL7, DN and SP thymocytes significantly 
upregulated both IL7Ra expression (p<0.0001 for DN, CD4 SP and CD8 SP thymocytes; Figure 
5-5F) and BCL-2 expression (p=0.01, p=0.0005, and p=0.001 for DN, CD4 SP, and CD8 SP 
thymocytes, respectively; Figure 5-5G) following exposure to DEX in the presence of IL7. 
Finally, to determine if this mechanism is applicable in vivo under normal physiologic conditions, 
we treated mice with DEX and assessed BCL-2 protein expression in the major thymocyte 
subpopulations. DN and CD4 SP thymocytes, but not DP thymocytes, significantly upregulated 
BCL-2 expression in response to DEX (p=0.007 and p=0.004 for DN and CD4 SP thymocytes, 
respectively; Figure 5-5H). Finally, to determine whether human thymocytes demonstrate a 
similar pattern of IL7Ra expression and IL7-induced DEX resistance throughout development, 
we performed ex vivo analysis of healthy human thymocytes. Similar to the pattern observed in 
murine thymocytes, DN and SP thymocytes had the most significant increase in cell surface 
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IL7Ra expression following exposure to DEX (Supplemental Figure 5-5E) and had the most 
profound IL7-induced DEX resistance (Supplemental Figure 5-5F). 
 
Developmental stage correlates with IL7-induced dexamethasone resistance in T-ALL 
 
 To further address the hypothesis that IL7R/JAK/STAT5-mediated DEX resistance may 
be retained from normal thymocyte development in a subset of T-ALLs, we performed RNA-seq 
on 76 primary diagnostic T-ALL samples from patients enrolled on COG AALL1231. Using a 
gene set derived from a comparison of early versus late developing thymocytes (303), we 
performed unbiased hierarchical clustering of these patient samples to classify samples as 
developmentally “early” or “late” (Figure 5-6A). We next performed detailed in vitro analysis of 
15 of the early T-ALL samples and 12 of the late T-ALL samples isolated from patient derived 
xenografts (PDXs). Additional information about these samples is presented in Supplemental 
Table 5-4. There were no differences in basal GR expression between these two groups 
(Supplemental Figure 5-6A). Upon analysis of cell surface IL7Ra expression, we found that the 
early samples tended to have higher basal IL7Ra expression and a more robust induction of 
IL7Ra upon exposure to DEX (Figure 5-6B). This higher basal IL7Ra expression was also 
associated with an increased response to IL7 stimulation, as measured by pSTAT5 
(Supplemental Figure 5-6B). Consistent with this finding, only the early sample group 
demonstrated a significant increase in DEX resistance in the presence of IL7 (p=0.0007 and 
p=0.69 for early and late samples, respectively; Figure 5-6C). To determine whether this 
resistance phenotype was associated with activating mutations in the IL7R/JAK/STAT pathway, 
we performed variant calling using the RNA-seq data and found no enrichment for IL7R 
pathway mutations in the early samples (Supplemental Figure 5-6C and Supplemental Table 5-
5), consistent with our previous analysis (132). Similar to the findings in CCRF-CEM cells, these 
early samples demonstrated an increase in BCL-2 protein expression in the presence of IL7, 
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which was further augmented upon concomitant exposure to DEX and attenuated with the 
addition of RUX (Figure 5-6D). Moreover, both RUX and ABT-199 significantly sensitized early 
T-ALL samples to DEX in the presence of IL7 (p<0.0001 and p=0.0005 for the addition of RUX 
or ABT-199, respectively, to DEX plus IL7; Figure 5-6E). To evaluate the utility of RUX for 
overcoming DEX resistance in vivo in a preclinical model, we transplanted mice with early T-
ALL T24 and treated them with DEX with or without RUX, using survival as the primary 
endpoint. As we observed in vitro (Supplemental Figure 5-6D), the combination of DEX and 
RUX demonstrated increased in vivo efficacy relative to either agent alone (p=0.003 for RUX 
versus DEX+RUX and p=0.02 for DEX versus DEX+RUX; Figure 5-6F).   
 
5.4: Discussion 
 
 The poor survival rates observed in children with relapsed T-ALL (284) suggest a need 
for strategies to enhance the efficacy of upfront therapy as a means of improving cure rates by 
decreasing the likelihood of disease relapse. While many studies have focused on 
understanding mechanisms of acquired drug resistance that arise during T-ALL treatment (304), 
the goal of our current study was instead to elucidate mechanisms of intrinsic drug resistance 
that dictate the initial response to therapy. In particular, the prognostic significance of the initial 
GC response in T-ALL (285) suggests a need for a deeper understanding of the mechanisms 
governing intrinsic differences in GC sensitivity. Here we demonstrate that functional analysis of 
a large number of diagnostic patient samples reveals recurrent patterns of intrinsic GC 
resistance across this otherwise genetically heterogeneous patient population. We confirm in 
this validation cohort that over half of the diagnostic T-ALL samples analyzed exhibit intrinsic 
DEX resistance in vitro, which has in turn been shown to correlate with clinical outcomes (305). 
Furthermore, we show that within this subset, half of the samples are resistant to DEX 
specifically in the presence of IL7. 
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  Our data support a model whereby GCs paradoxically induce their own resistance by 
upregulating IL7Ra expression. In the presence of IL7, this leads to increased downstream 
signal transduction and STAT5 transcriptional output. This ultimately results in the upregulation 
of BCL-2, which is sufficient to counteract the pro-apoptotic effect of DEX. Given the prevalence 
of this phenotype, our data suggest that a significant percentage of T-ALL patients may benefit 
from the upfront addition of JAK or BCL-2 inhibitors as a means of improving the efficacy of GC 
therapy. Furthermore, we demonstrate the synergistic potential of combining DEX with these 
agents, suggesting that combination therapy may allow for a reduction in DEX dosing, thereby 
minimizing the numerous acute and chronic toxicities associated with steroid exposure (306) 
while simultaneously maximizing efficacy. In addition, our data demonstrate that STAT5B is 
primarily responsible for the upregulation of BCL-2 expression in this context, consistent with 
previous reports demonstrating that knockdown of STAT5A is insufficient to modulate IL7-
mediated regulation of BCL-2 expression (289). Interestingly, this is also consistent with the 
finding that activating mutations in STAT5B, but not in STAT5A, commonly occur in T-ALL 
(282). These data support further investigation of the use of ABT-199 as a rational therapeutic 
strategy to enhance the efficacy of DEX in patients with STAT5B-mutated T-ALL.   
 In addition to mediating GC resistance in over one-third of diagnostic T-ALL samples, we 
demonstrate that IL7 similarly induces GC resistance in those populations of normal thymocytes 
in which IL7R signaling is important for survival and proliferation (4). Developing thymocytes are 
continuously exposed to endogenous GCs, but we and others (300) demonstrate that 
susceptibility to GC-induced apoptosis is variable over the course of thymocyte development. 
These data suggest that normal thymocyte populations must possess intrinsic mechanisms of 
GC resistance at distinct stages of development and/or under certain environmental conditions. 
In particular, we find that IL7-induced DEX resistance occurs in DN thymocytes and is enriched 
in T-ALL samples with an “early thymocyte” gene expression signature. Importantly, these early 
thymocytes undergo gene rearrangement to generate a fully rearranged TCR, which will be 
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tested for functionality and auto-reactivity in the subsequent DP stage, a key process in the 
generation of mature functional T-cells (4). Teleologically, susceptibility to GC-induced 
apoptosis would be maladaptive early in development, as it would limit the availability of cells for 
this selection process. Our data therefore suggest that IL7-induced GC resistance may protect 
these early thymocyte populations from apoptosis in the presence of endogenous GCs. 
Furthermore, we demonstrate that this mechanism of intrinsic resistance is retained in T-ALLs 
resembling early thymocytes, where it may be exploited to enable resistance to pharmacologic 
concentrations of GCs.   
 Taken together, our data provide strong rationale for the idea that differential sensitivity 
to GC therapy at the time of disease diagnosis reflects developmentally programmed 
mechanisms of intrinsic GC resistance that are retained during the process of leukemogenesis. 
This work supports further studies aimed at elucidating additional mechanisms of GC resistance 
at distinct stages of thymocyte development as a means of understanding the factors that 
contribute to intrinsic GC resistance in T-ALL.  
 
5.5: Methods 
 
Patient samples and patient derived xenografts 
 Diagnostic blood samples were obtained from patients enrolled on the COG trial 
AALL1231. Immunophenotyping was performed and reviewed by immunophenotyping experts 
in COG. To establish patient derived xenografts, cells were injected into NOD/SCID/Il2rgtm1wjl/Szj 
(NSG) mice obtained from Jackson Laboratories. Engraftment was monitored using flow 
cytometric analysis of peripheral blood with antibodies against human CD45 (BD Biosciences; 
560973) and CD7 (BioLegend; 343105).  
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CCRF-CEM cells 
 CCRF-CEM cells were purchased from the UCSF Cell Culture Facility (ATCC CCL-119). 
Cells were authenticated via short tandem repeat DNA profiling and were routinely tested for 
mycoplasma contamination using the PlasmoTest detection kit (InvivoGen).   
  
Preclinical trial 
 Five five-week-old male NSG mice per treatment arm were randomized to receive 
vehicle control, DEX, RUX, or the combination of DEX and RUX once the peripheral blood blast 
count reached 1%. RUX was administered in chow form (Incyte) continuously over the trial 
duration. DEX (Fresenius Kabi and Children’s Hospital of Philadelphia Pharmacy) was 
administered at 7.5mg/kg/day by intraperitoneal injection. Mice were euthanized when they 
became moribund.  
 
In vivo dexamethasone treatment in C57BL/6x129Sv/Jae mice and isolation of human and 
murine thymocytes 
 Six to eight-week-old male F1 C57BL/6x129Sv/Jae mice were obtained from the 
University of California, San Francisco Laboratory Animal Resource Center (LARC) breeding 
core. Mice were treated with 2mg/kg dexamethasone sodium phosphate (NDC 63323-516-10; 
University of California, San Francisco pharmacy) or vehicle control (phosphate buffered saline) 
once daily for three days. Healthy human thymocytes were obtained from children undergoing 
cardiothoracic surgery at the University of California, San Francisco. Antibodies against murine 
CD4 (BioLegend; 100425) and CD8 (BioLegend; 100707) or human CD4 (Biolegend; 317420) 
or CD8 (BioLegend; 344706) were used to identify thymocyte subpopulations.  
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In vitro viability assays 
 In vitro viability assays were performed by exposing cells to vehicle control or 
dexamethasone (Sigma; D4902), ruxolitinib (Selleckchem; S1378), tofacitinib (Selleckchem; 
S5001), CHZ868 (MedKoo; 407137), or ABT-199 (ApexBio; A8194) for 72 hours (CCRF-CEM 
cells), 48 hours (PDX cells), or 24 hours (thymocytes) with or without recombinant human or 
murine IL7 (Peprotech; 200-07 and 217-17). Cells were then stained with Hoechst 33258 
(Molecular Probes; H3569) and analyzed by flow cytometry.  
 
CRISPR/Cas9 genome editing of CCRF/CEM cells 
  Cas9 protein containing a nuclear localization signal (Cas9-NLS) was purchased from 
the QB3 MacroLab at the University of California, Berkeley. Trans-activating CRISPR RNA 
(tracrRNA) and single guide RNAs (sgRNAs) were purchased from Dharmacon. sgRNA 
sequences targeting IL7Ra, STAT5A, and STAT5B were obtained from the Brunello sgRNA 
library (307) and are as follows: IL7Ra – AAAGAGCAATATATGTGTGA; STAT5A – 
ACATTCTGTACAATGAACAG; STAT5B – GTTCATTGTACAATATATGG. The scramble control 
cells were generated using a non-targeting sgRNA: GGTTCTTGACTACCGTAATT.  
 Ribonucleoproteins were prepared according to established methods (308). 
Electroporation was performed using the Amaxa Cell Line Nucleofector Kit C (Lonza, VACA-
1004) and an Amaxa Nucleofector II Device with the electroporation code X-001. Editing was 
assessed by PCR amplification using the following primers: IL7Ra forward – 5’-
TGAACATGCCTCCACTCACC-3’; IL7Ra reverse – 5’-CACACCTGGGTTTGAAGATCC-3’; 
STAT5A forward – 5’- TGGGGATAGTTCCTGAGGCT-3’; STAT5A reverse – 5’ 
TGCCACCTCTTACACTTGCC-3’; STAT5B forward – 5’- TGTGCCCCTTAGGATGAAGC-3’; 
STAT5B reverse – 5’- AATCACAGGAGGCACTGTTCC-3’. The amplicons were Sanger 
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sequenced and the sequencing traces were analyzed using the TIDE analysis software (309). 
Clonal populations were generated using limiting dilution cell plating. 
   
Western blotting 
 For analysis of protein expression in whole cell lysates, CCRF-CEM cells were 
resuspended in RIPA buffer. For analysis of cytoplasmic and nuclear protein, protein fractions 
were generated using the NE-PER kit (ThermoFisher Scientific; 78833). Immunoblotting was 
performed with the following antibodies: STAT5A (Abcam; ab32043), STAT5B (Abcam; 
ab178941), GR (Cell Signaling Technology; 12041), GR pS211 (Cell Signaling Technology; 
4161), b-actin (Cell Signaling Technology; 3700), and p84 (Genetex; GTX70220). Donkey anti-
rabbit IRDye800 and donkey anti-mouse IRDye680 secondary antibodies (LI-COR Biosciences) 
were used and imaging was performed using the Odyssey Imaging System (LI-COR 
Biosciences).  
 
Quantitative PCR (qPCR) 
 CCRF-CEM cells were cultured in the presence or absence of 1µM DEX, 100ng/mL IL7, 
and/or 10µg/mL cycloheximide for 16 hours unless otherwise indicated. RNA was isolated using 
the RNeasy Mini Kit (Qiagen) and cDNA was generated using the Superscript III kit 
(ThermoFisher Scientific). Taqman quantitative PCR probes (Applied Biosystems) were used in 
conjunction with Taqman Master Mix (Applied Biosystems) to assess transcript levels for the 
following genes: GAPDH (Hs02786624_g1; VIC-MGB), IL7Ra (Hs00902334_m1; FAM-MGB), 
BCL2L11 (Hs00708019_s1; FAM-MGB), BCL2 (Hs00608023_m1; FAM-MGB), FKBP5 
(Hs01561006_m1; FAM-MGB), GILZ (Hs00608272_m1; FAM-MGB), NR3C1 
(H200353740_m1; FAM-MGB), MYC (Hs00153408_m1; FAM-MGB), and ARHGEF3 
(Hs00989814_m1; FAM-MGB). Experiments were performed in technical triplicate and were run 
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on a QuantStudio 5 Real-Time PCR Instrument (Applied Biosystems). The fold change in 
transcript expression was calculated relative to cells treated with vehicle control using the delta-
delta Ct method, unless otherwise indicated, with the use of GAPDH transcript for normalization. 
 
Measurement of cell surface IL7Ra 
 For analysis of cell surface IL7Ra expression, cells were treated with 1µM DEX for 24 
hours. Murine thymocyte experiments were performed in the presence of 100pg/mL 
recombinant murine IL7. Antibodies against human (BioLegend; 351315) or murine (Tonbo 
Biosciences; 20-1271) IL7Ra were used in conjunction with Hoechst 33258 to allow for gating 
on viable cells. Data are presented as the median fluorescent intensity (MFI) of the IL7Ra 
signal. 
 
Cytokine stimulation and intracellular flow cytometry 
 Phosphoflow cytometry for measurement of STAT protein phosphorylation following IL7 
stimulation was performed as previously described (132). Briefly, CCRF-CEM cells were 
exposed to vehicle control or 1µM DEX for 24 hours, allowed to rest for one hour in serum free 
media, and stimulated with IL7 at a concentration of 100ng/mL for 15 minutes. PDX cells were 
similarly allowed to rest in serum free media for one hour followed by stimulation with 100ng/mL 
IL7 for 15 minutes. Cells were subsequently fixed with 2% paraformaldehyde and permeabilized 
with methanol. STAT protein phosphorylation was assessed using antibodies against pSTAT1 
pY701 (BD Biosciences; BDB612564), pSTAT3 pY705 (BD Biosciences; BDB612569), pSTAT5 
pY694 (BD Biosciences; BDB612599), and pSTAT6 pY641 (BD Biosciences; BDB612601). BIM 
and BCL-2 protein expression were assessed following cell fixation and permeabilization using 
antibodies against BIM (Cell Signaling Technology; 2933) and anti-human (Life Technologies; 
A15796) or anti-mouse (BioLegend; 633509) BCL-2. GR expression was assessed using an 
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anti-GR antibody. A donkey anti-rabbit secondary antibody (Jackson ImmunoResearch 
Laboratories) was used for flow cytometric detection of BIM and GR protein.  
 
Luciferase reporter assay 
 CCRF-CEM cells were transiently transfected with the pGL4.52[luc2P/STAT5 RE/hygro] 
vector (Promega; E4651) using the Lipofectamine 3000 Transfection Reagent (Life 
Technologies). Eighteen hours after transfection, cells were treated in the absence or presence 
of 1µM DEX, 100ng/mL recombinant human IL7, and/or 500nM ruxolitinib for 36 hours. 
Luciferase activity was assessed with the ONE-Glo Luciferase Assay System (Promega) and a 
Biotek Synergy 2 instrument. Relative luminescence was calculated by normalizing values to 
those obtained from cells treated with vehicle control.  
 
RNA-seq analysis 
 Scramble control and STAT5 knockout CCRF-CEM cell clones were cultured in vehicle 
control or in the presence or absence of 1µM DEX and/or 100ng/mL recombinant human IL7 for 
4 or 16 hours. RNA was isolated using the RNeasy Mini Kit and cDNA was generated using the 
Superscript III kit and quantified using a NanoDrop spectrophotometer (ThermoFisher). RNA 
quality was assessed using an Agilent Bioanalyzer (Agilent Technologies). Libraries were 
prepared using 1ng of RNA and were sequenced on the HiSeq 2500 (Illumina) to generate 50bp 
single end reads.  
 GR regulated genes were identified using edgeR, as previously described (310), by 
comparing scramble control clones treated with vehicle to those treated with DEX for four hours. 
A gene set was created using the statistical thresholds of absolute log fold change >1 and false 
discovery rate (FDR) <0.05. This analysis was then applied to perform the same comparison 
between scramble control clones treated with vehicle versus DEX plus IL7 for four hours. For 
the analysis of STAT5 target genes, gene set enrichment analysis (GSEA) was performed as 
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previously described (311) by comparing scramble control clones treated with IL7 versus DEX 
plus IL7 using gene sets derived from published STAT5 ChIP-seq experiments in human CD4+ 
T-cells (299). The default settings were used for GSEA, including permutation based on 
phenotype. These data have been deposited in NCBI’s Gene Expression Omnibus and are 
accessible through GEO Series accession number GSE137893. 
 For the fresh diagnostic T-ALL samples, total RNA was prepared using Trizol 
(ThermoFisher) based extraction. Samples were purified and concentrated using the RNeasy 
Mini or RNeasy MinElute Kit alone with the DNase Set (Qiagen). RNA concentration was 
determined using a NanoDrop spectrophotometer. RNA quality was assessed using an Agilent 
2200 TapeStation (Agilent Technologies). 100ng of RNA was used to prepare libraries using the 
TruSeq RNA Exome RNA kit (Illumina). For RNA samples with DV200 below 30%, 200ng of total 
RNA was used to prepare libraries. Libraries were sequenced on a NextSeq 500 using 150bp 
paired-end chemistry. 
 Primary T-ALL cell transcript expression was calculated via a local software pipeline built 
around the Bowtie 2 Aligner (v2.3.4.1) and RSEM’s (v1.2.3.0) expectation-maximization 
quantification that utilized the Ensembl GRCh38 release 85 reference. After demultiplexing, 
converting primary sequence data to fastq format, and trimming adapters, sequences were 
aligned against an HG38 rRNA reference using the bwa (v0.7.12) aligner in order to screen out 
rRNA. Only non-rRNA aligning sequences advanced into the Bowtie 2/RSEM analysis stream. 
These data were used to generate gene signatures associated with early versus late thymocyte 
development via hierarchical clustering and dendrogram analysis.  
 All sequencing analysis, including read alignment, quality and performance metrics, 
post-processing, variant calling, and variant annotation were performed as previously described 
(312,313) using the hg38 build of the human genome. Briefly, reads were aligned with Burrows-
Wheeler Aligner (314) and processed using Picard (http://broadinstitute.github.io/picard) and the 
Genome Analysis Toolkit (GATK) (315) to perform base quality recalibration and multiple 
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sequence realignment. Single nucleotide variants and indels were detected with the MuTect 
(316) and BCFtools algorithms, respectively. Variants were negatively selected against based 
on IGSR SNP (317) and ExAC SNP (318) databases and positively selected for based on 
recurrently mutated sites or regions within COSMIC (Acute T Lymphoblastic Leukemia 
associated subset of mutations) (319) or as previously reported (282). Candidate somatic 
mutations were manually reviewed using Integrative Genomics Viewer (320). These data have 
been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series 
accession number GSE137768. 
 
BH3 profiling  
 BH3 profiling was performed according to established methods (321). CCRF-CEM cells 
were treated with or without 1µM DEX and/or 100ng/mL recombinant human IL7 for 16 hours 
prior to analysis. Thymocyte BH3 profiling was performed immediately after harvesting 
thymocytes. Cytochrome c staining was performed using an anti-cytochrome c antibody 
(BioLegend; 612310).  
 
shRNA-mediated knockdown of BCL2 and ARHGEF3 
 The miR30-PGK-NeoR-IRES-GFP cassette from LMN-GFP (307) was cloned into a 
pCDH Expression Lentivector (System Biosciences) to generate the construct pCDH-LMN-GFP. 
Short hairpin RNA (shRNA) sequences targeting human BCL2 are as follows: shBCL2-1 – 5’-
TTTTATTCCAATTCCTTTCGGA-3’; shBCL2-2 – 5’-TAGCTGATTTGAAACTTCCCAA-3’; 
shBCL2-3 – 5’-TACTTCATCACTATCTCCCGGT-3’; shBCL2-4 – 5’-
TTTAAGTACAGCATGATCCTCT-3’; and shBCL2-5 – 5’-TATCAGTCTACTTCCTCTGTGA-3’. 
shRNA sequences targeting human ARHGEF3 are as follows: shARHGEF3-1 – 5’-
TTTGATTCAACTCTTGTTCTGT-3’; shARHGEF3-2 – TATATCTTGTCACACAGCTTGA-3’; 
shARGHEF3-3 – TATAGCTTCTTCCAAGTGCTGC-3’. 97-mer oligonucleotides were generated 
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as previously described (322) and amplified using the following primers: forward – 5’- 
TACAATACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3’; reverse – 
ACTTAGAAGAATTCCGAGGCAGTAGGCA-3’. A non-targeting shRNA (shControl) sequence 
was used as a control:  5’-TAGATAAGCATTATAATTCCTA-3’. Oligonucleotides were cloned 
into the EcoRI and XhoI sites of pCDH-LMN-GFP and lentivirus was generated via calcium 
phosphate transfection of HEK293T cells using the packaging and envelope plasmids psPAX2 
and pCMV-VSVG. Viral supernatants were collected 48 hours after transfection and 
concentrated using Lenti-X Concentrator (Clontech). Following lentiviral transduction, GFP 
positive cells were sorted using a Sony SH800 instrument and subsequently expanded.  
 
Flow cytometry  
Flow cytometry was performed using a BD FACSVerse and data were analyzed using FlowJo 
software. 
 
Statistics 
 Statistical analyses were performed using Prism 8 (GraphPad). All tests were two-sided 
and the threshold for significance was p≤0.05. Comparisons between groups were made using 
t-tests, with one-way ANOVA and Tukey’s method for multiple comparisons adjustment for 
comparisons of three or more groups. For in vivo survival analysis, the log-rank test was used to 
perform pairwise comparisons between survival curves. Interactions between drugs were 
assessed using Bliss independence analysis (281). Error bars represent the standard error of 
the mean. 
 
Study Approval 
 Written informed consent for the use of diagnostic specimens for research was obtained 
from patients or their guardians at the time of sample collection, according to the Declaration of 
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Helsinki, the National Cancer Institute, and institutional review boards of participating sites. All 
animal experiments were conducted following protocols that were approved by the Institutional 
Animal Care and Use Committees and Institutional Review Boards of Children’s Hospital of 
Philadelphia or the University of California, San Francisco.  
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5.7: Figures 
 
 
Figure 5-1: JAK/STAT inhibition overcomes DEX resistance in a subset of primary T-ALL 
samples and in the T-ALL cell line CCRF-CEM. (A) Viability relative to vehicle control of cells 
from 73 primary diagnostic T-ALL samples exposed to 2.5µM DEX for 48 hours in the presence 
of 25ng/mL IL7. The red line indicates the 50% viability cutoff used to define “DEX resistant”. (B) 
Viability relative to vehicle control of cells from the 46 DEX resistant primary diagnostic T-ALL 
samples in (A) exposed to 2.5µM DEX and/or 0.5µM RUX for 48 hours in the presence of 
25ng/mL IL7. Statistical significance was assessed using one-way ANOVA with Tukey’s method 
for multiple comparisons adjustment. (C) Viability of CCRF-CEM cells exposed to DEX in the 
absence or presence of increasing concentrations of IL7 for 72 hours in technical triplicate. (D) 
Viability of CCRF-CEM cells exposed to DEX in the presence of 25ng/mL IL7 in the absence or 
presence of increasing concentrations of RUX in technical triplicate. The no IL7 (black line) and 
the 25ng/mL IL7 (red line) conditions are re-plotted from figure 5-1C. (E) Heatmap of Bliss 
independence scores calculated as the average of technical triplicates for the combination of 
DEX and RUX in CCRF-CEM cells cultured in the presence of 25ng/mL IL7 for 72 hours, in 
which positive values, indicated in red, are indicative of a synergistic interaction. All CCRF-CEM 
cell data are representative of three independent experiments. ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05. 
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Figure 5-2: DEX exposure augments IL7R expression and downstream JAK/STAT 
signaling. (A) Viability of scramble control (S1 and S2; left) and IL7R KO (I1 and I2; right) 
CCRF-CEM cell clones exposed to DEX in the absence (solid lines) or presence (dotted lines) 
of 25ng/mL IL7 in technical triplicate for 72 hours. (B) Fold change relative to the 16 hour time 
point of the DCt of IL7RA transcript relative to GAPDH as determined by qPCR performed in 
technical triplicate in CCRF-CEM cells exposed to 1µM DEX and 100ng/mL IL7 for the indicated 
period of time. (C) MFI of IL7Ra in CCRF-CEM cells treated with or without 1µM DEX and/or 
10µg/mL CHX in technical triplicate for 24 hours. Inset shows representative histograms of 
IL7Ra in CCRF-CEM cells treated with or without 1µM DEX and/or 10µg/mL CHX for 24 hours. 
(D) MFI of pSTAT5 in CCRF-CEM cells treated with or without 1µM DEX for 24 hours in the 
absence of IL7 followed by a one-hour exposure to vehicle control or RUX prior to a 15-minute 
stimulation with 100ng/mL IL7 in technical triplicate. Significance is relative to the DEX-treated 
condition in the absence of IL7 stimulation. (E) Relative luminescence of CCRF-CEM cells 
transfected with the STAT5 reporter construct and treated with or without 1µM DEX, 100ng/mL 
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IL7, and 500nM RUX in technical triplicate for 36 hours prior to lysis and measurement of 
luciferase activity. (F) GSEA plots of STAT5 gene expression signatures comparing scramble 
control clones (n=4) treated with 100ng/mL IL7 versus the combination of 1µM DEX and 
100ng/mL IL7 for 16 hours. Statistical significance was assessed using one-way ANOVA with 
Tukey’s method for multiple comparisons adjustment (B-E). With the exception of the RNA-seq 
experiment, all data are representative of three independent experiments. ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
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Figure 5-3: STAT5B, but not STAT5A, mediates the upregulation of BCL-2 expression in 
cells exposed to the combination of DEX and IL7. (A) Evaluation of STAT5A and STAT5B 
expression by Western blot in independent scramble control (S) and STAT5 single (A or B) and 
double (AB) KO CCRF-CEM cell clones (n=4 per genotype). (B) Viability of independent 
scramble control and STAT5 KO CCRF-CEM cell clones (n=4 per genotype) treated with 100nM 
DEX with or without 25ng/mL IL7 for 72 hours. (C) Venn diagram depicting the overlap between 
the top differentially expressed genes between scramble control CCRF-CEM cell clones (n=4) 
treated with DEX versus DEX+IL7 and STAT5B target genes. (D-E) Fold change in the FPKM 
values for (D) BCL2 transcript and (E) ARHGEF3 transcript as determined by RNA-seq analysis 
of scramble control (n=4) and STAT5A/B double KO (n=4) CCRF-CEM cell clones treated in the 
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absence or presence of 100ng/mL IL7 and/or 1µM DEX for 16 hours. (F) DMFI of BCL-2 protein 
expression in scramble control (n=4) and STAT5 KO (n=4) CCRF-CEM cell clones treated with 
100ng/mL IL7 and 1µM DEX relative to 100ng/mL IL7 alone for 48 hours. (G) BCL2L11 and 
BCL2 transcript expression in CCRF-CEM cells cultured in the absence or presence of 1µM 
DEX, 100ng/mL IL7, and/or 10µg/mL CHX for 16 hours as determined by qPCR performed in 
technical triplicate. Statistical significance was assessed using a paired t-test (B), two-sample t-
tests (D and E), or one-way ANOVA with Tukey’s method for multiple comparisons adjustment 
(F and G). With the exception of the RNA-seq experiment, all data are representative of three 
independent experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
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Figure 5-4: BCL-2 mediates IL7-induced DEX resistance. (A) Percent priming of CCRF-CEM 
cells treated in the absence or presence of 1µM DEX and/or 100ng/mL IL7 in technical triplicate 
for 16 hours followed by BH3 profiling with 0.5µM ABT-199 for 90 minutes. (B) Viability of 
CCRF-CEM cells treated with DEX in the absence or presence of 25ng/mL IL7 and increasing 
concentrations of ABT-199 for 72 hours in technical triplicate. The no IL7 (black line) and the 
25ng/mL IL7 (red line) conditions are re-plotted from figure 5-1C.  (C) Heatmap of Bliss 
independence scores calculated as the average of technical triplicates for the combination of 
DEX and ABT-199 in the presence of 25ng/mL IL7. (D) MFI of BCL-2 protein expression 
assessed in technical triplicate in untransduced CCRF-CEM cells and CCRF-CEM cells 
transduced with a non-targeting shRNA control (shControl) or a BCL2-targeting shRNA 
(shBCL2-1-5). Statistical significance is relative to the untransduced cells. (E) Viability of 
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untransduced or shRNA-transduced CCRF-CEM cells treated with DEX in the absence (left) or 
presence (right) of 25ng/mL IL7 in technical triplicate for 72 hours. (F) FPKM values for BCL2 
transcript obtained from published RNA-seq data from diagnostic samples from patients 
enrolled on COG AALL0434, stratified based on day 29 bone marrow MRD. (G) Schematic of 
the proposed model for the mechanism by which DEX paradoxically induces steroid resistance 
in T-ALL cells in the presence of IL7. In the presence of DEX (right), GR induces an increase in 
IL7R expression (i) leading to an increase in IL7R at the cell surface (ii). This in turn leads to an 
increase in STAT5 transcriptional activity (iii) that ultimately results in the upregulation of BCL-2 
(iv). Statistical significance was assessed using one-way ANOVA with Tukey’s method for 
multiple comparisons adjustment (A, D, and F). All CCRF-CEM cell data are representative of 
three independent experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – not 
significant. 
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Figure 5-5: IL7 induces DEX resistance in subpopulations of normal developing 
thymocytes. (A) Percentage of thymocyte subpopulations in thymi isolated from mice treated 
with vehicle control (n=3) or DEX (n=3) at 2mg/kg/day for three days. (B) Percent priming of 
thymocytes in the basal state following BH3 profiling with 1µM synthetic BIM peptide in technical 
triplicate for 90 minutes. (C) Histograms of the basal expression of IL7Ra in the major murine 
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thymocyte subpopulations. (D) Histograms of pSTAT5 in the major murine thymocyte 
subpopulations in the basal state (unfilled histograms) and following a 15-minute stimulation 
with 100ng/mL IL7 (filled histograms). (E) Viability of murine thymocyte subpopulations following 
ex vivo treatment for 24 hours with DEX in the absence or presence of increasing 
concentrations of IL7. (F) MFI of IL7Ra in murine thymocytes treated ex vivo in the presence of 
100pg/mL IL7 with or without 1µM DEX in technical triplicate for 24 hours. DP cells could not be 
analyzed due to lack of viable cells remaining after DEX exposure (not analyzed; N.A.). (G) MFI 
of BCL-2 in murine thymocytes treated ex vivo in the presence of 100pg/mL IL7 with or without 
1µM DEX in technical triplicate for 24 hours. DP cells could not be analyzed due to lack of viable 
cells remaining after DEX exposure (N.A.). (H) MFI of BCL-2 in thymocytes isolated from mice 
treated with vehicle control (n=3) or DEX (n=3) at 2mg/kg/day for three days. Statistical 
significance was assessed using two-sample t-tests (A, F, G, and H) or one-way ANOVA with 
Tukey’s method for multiple comparisons adjustment (B). All data are representative of three 
independent experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
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Figure 5-6: T-ALLs reflecting early stages of T-cell development demonstrate DEX 
resistance in the presence of IL7. (A) Heatmap depicting the clustering of 76 primary T-ALL 
samples by expression of genes that are upregulated in early developing thymocytes relative to 
later developing thymocytes. (B) MFI of cell surface IL7R in 15 early and 12 late T-ALL PDX 
samples following exposure to 1µM DEX for 24 hours in technical triplicate. (C) Viability relative 
to vehicle control of 15 early and 12 late T-ALL PDX samples treated with 1µM DEX in the 
absence or presence of 25ng/mL IL7 for 48 hours in technical triplicate. (D) MFI of BCL-2 
protein expression in 10 early T-ALL PDX samples following exposure to 100ng/mL IL7 with or 
without 1µM DEX and 500nM RUX for 16 hours in technical triplicate. Some samples were not 
analyzed due to limitations in cell numbers. (E) Viability relative to vehicle control of 15 early T-
ALL samples exposed to 25ng/mL IL7 with or without 1µM DEX and/or 500nM RUX or 1µM 
ABT-199 for 48 hours in technical triplicate. (F) Kaplan-Meier survival analysis of mice 
transplanted with early T-ALL T24 and treated with vehicle control (n=5), DEX (n=5), RUX 
(n=5), or the combination of DEX and RUX (n=5). Statistical significance was assessed using 
paired t-tests (B and C), one-way ANOVA with Tukey’s method for multiple comparisons 
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adjustment (D and E), or a log-rank test (F). ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – 
not significant. 
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Supplemental Figure 5-1: JAK1 and JAK3 inhibition overcome IL7-induced DEX 
resistance in T-ALL cells. (A) Viability of 11 representative primary diagnostic T-ALL samples 
exposed to increasing concentrations of DEX for 48 hours in the presence of 25ng/mL IL7. (B) 
Gating strategy used to assess viability by Hoechst stain and flow cytometry in CCRF-CEM 
cells. (C) Viability of CCRF-CEM cells exposed to DEX in the presence of 25ng/mL IL7 in the 
absence or presence of increasing concentrations of tofacitinib (left) or CHZ868 (right) for 72 
hours in technical triplicate. The data for the no IL7 (black line) and IL7 (red line) conditions on 
the left are re-plotted in the graph on the right. Viability data in (C) are representative of two 
independent experiments. 
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Supplemental Figure 5-2: The combination of IL7 and DEX augments the STAT5 
transcriptional program. (A) Histograms of IL7Ra expression in scramble control (S1 and S2) 
and IL7Ra KO (I1 and I2) CCRF-CEM cell clones. (B) Evaluation of GR expression by Western 
blot in CCRF-CEM cells treated with or without 1µM DEX and/or 100ng/mL IL7 for 24 hours. (C) 
Evaluation of total and phosphorylated GR (pS211) expression by Western blot in cytoplasmic 
and nuclear protein fractions from CCRF-CEM cells treated with or without 100ng/mL IL7 for 15 
minutes followed by vehicle control or 1µM DEX for one hour. An anti-b-actin antibody was used 
as a cytoplasmic loading control and an anti-p84 antibody was used as a nuclear loading 
control. (D) Heatmap of GR target genes as determined by RNA-seq in scramble control clones 
(n=4) treated with or without 1µM DEX and 100ng/mL IL7 for four hours. (E) Fold change in the 
fragments per kilobase million (FPKM) values of IL7RA transcript as determined by RNA-seq in 
four independent scramble control clones treated with or without 1µM DEX in the presence or 
absence of 100ng/mL IL7 for four hours. (F) Gating strategy used for measurement of 
intracellular proteins by flow cytometry in CCRF-CEM cells. (G) Representative histograms of 
pSTAT5 in CCRF-CEM cells treated with 1µM DEX in the absence of IL7 for 24 hours followed 
by a one-hour exposure to vehicle control or increasing concentrations of RUX prior to a 15-
minute stimulation with 100ng/mL IL7. (H) Fold change in the MFI of pSTAT1, pSTAT3, or 
pSTAT6 following a 15 minute stimulation with 100ng/mL IL7 in CCRF-CEM cells cultured in 
vehicle control or 1µM DEX in technical triplicate for 24 hours. Statistical significance was 
assessed using one-way ANOVA with Tukey’s method for multiple comparisons adjustment. 
With the exception of the RNA-seq experiment, all data are representative of three independent 
experiments. 
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Supplemental Figure 5-3: BCL2 is a STAT5 target gene that is enriched in cells treated 
with DEX and IL7 relative to IL7 alone. (A) Evaluation of GR expression by Western blot in 
scramble control and STAT5 KO CCRF-CEM cell clones (n=4 per genotype). (B) Viability of 
scramble control and STAT5 KO CCRF-CEM cell clones (n=4 per genotype) treated with DEX 
without (solid lines) or with (dotted lines) 25ng/mL IL7 for 72 hours. (C) Fold change in the 
FPKM for IL7RA in scramble control (n=4) and STAT5A/B KO (n=4) CCRF-CEM cell clones 
following exposure to 1µM DEX for four hours relative to vehicle control. (D) Fold change in the 
FPKM for BCL2L1, MCL1, and BCL2L2 transcripts as determined by RNA-seq analysis of 
scramble control (n=4) and STAT5A/B double KO (n=4) CCRF-CEM cell clones treated in the 
absence or presence of 100ng/mL IL7 and/or 1µM DEX for 16 hours. (E) Histograms of BCL-2 
protein expression in a representative clone from each group treated with 100ng/mL IL7 in the 
absence (unfilled histograms) versus presence (filled histograms) of 1µM DEX for 48 hours. (F) 
Fold change in transcript expression of four known primary GR target genes and BCL2 following 
exposure to 1µM DEX and 100ng/mL IL7 for various time points relative to cells exposed to 
vehicle control as determined by qPCR performed in technical triplicate. (G) MFI of BIM and 
BCL-2 protein expression performed in technical triplicate in CCRF-CEM cells exposed to 
vehicle control or 1µM DEX with or without 100ng/mL IL7 in the absence or presence of 
10µg/mL CHX for 24 hours. Significance is relative to the vehicle control condition. Statistical 
significance was assessed using a two-sample t-test (C) or one-way ANOVA with Tukey’s 
method for multiple comparisons adjustment (F and G). With the exception of the RNA-seq 
experiment, all data are representative of three independent experiments. ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05, N.S. – not significant.  
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Supplemental Figure 5-4: ARHGEF3 is not a mediator of IL7-induced DEX resistance. (A) 
Representative histograms of BCL-2 protein expression in untransduced CCRF-CEM cells and 
CCRF-CEM cells transduced with a non-targeting shRNA control (shControl) or a BCL2-
targeting shRNA (shBCL2-1-5). (B) Fold change in the transcript expression of ARHGEF3 in 
CCRF-CEM cells transduced with shControl or an ARHGEF3-targeting shRNA (shARHGEF3-1-
3). (C) Viability of shRNA-transduced CCRF-CEM cells treated with DEX in the presence of 
25ng/mL IL7 in technical triplicate for 72 hours. (D) FPKM values for ARHGEF3 transcript 
obtained from published RNA-seq data from diagnostic samples from patients enrolled on COG 
AALL0434, stratified based on day 29 bone marrow MRD. Statistical significance was assessed 
using one-way ANOVA with Tukey’s method for multiple comparisons adjustment (B and D). All 
CCRF-CEM cell data are representative of three independent experiments. ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
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Supplemental Figure 5-5: DN and SP thymocytes demonstrate IL7-induced DEX 
resistance. (A) Absolute number of thymocytes in thymi isolated from mice treated with vehicle 
control (n=3) or DEX (n=3) at 2mg/kg/day for three days. (B) Representative FACS plots 
demonstrating the distribution of the major thymocyte subpopulations in thymi isolated from 
mice treated with vehicle control or DEX at 2mg/kg/day for three days. (C) Absolute number of 
thymocytes in each of the major thymocyte subpopulations in thymi isolated from mice treated 
with vehicle control (n=3) or DEX (n=3) at 2mg/kg/day for three days. (D) Histograms of the 
basal expression of GR in the major murine thymocyte subpopulations. (E) MFI of IL7R in 
human thymocytes treated ex vivo in the presence or absence of 1µM DEX in technical triplicate 
for 24 hours. (F) Viability of human thymocytes treated ex vivo with 1µM DEX with or without 
25ng/mL IL7 in technical triplicate for 24 hours. Statistical significance was assessed using two-
sample t-tests (A, C, E, and F). All murine thymocyte data are representative of three 
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independent experiments. All human thymocyte data are representative of two independent 
experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Supplemental Figure 5-6: IL7R/JAK/STAT pathway mutations are not enriched in early 
versus late T-ALLs. (A) MFI of GR protein in 12 early and 6 late T-ALLs. Some samples were 
not analyzed due to limitations in cell number. Statistical significance was analyzed using a two-
sample t-test. B) MFI of pSTAT5 in 12 early and 9 late T-ALL PDX samples following stimulation 
with 100ng/mL IL7 for 15 minutes in technical triplicate. Some samples were not analyzed due 
to limitations in cell number. (C) Oncoplot depicting the occurrence of mutations in genes 
previously implicated in T-ALL in 15 early and 12 late T-ALL PDX samples. (D) Viability relative 
to vehicle control of cells from T-ALL T24 exposed to 25ng/mL IL7 with or without 1µM DEX 
and/or 500nM RUX in vitro for 48 hours. N.S. – not significant. 
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5.8: Bridge to Chapters 6, 7, and 8 
 
 Chapter 5 presents studies that defined the mechanistic basis for cytokine-induced DEX 
resistance in T-ALL. Using both genetic and pharmacologic approaches, we demonstrated that 
activation of STAT5 downstream of cytokine receptor signaling promotes the upregulation of 
anti-apoptotic proteins. These proteins alter the apoptotic potential of the cell, thereby rendering 
it refractory to DEX-induced apoptosis. Inhibition of JAK/STAT signaling with RUX is sufficient to 
restore this apoptotic potential, underscoring the synergy observed upon combined treatment 
with DEX and RUX in the presence of cytokine. The studies described in Chapters 6, 7, and 8 
serve as logical extensions of this work and in many instances provide further validation and 
extended generalizability of these initial findings. 
 Chapter 6 describes the derivation of a novel genetic classifier with prognostic relevance 
in pediatric T-ALL. Specifically, it establishes the feasibility of utilizing gene expression profiling 
as a biomarker for response to induction chemotherapy, which relies heavily on the use of GCs. 
Intriguingly, through entirely orthogonal methods, this study confirmed the findings in Chapter 5 
regarding the relationship between GC response and the underlying developmental origins of T-
ALL. Application of this novel genetic classifier to both an experimental and validation cohort 
revealed that T-ALLs of the early T-cell precursor (ETP) subset, reflecting an early stage of T-
cell development, have a distinct pattern of gene expression and are highly enriched for poor 
responses to induction chemotherapy. While most of the non-ETP samples demonstrated a 
gene expression pattern that was nearly the perfect inverse of the ETP gene expression pattern, 
a subset showed striking resemblance to the ETP samples and were highly enriched for the 
presence of minimal residual disease at the end of induction. These data demonstrate that 
developmental origins profoundly influence response to induction chemotherapy and suggest 
that immunophenotypic analysis of T-ALL is insufficient to appreciate this developmental 
heterogeneity.  
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 A key finding of the studies in Chapter 5 relates to the requirement for DEX-induced 
upregulation of IL7R as a central component of this drug resistance mechanism. While this 
study utilized the FDA-approved JAK1/2 inhibitor RUX to establish the therapeutic feasibility of 
overcoming IL7-induced DEX resistance by targeting activation of the IL7R/JAK/STAT5 axis, 
Chapter 7 describes an entirely distinct therapeutic approach inspired specifically by this key 
component of the mechanism. Newly synthesized IL7R reaches the cell surface via trafficking 
through the cellular secretory pathway. In Chapter 7, we tested the feasibility of inhibiting the 
secretory pathway as a means of preventing localization of IL7R to the cell surface. A key 
mediator of trafficking through this pathway is the Sec61 translocon, which facilitates entry of 
nascent peptides corresponding to cell surface or secreted proteins into the endoplasmic 
reticulum. Using a novel inhibitor of the Sec61 translocon called KZR-508445, we demonstrated 
that Sec61 inhibition effectively attenuates the DEX-induced increase in cell surface IL7R 
expression and overcomes IL7-induced DEX resistance to the same degree as RUX, thereby 
establishing the feasibility of this alternative therapeutic approach to target this drug resistance 
mechanism. 
 Finally, Chapter 8 represents a thematic extension of these findings in T-ALL as applied 
to a distinct disease entity known as hemophagocytic lymphohistiocytosis (HLH). HLH shares 
many key features with T-ALL, including a central role for T-cells in the disease process, the 
prevalence of common gamma chain cytokines, including IL7, and the use of DEX as a key 
component of therapy. We hypothesized that, as observed in T-ALL, cytokines may mediate 
DEX resistance in T-cells, and that this could be mitigated upon combined exposure with RUX. 
Indeed, we demonstrated that cytokines potently mediate DEX resistance in CD8 T-cells, and 
analogous to our work in T-ALL, do so via modulation of the cellular apoptotic potential. Using 
both in vivo and ex vivo model systems, we provide preclinical data in favor of combining DEX 
and RUX as a means of improving clinical outcomes for patients with HLH.   
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Chapter 6: Post-Induction Minimal Residual Disease is Associated with an Early T-Cell 
Precursor (ETP)-Like Gene Expression Signature in T-ALL 
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6.1: Abstract 
 
 T-cell acute lymphoblastic leukemia (T-ALL) is a malignancy that arises following the 
acquisition of mutations and developmental arrest in early developing T-cells. Due to the 
significant heterogeneity of this disease, there are currently no established molecular or 
cytogenetic biomarkers with prognostic significance, impeding efforts to implement risk-adapted 
therapeutic approaches. We integrated RNA-sequencing and clinical outcome data from 233 
pediatric T-ALL patients who were enrolled on the Children’s Oncology Group (COG) clinical 
trials AALL0434 and AALL1231 to evaluate the prognostic utility of gene expression profiling in 
pediatric T-ALL. We demonstrated that patterns of gene expression at the time of disease 
diagnosis are predictive of minimal residual disease (MRD) at the end of the induction phase of 
therapy. Using a regression-based approach, we identified a novel genetic classifier containing 
119 genes that is sufficient to retain the value of gene expression profiling for MRD prediction. 
Consistent with previous findings, T-ALLs with the early T-cell precursor (ETP) 
immunophenotype were almost uniformly MRD+. Intriguingly, we found that non-ETP T-ALLs 
that are MRD+ have gene expression signatures that closely resemble those of ETP T-ALLs 
despite having distinct immunophenotypic features. Furthermore, ex vivo drug sensitivity 
profiling of non-ETP T-ALLs revealed that MRD+ samples were more resistant to the 
glucocorticoid dexamethasone, a central component of induction chemotherapy for T-ALL. 
Taken together, these data demonstrate the prognostic significance of gene expression profiling 
in T-ALL and establish the feasibility of using a targeted gene expression profile to predict post-
induction MRD status at disease diagnosis.   
 
6.2: Introduction 
 
 Survival rates for patients with relapsed or refractory T-cell acute lymphoblastic leukemia 
(T-ALL) remain at less than 10% (284) and there are currently no effective salvage therapies 
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available for these patients. As a result, the primary goal of T-ALL therapy is to optimize the 
efficacy of frontline agents in order to decrease the likelihood of future relapse. Furthermore, 
unlike B-cell ALL (B-ALL) where numerous molecular and cytogenetic features carry known 
prognostic significance and can be used for risk stratification (28), such biomarkers do not exist 
for T-ALL (282). These data suggest that efforts to reduce the incidence of relapsed T-ALL will 
depend on an improved ability to accurately risk stratify patients to enable appropriate and early 
interventions in patients at risk for poor treatment responses. 
 In the absence of molecular or cytogenetic biomarkers, minimal residual disease (MRD) 
at the end of induction, the first month of therapy, has historically been the most important 
prognostic factor. On the Children’s Oncology Group (COG) trial AALL0434, patients with overt 
induction failure, defined as having >25% leukemic blasts in the bone marrow at the end of 
induction, had a disease free survival of only 54.8%, compared to 84.3% for the entire cohort 
(323). At the opposite extreme, on the European AIEOP-BFM-ALL 2000 trial, MRD negativity at 
the end of the first month of therapy was the most favorable prognostic factor (324). While these 
data highlight the prognostic significance of post-induction MRD, it is important to note that the 
use of MRD for risk stratification does not allow for risk-adapted modifications to therapy during 
induction, where they may effectively induce deeper remissions and decrease the likelihood of 
future relapse.  
 While there are no validated molecular or cytogenetic predictors of outcome for pediatric 
T-ALL, key cellular processes, such as transcriptional regulation and signal transduction, are 
commonly dysregulated in T-ALL despite underlying genetic diversity (177). We therefore 
hypothesized that genetically diverse T-ALLs may converge upon a smaller number of gene 
expression patterns that underlie the dysregulation of these key processes, and that these gene 
expression patterns may in turn have prognostic significance. Here, we demonstrate that gene 
expression profiling of diagnostic T-ALL samples effectively predicts post-induction MRD status. 
The early T-cell precursor (ETP) subset of T-ALLs, defined by distinct immunophenotypic 
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characteristics, is known to demonstrate poor responses to lymphoid-directed therapies, 
including glucocorticoids (GCs), which are prevalent during induction, resulting in high rates of 
post-induction MRD positivity in this subset (325). Intriguingly, we demonstrate that non-ETP T-
ALLs that are MRD positive but immunophenotypically indistinct from other non-ETP T-ALLs 
have an ETP-like gene expression signature. These data demonstrate the feasibility of utilizing 
gene expression profiling for prognostic purposes at disease diagnosis and suggest that the 
underlying developmental features of T-ALL cells are key drivers of the response to induction 
chemotherapy.  
 
6.3: Results 
 
Unbiased hierarchical clustering distinguishes MRD+ and MRD- T-ALLs 
  In an initial analysis to determine whether there are recurrent gene expression patterns 
within pediatric T-ALL that may in turn have prognostic utility, we utilized published RNA-
sequencing (RNA-seq) data obtained from diagnostic samples from 189 patients with T-ALL 
enrolled on COG AALL0434 (177). Unbiased hierarchical clustering of these data produced two 
primary clusters of samples characterized by distinct patterns of gene expression (Figure 6-1A). 
It has previously been shown that ETP T-ALL is associated with a gene expression pattern that 
is distinct from that of non-ETP T-ALL (325). Consistent with these data, our hierarchical 
clustering demonstrated that all of the ETP T-ALLs clustered together in cluster 1, while the 
near-ETP and non-ETP T-ALLs were dispersed between cluster 1 and cluster 2 (Figure 6-1A). 
On COG AALL0434, as with previous cohorts (326), patients with ETP T-ALL were commonly 
MRD+ at the end of induction (323) (Supplemental Figure 6-1). Interestingly, when we looked at 
the distribution of MRD+ and MRD- non-ETP T-ALLs, we found that 54% of the non-ETP T-
ALLs that clustered with the ETP T-ALLs in cluster 1 were MRD+, as opposed to only 16% of 
the non-ETP T-ALLs in cluster 2 (Figure 6-1B). 
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The expression pattern of 119 genes is sufficient to retain the prognostic significance of gene 
expression profiling 
 While this hierarchical clustering analysis demonstrates the potential for utilizing gene 
expression profiling for prognostic purposes, there are significant barriers to the clinical 
implementation of diagnostic tests that rely on whole transcriptome analyses. To determine 
whether a smaller number of genes may be sufficient to predict post-induction MRD status, we 
utilized a regression-based approach with leave-one-out cross-validation to distill the T-ALL 
transcriptome down to 119 genes that retained the predictive value of the whole transcriptome 
analysis. Using the genes within this signature, we derived a sample score metric, calculated 
based on the weighted contribution of each of the 119 genes to the prediction of MRD status. 
These sample scores were scaled from 0 to 100, and each sample was subsequently assigned 
a sample score, with a score of 0 corresponding to the lowest risk of being MRD+ and a score 
of 100 corresponding to the highest risk. 
 We then assessed the distribution of samples scores across the samples in the 
AALL0434 cohort. Consistent with the finding that ETP T-ALLs were largely MRD+, we found 
that this subset was associated with high sample scores and a uniform pattern of expression of 
the 119 genes in the signature. In contrast, the majority of non-ETP T-ALLs had an inverse 
gene expression pattern relative to the ETP T-ALLs and tended to have lower sample scores, 
consistent with lower rates of MRD positivity. However, similar to the initial whole transcriptome 
analysis, those non-ETP T-ALLs with high sample scores had a gene expression pattern that 
was identical to that of the ETP T-ALLs (Figure 6-2A-B). Finally, to determine if the sample 
score metric derived from this 119-gene signature has prognostic value for predicting MRD 
status in the non-ETP T-ALL subset, we examined the frequency of MRD positivity in samples 
across the entire sample score distribution. This analysis revealed that increasing sample 
scores are associated with higher rates of MRD positivity (Figure 6-2C). Taken together, this 
analysis demonstrates that the expression pattern of 119 genes is sufficient to identify non-ETP 
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T-ALLs that appear ETP-like at a transcriptional level and that are enriched for being MRD+ at 
the end of induction. 
 
BCL2 expression is associated with developmental stage and MRD status 
 Glucocorticoids (GCs) are a central component of induction chemotherapy for T-ALL, 
and a poor clinical response to GC therapy is thought to be an important driver of post-induction 
MRD positivity (31). We previously demonstrated that the anti-apoptotic protein BCL-2 is a key 
driver of intrinsic GC resistance in diagnostic T-ALL samples (254). Furthermore, we and others 
(327) have demonstrated that BCL-2 expression changes as a function of early T-cell 
development, with the earliest thymocytes expressing high levels of BCL-2, owing to cytokine-
mediated pro-survival signaling. This pro-survival signal is then inhibited at later stages of 
development, resulting in a reduction in BCL-2 expression (4). We therefore hypothesized that 
BCL2 expression may correlate with MRD status in the AALL0434 cohort. Consistent with the 
pattern of expression in normal thymocyte development, we found that ETP T-ALLs had 
significantly higher BCL2 expression relative to the near-ETP and non-ETP samples (Figure 6-
3A). Interestingly, when we separated the non-ETP T-ALL samples by MRD status, we found 
that the MRD+ non-ETP T-ALLs, which transcriptionally resemble ETP T-ALLs, had significantly 
higher BCL2 expression (Figure 6-3B).  
 
High sample scores and an ETP-like gene expression pattern are associated with in vitro GC 
resistance.  
 To further validate the prognostic utility of this 119-gene signature and associated 
sample score metric, we applied this model to an independent validation cohort of 44 diagnostic 
samples from patients enrolled on COG AALL1231 for which RNA-seq data were previously 
generated (254). This analysis revealed the same gene expression pattern amongst the ETP 
samples as was observed in the AALL0434 cohort. Similarly, we found that the ETP T-ALLs had 
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consistently high sample scores. Additionally, we validated the finding that a subset of non-ETP 
T-ALLs have an ETP-like gene expression signature, high sample scores, and are enriched for 
being MRD+ (Figure 6-4A). Given that MRD positivity is thought to primarily reflect GC 
resistance, we asked whether our sample score metric correlates with in vitro sensitivity to the 
GC dexamethasone (DEX). In an analysis of 28 samples from AALL1231, we found a 
statistically significant correlation between sample score and in vitro DEX responses, with a high 
sample score predicting relative DEX resistance (Figure 6-4B). These data are consistent with 
GCs being an important driver of post-induction MRD and suggest that this 119-gene signature 
may be used to identify GC resistant T-ALLs. 
 
6.4: Discussion 
 
 The considerable molecular and cytogenetic heterogeneity of T-ALL (282) poses 
significant challenges to the introduction of risk-adapted therapies, which will be necessary to 
improve clinical outcomes in patients at risk for disease relapse. Historically, MRD has been one 
of the most important prognostic factors for predicting long-term outcomes in T-ALL. However, a 
significant limitation to the use of MRD as a biomarker is that this information is not available 
until patients have completed the first month of therapy, precluding the ability to modify therapy 
in a risk-adapted manner during induction.  
 To address this problem, we asked whether gene expression profiling performed on 
diagnostic T-ALL samples may have similar prognostic utility to MRD. We demonstrated using 
whole-transcriptome analysis that diagnostic samples from patients later found to be MRD+ 
clustered separately from those found to be MRD-. Specifically, non-ETP T-ALLs from MRD+ 
patients clustered more closely with ETP T-ALLs, which are highly enriched for being MRD+. 
We went on to demonstrate that knowing the expression status of only 119 genes is sufficient to 
retain the predictive value of gene expression profiling. By developing a sample score metric 
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derived from the expression of this 119-gene signature, we demonstrated that MRD+ samples 
have higher sample scores than MRD- samples. While non-ETP T-ALLs on average had lower 
sample scores than the ETP T-ALLs, MRD+ non-ETP T-ALLs had higher sample scores, higher 
BCL2 expression, and a gene expression pattern identical to that of ETP T-ALLs. Finally, we 
validated the prognostic utility of this gene expression signature in an independent cohort of 
patients enrolled on COG AALL1231, where we integrated this analysis with ex vivo drug 
sensitivity profiling to demonstrate that resistance to GCs is associated with high sample scores, 
and therefore with higher rates of MRD positivity.  
 Taken together, these data demonstrate that gene expression profiling is a powerful tool 
both for predicting the response to induction chemotherapy and for providing additional insights 
into the underlying biology of T-ALL. One of the most intriguing findings from this analysis 
relates to the gene expression similarities between ETP T-ALLs and MRD+ non-ETP T-ALLs, 
which are immunophenotypically-defined subsets. MRD positivity has been shown to reflect 
intrinsic resistance to GC therapy (31), a central component of induction regimens for T-ALL. In 
addition to their therapeutic applications, GCs are unique in that they are also endogenous 
hormones that play crucial roles in shaping lymphoid cell development. Consistent with this, 
sensitivity to GC-induced apoptosis is known to vary as a function of normal thymocyte 
development, with early thymocytes demonstrating a high degree of GC resistance owing to 
strong pro-survival signals that antagonize the pro-apoptotic effects of GCs. In contrast, 
thymocytes at later stages of development are exquisitely sensitive to GCs, a feature that 
facilitates the appropriate deletion of thymocytes with non-functional T-cell receptor (TCR) 
rearrangements, ensuring the maturation of only functional and non-autoreactive T-cells (300). 
We previously demonstrated that this pattern of GC sensitivity across thymocyte development is 
retained in T-ALL (254). The present study provides independent validation of these findings, as 
it demonstrates that ETP T-ALLs, as well as non-ETP T-ALLs with gene expression signatures 
that resemble developmentally early T-ALLs, are enriched for being MRD+, a surrogate for GC 
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resistance (31). This suggests that in addition to its prognostic utility, gene expression profiling 
and analysis of developmentally-associated gene expression patterns may identify candidate 
therapeutic targets for enhancing drug responses in patients who are likely to be MRD+. One 
such potential target is BCL2, which we show here to be elevated in ETP T-ALLs and MRD+ 
non-ETP T-ALLs. Indeed, in vitro analysis demonstrates that targeting BCL2 is sufficient to 
overcome GC resistance in T-ALLs resembling earlier developing thymocytes (254), and the 
findings presented here provide rationale for further investigation of this therapeutic strategy.  
 Importantly, this study demonstrates that the expression pattern of a relatively small 
number of genes is sufficient to distinguish T-ALL samples on the basis of their developmental 
origins and future MRD status. This approach is therefore readily translatable to a clinically 
tractable targeted gene expression assay. A similar approach has demonstrated feasibility in the 
context of pediatric Philadelphia-chromosome like (Ph-like) ALL. Specifically, the unique Ph-like 
gene expression signature was used to define a genetic classifier to identify Ph-like ALL, 
resulting in the development of a targeted gene expression assay known as the LDA card, 
which was effectively incorporated into clinical practice for patients enrolled on COG AALL1131 
(328). This demonstrates the feasibility of direct clinical translation of a targeted gene 
expression assay for pediatric T-ALL.  
 Taken together, this study provides strong rationale for the further development and 
clinical translation of a targeted gene expression-based assay as a potential alternative to post-
induction MRD. We believe that such an assay has the potential to improve risk stratification 
and enable the implementation of a precision medicine approach to treating pediatric T-ALL. 
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6.5: Methods 
 
RNA-sequencing 
 This analysis utilized previously published RNA-seq data from patients enrolled on COG 
AALL0434 (177) and COG AALL1231 (254). 
 
Development of the 119-gene signature 
 The 119-gene signature was derived from the whole-transcriptome analysis of the 
AALL0434 cohort using a regression-based approach with leave-one-out cross validation to 
identify a gene signature required for optimal distinction between MRD+ and MRD- samples. 
 
In vitro drug sensitivity profiling 
 Fresh diagnostic T-ALL samples were obtained from patients enrolled on COG 
AALL1231. Written informed consent for the use of diagnostic specimens for research was 
obtained from patients or their guardians at the time of sample collection, according to the 
Declaration of Helsinki, the National Cancer Institute, and institutional review boards of 
participating sites. Cells were cultured in the presence of 25ng/mL recombinant human 
interleukin-7 (Peprotech) and treated with vehicle control or 2.5µM DEX for 48 hours. Cells were 
then stained with Hoechst 33258 (Molecular Probes) and analyzed by flow cytometry performed 
using a BD FACSVerse. Data were analyzed using FlowJo software. 
 
Statistical Analysis 
 Statistical analyses were performed using Prism 8 (GraphPad). All tests were two-sided 
and the threshold for significance was p≤0.05. Error bars represent the standard deviation. 
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6.7: Figures 
 
 
Figure 6-1: MRD+ non-ETP T-ALLs cluster with ETP T-ALLs. (A) Heatmap depicting the 
gene expression patterns of 189 diagnostic samples from the AALL0434 cohort following 
unbiased hierarchical clustering. (B) Distribution of MRD+ and MRD- non-ETP T-ALL samples 
between cluster 1 and cluster 2. Statistical significance was assessed using Fisher’s exact test. 
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Figure 6-2: The expression pattern of 119 genes has prognostic significance. (A) Heatmap 
depicting the gene expression pattern of 119 genes in samples from AALL0434 organized by 
ETP status and sample score. (B) Distribution of sample scores across the ETP, near-ETP, and 
non-ETP samples. (C) Distribution of MRD status by sample score in the non-ETP T-ALL 
subset. 
 
  
 140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3: BCL2 expression is associated with developmental stage and ETP status. (A) 
FPKM values for BCL2 transcript in ETP, near-ETP, and non-ETP T-ALL samples. Statistical 
significance was assessed using one-way ANOVA with Tukey’s method for multiple 
comparisons adjustment. (B) FPKM values for BCL2 transcript in MRD- and MRD+ non-ETP T-
ALLs. Statistical significance was assessed using two-sample t-tests. ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05. 
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Figure 6-4: High samples scores are associated with in vitro GC resistance. (A) Heatmap 
depicting the gene expression pattern of 119 genes in samples from AALL1231 organized by 
ETP status and sample score, with indication of MRD status. (B) Viability relative to vehicle 
control of 28 fresh diagnostic samples from AALL1231 treated with 2.5µM DEX for 48 hours 
versus sample score. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Supplemental Figure 6-1: ETP T-ALLs are commonly MRD+. Distribution of MRD status in 
ETP, near-ETP, and non-ETP T-ALLs from AALL0434. 
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Chapter 7: KZR-508445 is a Novel Inhibitor of the Sec61 Translocon that Overcomes 
Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia  
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7.1: Abstract 
 
 Glucocorticoids (GCs) are a central component of therapy for T-cell acute lymphoblastic 
leukemia (T-ALL), and upfront resistance to GCs is a poor prognostic factor. We previously 
demonstrated that over one-third of primary patient T-ALLs are resistant to the GC 
dexamethasone (DEX) when cultured in the presence of interleukin-7 (IL7). Mechanistically, we 
demonstrated that resistance occurs following DEX-induced upregulation of IL7 receptor (IL7R) 
expression, leading to increased downstream pro-survival signaling. This newly synthesized 
IL7R reaches the cell surface via trafficking through the cellular secretory pathway, so we 
hypothesized that inhibiting the translocation of nascent IL7R peptide into the secretory pathway 
would effectively overcome IL7-induced DEX resistance. Sec61 is a protein-conducting channel 
in the membrane of the endoplasmic reticulum (ER) that is required for the cotranslational 
insertion of nascent polypeptides into the ER. Here, we demonstrate that KZR-508445, a novel 
inhibitor of the Sec61 translocon, potently attenuates the DEX-induced increase in cell surface 
IL7R in a T-ALL cell line and primary patient T-ALL cells and synergizes with DEX in the 
presence of IL7.  
 
7.2: Introduction 
 
 Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with T-
cell ALL (T-ALL) accounting for approximately 15% of cases. While outcomes for children 
diagnosed with T-ALL have improved dramatically over the past several decades, survival rates 
for patients with relapsed or refractory T-ALL remain dismal, indicating a need for strategies to 
enhance the efficacy of frontline treatment protocols in order to induce deeper remissions and 
decrease the likelihood of disease relapse (32). Glucocorticoids (GCs) are a central component 
of T-ALL therapy and represent a particularly important target for strategies aimed at improving 
clinical outcomes. Specifically, the sensitivity of T-ALL cells to GCs at the time of disease 
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diagnosis is one of the strongest known prognostic factors for predicting future relapse, with 
patients who respond well to GCs during the first weeks of therapy facing significantly better 
outcomes relative to patients who respond poorly (285).  
Through ex vivo analysis of primary diagnostic T-ALL samples, we have demonstrated 
that up to 75% of these samples are intrinsically resistant to dexamethasone (DEX), a synthetic 
GC used in T-ALL therapy. Furthermore, we have discovered that approximately half of these 
DEX resistant samples are resistant specifically when cultured in the presence of interleukin-7 
(IL7) (132), a pro-survival cytokine that has previously been implicated in T-ALL pathogenesis 
and disease maintenance (329,330). Mechanistically, we have demonstrated that in these 
primary samples and in a cell line model of IL7-induced GC resistance, DEX paradoxically 
induces its own GC resistance by upregulating IL7 receptor (IL7R) expression. In the presence 
of IL7 ligand, this leads to an increase in pro-survival signaling through the IL7R/JAK/STAT5 
pathway ending with the upregulation of the pro-survival protein BCL-2, which directly 
antagonizes GC-induced apoptosis (254). Given that upregulation of IL7R is a critical 
component of this resistance mechanism, we hypothesized that therapeutic strategies to inhibit 
the DEX-induced upregulation of IL7R would overcome IL7-induced GC resistance.  
Secreted and membrane-associated proteins, including IL7R, require processing 
through the cellular secretory pathway to reach the cell surface. These proteins are targeted to 
the secretory pathway by the translation of a signal sequence on the nascent peptide, which is 
subsequently recognized by the Sec61 complex. This Sec61 complex is a component of the 
mammalian translocon, a protein-conducting channel on the membrane of the endoplasmic 
reticulum (ER). Upon recognition of the signal sequence, these peptides undergo productive 
translocation into the lumen of the ER, where post-translational processing is initiated to 
produce functional secreted or membrane-associated proteins (331). Small molecule inhibitors 
of the Sec61 translocon represent a novel therapeutic strategy to inhibit the processing of a 
subset of cell surface proteins, including cytokine receptors. Specifically, these compounds act 
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in a signal sequence-specific manner to prevent the interaction of these proteins with Sec61, 
thereby blocking their translocation into the ER and ultimately their secretion or expression at 
the cell surface (332). Sec61 modulators have demonstrated preclinical efficacy both as 
antimicrobial and anticancer agents (333,334). In the present study, we demonstrate that a 
novel inhibitor of the Sec61 translocon, KZR-508445, potently overcomes IL7-induced GC 
resistance in a cell line model and in primary patient T-ALL samples, concomitant with a 
reduction in cell surface IL7R expression. This study establishes the feasibility of targeting the 
Sec61 translocon as a means of augmenting responses to GC therapy in pediatric T-ALL and 
provides preclinical evidence supporting further development of KZR-508445 and related 
compounds for this purpose. 
 
7.3: Results 
 
Sec61 inhibition overcomes IL7-induced DEX resistance in patient T-ALL samples 
 The Sec61 translocon is an attractive therapeutic target for overcoming IL7-induced DEX 
resistance due to the dynamic regulation of IL7R expression in response to DEX. Specifically, 
we analyzed published RNA-seq data generated from clonal cell populations derived from the 
human T-ALL cell line CCRF-CEM that were treated with DEX for 4 hours (254). Using a false 
discovery rate cutoff of ≤0.05, we generated a list of 136 genes that were upregulated by at 
least two-fold following DEX exposure. We then compared this list to a list of over 6,500 
predicted Sec61 client proteins, and identified only 25 DEX targets that interact with the Sec61 
translocon, one of which is IL7R (Supplemental Figure 7-1).  
 CT8 is a tool compound belonging to a class of cyclic heptadepsipeptides known as 
cotransins, which function to inhibit cotranslational translocation via the Sec61 translocon 
(Figure 7-1A). As an initial evaluation of the efficacy of this therapeutic strategy for overcoming 
IL7-induced DEX resistance, we utilized cells from 28 fresh diagnostic T-ALL samples that 
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demonstrate IL7-induced DEX resistance. We exposed these cells to DEX in the presence of 
IL7 either alone or in combination with the JAK1/2 inhibitor ruxolitinib (RUX) or CT8, and found 
that RUX and CT8 equivalently overcame IL7-induced DEX resistance (Figure 7-1B), 
suggesting that Sec61 inhibition may be equally as effective as JAK/STAT pathway inhibition for 
augmenting DEX sensitivity. 
 
KZR-508445 is an optimized cotransin that potently modulates IL7R expression and overcomes 
IL7-induced DEX resistance 
 Based on these promising initial findings with CT8, we pursued further evaluation of this 
therapeutic strategy utilizing KZR-508445, a novel derivative of CT8 with improved potency and 
in vivo stability (Figure 7-2A). The CCRF-CEM cell line demonstrates significant upregulation of 
cell surface IL7R protein in response to DEX exposure, which was effectively reduced by 
nanomolar concentrations of KZR-508445 (Figure 7-2B). Interestingly, while all common g-chain 
cytokine receptors are Sec61 clients, the relative potency of KZR-508445 for reducing cell 
surface expression of these receptor chains was significantly greater for IL7R relative to all 
other common g-chain cytokine receptors, with only 36% of the basal level of IL7R remaining at 
the cell surface in response 15.6nM KZR-508445, versus greater than 75% for all other 
common g-chain cytokine receptors (Supplemental Figure 7-2A).  
 We next evaluated the effect of combining KZR-508445 with DEX on cell viability in 
CCRF-CEM cells, which demonstrate IL7-induced DEX resistance (254). In the presence of IL7, 
KZR-508445 effectively enhanced DEX sensitivity (Figure 7-2C) in a manner that was highly 
synergistic with DEX (Figure 7-2D). Importantly, at concentrations at which synergy was 
observed, KZR-508445 demonstrated minimal single agent effects on cell viability 
(Supplemental Figure 7-2B) or cell proliferation (Supplemental Figure 7-2C), suggesting that the 
observed effects on cell viability in the presence of DEX are not due to an overall reduction in 
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secretory and membrane protein biogenesis. Finally, we evaluated the effect of KZR-508445 on 
expression of the STAT5 target BCL-2, which is significantly upregulated upon exposure to DEX 
and IL7. Consistent with its ability to overcome IL7-induced DEX resistance, KZR-508445 
inhibited the increase in BCL-2 protein expression in a dose-dependent manner (Figure 7-2E). 
 
The efficacy of KZR-508445 in T-ALL is due to the interaction between Sec61, the IL7R signal 
peptide, and KZR-508445 
 To assess the mechanism by which KZR-508445 inhibits the DEX-induced upregulation 
of cell surface IL7R, we evaluated transcript and protein expression of IL7R in CCRF-CEM cells 
treated with vehicle control or DEX in the presence or absence of KZR-508445. As previously 
shown (254), DEX induced a significant increase in IL7RA transcript expression and in cell 
surface IL7R protein. This increase in transcript levels was sustained with the addition of KZR-
508445, despite restoration of cell surface IL7R protein to basal levels (Figure 7-3A), consistent 
with KZR-508445 acting post-transcriptionally to attenuate IL7R expression.   
 Next, to confirm that this modulation of IL7R expression is due specifically to an 
interaction between the Sec61 translocon, IL7R peptide, and KZR-508445, we generated 
expression constructs containing wild-type IL7R and performed site-directed mutagenesis to 
engineer two leucine substitutions into the IL7R signal sequence (Figure 7-3B). These 
mutations increase the hydrophobicity of the signal sequence, which is predicted to confer 
resistance to KZR-508445 by impairing its interaction with IL7R. We then transiently transfected 
HEK-293T cells with the wild-type and mutant constructs and assessed cell surface IL7R 
expression. The introduction of these leucine substitutions did not affect basal expression of 
IL7R at the cell surface (Supplemental Figure 7-3A). However, upon exposure to increasing 
concentrations of KZR-508445, cells expressing the mutant IL7R showed impaired 
downregulation of cell surface IL7R (Figure 7-3C), confirming that KZR-508445-mediated 
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modulation of IL7R expression is due specifically to the interaction between this compound, the 
IL7R signal sequence, and the Sec61 translocon. 
 We next asked whether modulation of IL7R expression is necessary for KZR-508445 to 
enhance DEX sensitivity in CCRF-CEM cells. As previously described (254), we used 
CRISPR/Cas9 genome editing to generate clonal populations of IL7R knockout CCRF-CEM 
cells (Supplemental Figure 7-3B). We then treated these cells with DEX with or without KZR-
5088445, and found that KZR-508445 had minimal effects to modulate DEX sensitivity in the 
absence of IL7R expression (Figure 7-3D), suggesting that downregulation of IL7R expression 
underlies the sensitization to DEX. Further supporting this idea, we also did not observe any 
effect of KZR-508445 to enhance sensitivity to other chemotherapeutic agents used in the 
treatment of T-ALL, none of which demonstrate IL7-induced resistance (Supplemental Figure 7-
3C). These data suggest that KZR-508445 is not a general chemosensitizer, but instead acts 
specifically on IL7R to overcome a mechanism of resistance that is unique to DEX.  
 
KZR-508445 is effective in primary patient samples and in an in vivo model system 
 Following the observed efficacy of KZR-508445 in CCRF-CEM cells, we next sought to 
determine whether this compound effectively overcomes IL7-induced DEX resistance in primary 
patient T-ALL samples. We utilized 16 human T-ALLs that demonstrate IL7-induced DEX 
resistance, and found that ex vivo exposure to KZR-508445 effectively inhibited the DEX-
induced increase in cell surface IL7R expression (Figure 7-4A). As observed with CT8, KZR-
508445 also overcame IL7-induced DEX resistance, restoring DEX sensitivity to that observed 
in the absence of IL7 (Figure 7-4B). This improved DEX sensitivity was further associated with 
inhibition of the BCL-2 upregulation observed with the combination of DEX and IL7 (Figure 7-
4C). 
 Finally, we asked whether KZR-508445 is effective in vivo. First, we established 
tolerability by treating non-tumor-bearing NSG mice with three different doses of KZR-508445 
 150 
administered by weekly intravenous injection. At even the highest dose of KZR-508445, we 
observed no loss of bodyweight (Supplemental Figure 7-4A) or significant modulation of any 
measured hematologic parameters (Supplemental Figure 7-4B-D). We then generated an in 
vivo model of T-ALL by transplanting CCRF-CEM cells into NSG mice. To assess the 
pharmacodynamics of a 22.5mg/kg dose of KZR-508445, we treated mice and measured cell 
surface expression of CD62L, a Sec61 client, on the cell surface of CCRF-CEM cells in 
peripheral blood after 24 hours. This revealed significant downregulation of CD62L 
(Supplemental Figure 7-4C), suggesting that this dose of KZR-508445 is sufficient to modulate 
expression of Sec61 clients in vivo. We then conducted a four-arm trial by treating xenografts 
with vehicle control, 15mg/kg/day DEX, 22.5mg/kg KZR-508445 twice weekly, or the 
combination of DEX and KZR-508445. Upon analysis of the percentage of CCRF-CEM cells in 
the peripheral blood of vehicle- and drug-treated mice, we found that both DEX and KZR-
508445 effectively attenuated peripheral disease burden, with a trend towards further 
attenuation with the combination of DEX and KZR-508445 (Figure 7-4D). 
 
7.4: Discussion 
 
 The IL7R signal transduction pathway plays a well-established role in leukemogenesis 
(289,290), with its importance underscored by the prevalence of mutations in IL7R or 
components of the downstream signal transduction machinery (182,291), indicating a selective 
pressure for activation of this pathway in T-ALL. We previously demonstrated that cytokine-
mediated activation of this pathway is a prevalent mediator of resistance to GCs, a central 
component of therapy for T-ALL. In particular, we showed that a key feature of this resistance 
mechanism is the GC-induced upregulation of IL7R, which potentiates downstream signal 
transduction leading to the upregulation of pro-survival factors that antagonize DEX-induced 
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apoptosis (254). Here, we demonstrate that targeting the localization of newly synthesized IL7R 
to the cell surface is an effective means of overcoming IL7-induced DEX resistance. 
 Specifically, this study demonstrates the efficacy of KZR-508445, a novel inhibitor of the 
Sec61 translocon, in a T-ALL cell line and in primary patient T-ALL samples. We demonstrate 
that KZR-508445 potently inhibits the DEX-induced increase in cell surface IL7R with relative 
sparing of other cytokine receptors that mediate important T-cell biological functions, suggesting 
that there may be a range of drug doses that are sufficient for targeting IL7R in T-ALL without 
significant modulation of common g-chain cytokine receptors in other T-cell populations. Using a 
genetic approach, we show that this relative selectivity and potency is conferred by the specific 
amino acid sequence of the IL7R signal sequence. Furthermore, we find that the reduction in 
IL7R expression is associated with increased sensitivity to DEX in the presence of IL7, 
concomitant with a reduction in expression of BCL-2, a downstream transcriptional target of 
IL7R/JAK/STAT5 pathway signaling. Finally, we provide tolerability data demonstrating that 
KZR-508445 is well-tolerated in vivo, and show that KZR-508445 effectively attenuates disease 
burden in a xenograft model of T-ALL. 
 Taken together, these data establish the potential for enhancing GC sensitivity in T-ALL 
through inhibition of the Sec61 translocon. Despite the vast number of proteins that require 
trafficking through the cellular secretory pathway prior to secretion from the cell or localization to 
the plasma membrane, we observed minimal single-agent effects of KZR-508445 in CCRF-
CEM cells or in patient T-ALL samples, suggesting that the relative selectivity for IL7R is 
sufficient to establish a therapeutic window for use in T-ALL. While the relationship between the 
structure of cotransin derivatives and their selectivity for different Sec61 clients remains poorly 
understood, it is well-established that this selectivity differs on the basis of the side chains 
associated with these derivatives (335). This suggests the potential for further development of 
KZR-508445 and related compounds for clinical use in T-ALL and for other diseases with 
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unique pathophysiologic or therapeutic dependencies on secreted or membrane-associated 
proteins.  
 
7.5: Methods 
 
Flow cytometry 
 Flow cytometry was performed using a BD FACSVerse and data were analyzed using 
FlowJo software.  
 
Patient T-ALL samples  
 Diagnostic blood samples were obtained from patients enrolled on the COG trial 
AALL1231. Written informed consent for the use of diagnostic specimens for research was 
obtained from patients or their guardians at the time of sample collection, according to the 
Declaration of Helsinki, the National Cancer Institute, and institutional review boards of 
participating sites. Fresh T-ALL cells were used in the analysis in Figure 7-1. For the analysis in 
Figure 7-4, cells were obtained following passaging through NOD/SCID/Il2rgtm1wjl/Szj (NSG) 
mice as patient-derived xenografts (PDXs). These NSG mice were obtained from Jackson 
Laboratories and T-ALL engraftment was monitored using flow cytometric analysis of peripheral 
blood with antibodies against human CD45 (BD Biosciences) and CD7 (BioLegend). All PDX 
experiments were conducted following protocols that were approved by the Institutional Animal 
Care and Use Committee of Children’s Hospital of Philadelphia.  
 
CCRF-CEM cells 
 CCRF-CEM cells were purchased from the UCSF Cell Culture Facility (ATCC CCL-119). 
Cells were maintained in RPMI (Mediatech) supplemented with 10% fetal bovine serum (VWR) 
and antibiotics. Cells were authenticated via short tandem repeat DNA profiling and were 
routinely tested for mycoplasma contamination using the PlasmoTest detection kit (InvivoGen). 
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In vitro viability assays 
 
 In vitro viability assays were performed by exposing CCRF-CEM cells and patient-
derived T-ALL cells to vehicle control or to the following drugs at the concentrations indicated in 
the associated figure legends: DEX (Sigma), RUX (Selleckchem), CT8 (Kezar Life Sciences), 
KZR-508445 (Kezar Life Sciences), cytarabine (Sigma), methotrexate (Sigma), etoposide 
(Sigma), and vincristine (Sigma). Viability assays were performed in the absence or presence of 
recombinant human IL7 (Peprotech) as indicated in the figure legends. Cells were treated for 72 
hours (CCRF-CEM cells) or 48 hours (patient-derived T-ALL cells), and were then stained with 
Hoechst 33258 (Molecular Probes) and analyzed by flow cytometry. Data are presented as the 
percentage of viable (Hoechst-negative) cells in the drug-treated condition relative to the 
corresponding vehicle-treated condition. 
 
Measurement of cell surface cytokine receptor expression 
 The effect of KZR-508445 on common g-chain cytokine receptors was assessed in 
human CD8 T-cells isolated from TRIMA residuals enriched for peripheral blood mononuclear 
cells (PBMCs) and obtained from the Vitalant blood bank. PBMCs were isolated using a Ficoll 
(GE Healthcare) density gradient in a SepMate PBMC Isolation Tube (STEMCELL 
Technologies). 5 x 107 cells were labeled with biotinylated antibodies against CD4 (clone 
A161A1; BioLegend), CD19 (clone HIB19; BioLegend), CD11b (clone ICRF44; BioLegend), 
CD24 (clone ML5; BioLegend), and B220 (clone RA3-6B2; Biolegend). Negative selection was 
performed by depleting biotin-labeled cells with Biotin Binder Dynabeads (Life Technologies). 
The remaining cells were cultured in RPMI (Mediatech) supplemented with 10% fetal bovine 
serum (VWR), glutamine, antibiotics, and 20ng/mL recombinant human IL-2 (Peprotech). Cells 
were activated by the addition of Human T-Activator CD3/CD28 Dynabeads (Life Technologies). 
 For analysis of cell surface cytokine receptor expression, CCRF-CEM cells, patient-
derived T-ALL cells, or human CD8 T-cells were treated with or without 1µM DEX and/or the 
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indicated concentrations of KZR-508445 for 24 hours. Cells were then stained with antibodies 
against the following proteins: IL2Ra (clone M-A251; BioLegend), IL2Rb (clone TU27; 
BioLegend), IL2Rg (clone TUGh4; BioLegend), IL4R (clone G077F6; BioLegend), IL7R (clone 
A019D5; BioLegend), IL9R (clone AH9R7; BioLegend), IL15R (clone JM7A4; BioLegend), and 
IL21R (clone 17A12; BioLegend). Cells were also stained with Hoechst 33258 to facilitate gating 
on the live cell population. Data were recorded as the median fluorescent intensity (MFI) of IL7R 
in the Hoechst-negative gate. 
 
Proliferation assay 
 To assess the effects of KZR-508445 on cell proliferation, CCRF-CEM cells were treated 
with increasing concentrations of KZR-508445 for 72 hours and analyzed using Cell Titer Glo 
reagent (Promega) according to the manufacturer’s instructions. 
 
Measurement of BCL-2 protein expression 
 CCRF-CEM cells and patient-derived T-ALL cells were treated under the indicated drug 
conditions for 24 hours. Cells were then fixed with 2% paraformaldehyde and permeabilized 
with methanol. Cells were stained with an anti-cleaved caspase 3 antibody (clone C92-605; BD 
Biosciences) and an anti-BCL-2 antibody (clone Bcl2/100; Life Technologies) and analyzed by 
flow cytometry. Data were recorded as the MFI of BCL-2 in the cleaved caspase 3-negative 
gate.   
 
IL7R cloning and site-directed mutagenesis 
 RNA was isolated from CCRF-CEM cells using the RNeasy Mini kit (Qiagen) and cDNA 
was generated using the Superscript III kit (ThermoFisher). IL7R cDNA was amplified using the 
following primers: forward – 5’-GAGCTAGAGCTAGCGGCCACCATGACAATTCTAG-3’; reverse 
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– 5’- CCCTCAGCGGCCGCGAACTGGTTTTGGTAGAAGCTG-3’. IL7R cDNA was cloned into 
the pCDH Expression Lentivector system (System Biosciences) using the EcoRI and BamHI 
restriction enzyme sites. The IL7R signal sequence mutant was generated by site-directed 
mutagenesis performed with the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies) and the following oligonucleotide: 5’- 
GGTACAACTTTTTTAATGGTTTTTTTATTACTTCAAGTCGTTTCTGG-3’. 
 
Transfection of HEK-293T cells 
 Wild-type and mutant IL7R constructs were transfected into HEK-293T cells using 
Lipofectamine 3000 (Life Technologies) according to the manufacturer’s instructions. Sixteen 
hours after transfection, cells were treated with the indicated concentrations of KZR-508445 for 
24 hours prior to analysis of cell surface IL7R expression by flow cytometry, as described 
above. 
 
Quantitative PCR (qPCR) 
 For analysis of IL7RA transcript expression, CCRF-CEM cells were treated with or 
without 1µM DEX and/or 200nM KZR-508445 for 16 hours. RNA was isolated using the RNeasy 
Mini kit and cDNA was generated using the Superscript III kit. Taqman quantitative PCR probes 
(Applied Biosystems) were used in conjunction with Taqman Master Mix (Applied Biosystems) 
to assess transcript levels of the following genes: GAPDH (Hs02786624_g1; VIC-MGB) and 
IL7RA (Hs00902334_m1; FAM-MGB). Experiments were performed in technical triplicate and 
were run on a QuantStudio 5 Real-Time PCR Instrument (Applied Biosystems). The fold change 
in transcript expression was calculated relative to vehicle-treated cells using the delta-delta Ct 
method, with the use of GAPDH transcript for normalization.   
 
  
 156 
CRISPR/Cas9 genome editing of CCRF-CEM cells  
 IL7R knockout CCRF-CEM cells were generated as previously described (254).  
 
In vivo drug treatment and analysis 
 All in vivo experiments were conducted following protocols that were approved by the 
Institutional Animal Care and Use Committee of the University of California, San Francisco. To 
assess in vivo drug tolerability, non-tumor-bearing female NSG mice were treated with vehicle 
control (10% ethanol and 10% Kolliphor) or KZR-508445 via weekly intravenous injection of the 
indicated doses. Bodyweight was assessed weekly. Hematologic parameters were assessed 
using the Hemavet System (Drew Scientific). To assess the effects of KZR-508445 on leukemic 
cell burden, female NSG mice were transplanted with 2 x 106 CCRF-CEM cells via tail vein 
injection. Beginning on day 4 post-injection, mice were treated with vehicle (PBS) or DEX at 
15mg/kg/day and/or vehicle (10% ethanol and 10% Kolliphor) or KZR-508445 at 22.5mg/kg 
twice weekly. Peripheral blood leukemia burden was assessed by subjecting blood to RBC lysis 
followed by staining with an anti-human CD45 antibody (clone 2D1; BioLegend) and an anti-
human CD62L antibody (clone DREG-56; BioLegend). 
 
Statistical analysis 
 Statistical analyses were performed using Prism 8 (GraphPad). All tests were two-sided 
and the threshold for significance was p≤0.05. Comparisons between groups were made using 
t-tests, with one-way ANOVA and Tukey’s method for multiple comparisons adjustment for 
comparisons of three or more groups. Interactions between drugs were assessed using Bliss 
independence analysis (281). Error bars represent the standard error of the mean.   
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7.7: Figures 
 
 
 
 
Figure 7-1: CT8 overcomes IL7-induced DEX resistance in patient-derived T-ALL cells. (A) 
Chemical structure of CT8. (B) Viability relative to vehicle control of cells from 28 fresh 
diagnostic T-ALL samples cultured in the presence of 25ng/mL IL7 with or without 2.5µM DEX 
and/or 500nM RUX or 2µM CT8 for 48 hours. Statistical significance was assessed using one-
way ANOVA with Tukey’s method for multiple comparisons adjustment. ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
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Figure 7-2: KZR-508445 modulates cell surface IL7R expression and overcomes IL7-
induced DEX resistance in CCRF-CEM cells. (A) Chemical structure of KZR-508445. (B) MFI 
and representative histograms of cell surface IL7R in CCRF-CEM cells treated with or without 
1µM DEX and increasing concentrations of KZR-508445 for 24 hours in technical triplicate. (C) 
Viability relative to vehicle control of CCRF-CEM cells treated with increasing concentrations of 
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DEX in the presence of 25ng/mL IL7 and/or the indicated concentrations of KZR-508445 for 72 
hours in technical triplicate. (D) Heatmap of Bliss independence scores calculated as the 
average of technical triplicates for the combination of DEX and KZR-508445 in CCRF-CEM cells 
cultured in the presence of 25ng/mL IL7 for 72 hours, in which positive values, indicated in red, 
are indicative of a synergistic interaction. (E) MFI of BCL-2 protein expression in CCRF-CEM 
cells treated with 100ng/mL IL7 with or without 1µM DEX and/or the indicated concentration of 
KZR-508445 for 24 hours in technical triplicate. Statistical significance is relative to the DEX-
treated condition in the absence of KZR-508445. Statistical significance was assessed using 
one-way ANOVA with Tukey’s method for multiple comparisons adjustment. All data are 
representative of three independent experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Figure 7-3: KZR-508445 overcomes IL7-induced DEX resistance by interfering with the 
interaction between nascent IL7R peptide and the Sec61 translocon. (A) Fold change in 
the transcript expression of IL7RA (left) and MFI of IL7R protein (right) in CCRF-CEM cells 
treated with vehicle or 1µM DEX with or without 200nM KZR-508445 for 16 hours (transcript) or 
24 hours (protein) in technical triplicate. Statistical significance was assessed using one-way 
ANOVA with Tukey’s method for multiple comparisons adjustment. (B) Sequence of the wild-
type IL7R signal sequence and location of the mutations introduced by site-directed 
mutagenesis. (C) MFI of cell surface IL7R in HEK-293T cells transiently transfected with 
constructs containing wild-type or mutant IL7R and treated with increasing concentrations of 
KZR-508445 for 24 hours. (D) Viability relative to vehicle control in two IL7R knockout CCRF-
CEM-derived clones treated with increasing concentrations of DEX with or without 100nM KZR-
508445 for 72 hours in technical triplicate. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – 
not significant. All data are representative of three independent experiments. 
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Figure 7-4: KZR-508445 effectively overcomes IL7-induced DEX resistance in patient-
derived T-ALL cells and is effective in an in vivo model of T-ALL. (A) Fold change in the 
MFI of IL7R in cells from 16 patient-derived T-ALL samples treated with 1µM DEX with or 
without 50nM KZR-508445 for 24 hours. (B) Viability relative to vehicle control of cells from 16 
patient-derived T-ALL samples treated in the presence or absence of 25ng/mL IL7 with or 
without 1µM DEX and/or 50nM KZR-508445 for 48 hours. (C) Fold change in the MFI of BCL-2 
in cells from 10 patient-derived T-ALL samples cultured in the presence of 100ng/mL IL7 and 
treated with or without 1µM DEX and/or 50nM KZR-508445 for 24 hours. (D) Percentage of 
human CD45+ cells in peripheral blood taken on day 11 of treatment from mice transplanted 
with CCRF-CEM cells. Statistical significance was assessed using one-way ANOVA with 
Tukey’s method for multiple comparisons adjustment. ****p<0.0001, ***p<0.001, **p<0.01, 
*p<0.05, N.S. – not significant. 
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Supplemental Figure 7-1: 25 Sec61 clients are upregulated by DEX. Log fold change in the 
expression of the DEX target genes corresponding to Sec61 client proteins in clonal populations 
of CCRF-CEM cells treated with 1µM DEX for four hours. 
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Supplemental Figure 7-2: KZR-508445 shows selective potency for IL7R and has minimal 
single-agent effects on cell viability and proliferation. (A) MFI relative to baseline values of 
common g-chain cytokine receptors in human CD8 T-cells treated with increasing 
concentrations of KZR-508445 for 24 hours in technical triplicate. (B) Viability relative to vehicle 
control of CCRF-CEM cells treated with increasing concentrations of KZR-508445 for 72 hours 
in technical triplicate. (C) Relative luminescence of CCRF-CEM cells treated with increasing 
concentrations of KZR-508445 for 72 hours in technical triplicate and analyzed using Cell Titer 
Glo. All data are representative of three independent experiments. 
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Supplemental Figure 7-3: KZR-508445 sensitizes CCRF-CEM cells to DEX but not to other 
chemotherapies. (A) Representative histograms of cell surface IL7R in HEK-293T cells 
transfected with empty vector or wild-type or mutant IL7R constructs. (B) Representative 
histograms of cell surface IL7R in IL7R KO CCRF-CEM cell clones relative to wild-type 
scramble control clones. (C) Viability relative to vehicle control of CCRF-CEM cells treated with 
increasing concentrations of the indicated chemotherapeutic agent with or without 25ng/mL IL7 
and 100nM KZR-508445 for 72 hours in technical triplicate. All data are representative of three 
independent experiments. 
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Supplemental Figure 7-4: KZR-508445 is well-tolerated in vivo. (A) Change in bodyweight 
over time of NSG mice treated with vehicle control or the indicated dose of KZR-508445. (B) 
White blood cell count of NSG mice treated with vehicle control or the indicated dose of KZR-
508445 for 14 days. (C) Hemoglobin levels of NSG mice treated with vehicle control or the 
indicated dose of KR-508445 for 14 days. (D) Platelet count of NSG mice treated with vehicle 
control or the indicated dose of KZR-508445 for 14 days. (E) Fold change in the MFI of CD62L 
on CD45+ cells in the peripheral blood of NSG mice 24 hours after in vivo treatment under the 
indicated conditions. Statistical significance was assessed using one-way ANOVA with Tukey’s 
method for multiple comparisons adjustment.  ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Chapter 8: Ruxolitinib Sensitizes CD8 T-Cells to Dexamethasone-Induced Apoptosis in a 
Preclinical Model of Hemophagocytic Lymphohistiocytosis 
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8.1: Abstract 
 
 Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome 
characterized by excessive immune system activation, leading to hypercytokinemia and life-
threatening organ damage. Frontline therapy for HLH consists primarily of the glucocorticoid 
dexamethasone (DEX) and the chemotherapeutic agent etoposide. Many patients, however, are 
refractory to treatment or relapse after an initial response, resulting in a five-year survival rate of 
only 61%. Recently, there has been considerable interest in targeting cytokines or their 
downstream signal transduction effectors as a means of improving clinical outcomes. Many 
HLH-associated cytokines activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib 
(RUX) has shown efficacy in murine models of HLH and in clinical case reports of refractory 
HLH. Importantly, JAK/STAT signaling has been shown in other disease contexts to induce DEX 
resistance in T cells, which are key drivers of HLH. We therefore hypothesized that cytokine-
mediated JAK/STAT signaling might contribute to DEX resistance in HLH and that this could be 
overcome by combination treatment with RUX. Here, we show that plasma from HLH patients 
confers resistance to DEX in human CD8 T cells. Using lymphocytic choriomeningitis virus to 
induce an HLH-like disease in perforin-null mice, we further demonstrate that DEX and RUX act 
cooperatively in vivo to attenuate a number of disease parameters. Mechanistically, we 
establish that the hypercytokinemia of HLH reduces the apoptotic potential of CD8 T cells, 
leading to relative DEX resistance. Upon concomitant exposure to RUX, this apoptotic potential 
is restored, thereby sensitizing CD8 T cells to DEX-induced apoptosis.  
 
 
8.2: Introduction 
 
 Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory disease caused by 
primary or acquired defects in immune function, often in mediators of cellular cytotoxicity. In this 
setting, stimuli such as infections, malignancies, or autoimmunity appropriately activate the 
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immune system, but the immune system is unable to control the trigger. The resulting inability to 
terminate the immune response leads to excessive expansion and activation of innate immune 
cells and CD8 T cells. These cells in turn secrete large quantities of inflammatory cytokines, 
producing a cytokine storm that both drives further activation of immune cells and mediates 
many of the clinical manifestations of HLH, including fever, cytopenias, hyperferritinemia, and 
multiorgan damage (336).   
 Most patients who meet the clinical criteria for a diagnosis of HLH are treated according 
to the HLH-94 or HLH-2004 protocols, which rely primarily on immunosuppression mediated by 
the glucocorticoid (GC) dexamethasone (DEX) and the chemotherapeutic agent etoposide. If 
left untreated, HLH is uniformly fatal. Even with treatment, the five-year overall survival rate on 
the HLH-2004 trial was only 61% (38), reflecting the fact that many patients are refractory to 
therapy and many more relapse after an initial therapeutic response. As a result, there is 
significant interest in identifying novel therapeutic agents, including those that may act in 
conjunction with existing frontline therapies to enhance these clinical outcomes. 
  The development of these novel therapeutic approaches requires a thorough 
understanding of the mechanisms of disease pathogenesis. Notably, the hypercytokinemia of 
HLH is an important mediator of both disease progression and end organ damage (336). One 
therapeutic strategy, then, involves targeting cytokines themselves or the signal transduction 
pathways triggered by activation of the corresponding cytokine receptors. One such HLH-
associated cytokine is interferon-g (IFN-g), and the FDA recently approved emapalumab, a 
human monoclonal antibody against IFN-g, for the treatment of pediatric and adult HLH, 
representing the first approval of a cytokine-directed therapy for HLH (40). IFN-g, as well as the 
majority of other cytokines implicated in HLH, exert their cellular effects through activation of the 
Janus kinases (JAKs), which in turn activate the signal transducer and activator of transcription 
(STAT) family of transcription factors. Given its central role in cytokine receptor signaling, the 
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JAK/STAT pathway represents an attractive therapeutic target with the potential to modulate 
both IFN-g-mediated effects as well as the effects of a multitude of other cytokines. Indeed, 
multiple studies in murine models of primary and secondary HLH have revealed that the JAK1/2 
inhibitor ruxolitinib (RUX) effectively improves HLH pathology (42,337,338). Similarly, a number 
of case reports have demonstrated the efficacy of RUX as a salvage therapy for refractory HLH 
(339,340). However, while RUX has shown efficacy as a single agent in refractory disease, it is 
currently unknown whether RUX may be effectively used in combination with DEX. 
 As evidence in favor of a combinatorial approach, we previously demonstrated that 
cytokine-mediated JAK/STAT signaling confers DEX resistance in T cell acute lymphoblastic 
leukemia (T-ALL) cells (132,254). GCs, including DEX, act by binding to a cytoplasmic GC 
receptor (GR) that translocates to the nucleus upon ligand binding (1) where it acts as a 
transcription factor to activate a gene expression program that induces apoptosis in lymphoid 
cells (49). We demonstrated in T-ALL cells that the activation of STAT5 in response to the 
common gamma chain (cg) cytokine interleukin-7 (IL-7) results in the upregulation of the anti-
apoptotic protein BCL-2, which antagonizes this DEX-induced apoptotic program. Importantly, 
combined treatment with RUX overcame IL-7-induced DEX resistance (254). In the context of 
HLH, many disease-associated cytokines similarly induce gene expression changes that 
promote cell survival, thereby creating the potential to interfere with DEX-induced apoptosis. In 
light of our previous findings in T-ALL, we hypothesized that the rampant hypercytokinemia of 
HLH and the excessive activation of the JAK/STAT signaling pathway may facilitate a similar 
mechanism of DEX resistance, which may in turn contribute to poor clinical outcomes in HLH. 
We therefore evaluated the feasibility and efficacy of combining DEX and RUX as a potential 
rational therapeutic strategy in the treatment of HLH.  
 In the current study, we demonstrate that the cytokine composition of plasma from 
patients with HLH contains elevated levels of cg cytokines and is indeed sufficient to confer DEX 
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resistance in CD8 T cells. Using the Prf1-/- model of primary HLH, we further show that DEX and 
RUX cooperatively attenuate many manifestations of disease. Mechanistically, we demonstrate 
that the hypercytokinemia of HLH increases expression of pro-survival proteins in CD8 T cells, 
thus reducing the apoptotic potential of these cells to a point where DEX is no longer sufficient 
to induce apoptosis. We show that concomitant treatment with RUX lowers the apoptotic 
threshold of CD8 T cells, thereby restoring DEX sensitivity. These findings have important 
clinical implications, as they demonstrate that a therapeutic strategy combining DEX and RUX 
has the potential to more effectively control hyperinflammation and immunopathology in HLH 
and related cytokine storm syndromes.  
 
8.3: Results 
 
The cytokine composition of plasma from patients with HLH confers DEX resistance in CD8 T 
cells 
DEX is a central component of therapy for patients with HLH, but the persistence of poor 
clinical outcomes on recent trials suggests that DEX resistance may be an important therapeutic 
obstacle. We previously demonstrated that cytokine-mediated JAK/STAT signaling confers DEX 
resistance in T-ALL cells (132,254). Given that HLH is characterized by both hypercytokinemia 
and excessive activation and expansion of CD8 T cells, we hypothesized that a similar 
mechanism of cytokine-induced DEX resistance might contribute to poor clinical outcomes in 
these patients. To test this hypothesis, we obtained plasma from patients with HLH and from 
healthy controls representing a similar distribution of ages and genders and confirmed that a 
number of disease-associated proteins were significantly elevated in the plasma from the HLH 
patients (Supplemental Figure 8-1A). We then activated and expanded human CD8 T cells from 
a single healthy donor and exposed the same T cells to plasma from control or HLH patients 
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and assessed viability following treatment with DEX. A significant proportion of the plasma 
samples from HLH patients induced DEX resistance in these CD8 T cells (Figure 8-1A).  
Given our previous findings that IL-7-mediated signaling through the JAK/STAT5 axis is 
sufficient to confer DEX resistance in T-ALL cells (132,254), we asked whether IL-7 and other cg 
cytokines were elevated in the plasma from HLH patients. When compared to the plasma from 
healthy controls, a number of plasma samples from the HLH patients contained high levels of 
these cytokines, especially IL-7 and IL-15 (Figure 8-1B). Subsequent analyses focused on IL-2, 
-4, -7, -9, and -15, as these were elevated above the level in the control samples in at least a 
subset of HLH plasma samples. To determine whether any of these cytokines independently 
confer DEX resistance, we exposed human CD8 T cells to DEX in the presence or absence of 
recombinant cytokine and found that all of these cytokines resulted in some degree of 
resistance (Figure 8-1C). Furthermore, the extent to which each cytokine protected CD8 T cells 
from DEX-induced cell death was directly proportional to the extent to which each cytokine 
activated STAT5 (Figure 8-1D), consistent with our previous finding that STAT5 mediates 
cytokine-induced DEX resistance in T cells (254).  
 
DEX and RUX cooperatively enhance treatment of a murine model of HLH 
The finding that cytokine-induced DEX resistance in CD8 T cells correlates with the 
degree of JAK/STAT5 pathway activation suggests that inhibition of this pathway may enhance 
DEX sensitivity. Thus, we reasoned that inhibiting JAK1/2 with RUX might augment DEX 
responses in an in vivo model of HLH. To test this, we employed a previously described murine 
model of primary HLH (338) to ask whether combining DEX with RUX more effectively 
attenuates disease manifestations relative to treatment with DEX alone. In this model, Perforin 1 
knockout (Prf1-/-) mice are infected with LCMV-Armstrong, which induces an HLH-like disease 
that accurately recapitulates many features of human disease (Figures 8-2A-G and 
Supplemental Figure 8-2A). Levels of the cg cytokines IL-2 and IL-7 were also markedly 
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increased in the serum of infected animals (Supplemental Figure 8-2B). We first determined that 
a DEX dose of 1.5mg/kg/day is sufficient to induce observable modulation of disease 
parameters (Supplemental Figures 8-2C-E) and utilized this dose for subsequent combination 
experiments. Beginning on day 4 post infection (p.i.), we treated mice with DEX alone or in 
combination with RUX-supplemented rodent chow (Incyte), and animals were monitored for 
morbidity and mortality. While this dose of DEX did not improve weight loss (Figure 8-2A), it did 
significantly extend survival relative to vehicle-treated animals, though all animals in both of 
these groups succumbed to disease by day 16 p.i. (Figure 8-2B). In mice treated with RUX 
alone or RUX in combination with DEX, there was no observed weight loss or reduction in 
survival relative to naïve mice (Figure 8-2A-B).  
In a more detailed analysis of disease, naïve and vehicle- and drug-treated LCMV-
infected animals were examined for anemia, thrombocytopenia, and organomegaly. Consistent 
with the observed weight loss pattern, RUX treatment, both alone and in combination with DEX, 
restored hematocrit and platelet values to those seen in naïve mice, while DEX alone did not 
significantly alter these parameters (Figures 8-2C-D). LCMV-infected Prf1-/- mice develop 
severe splenomegaly, and while both DEX and RUX demonstrated moderate single agent 
effects to reduce spleen size, combination treatment resulted in spleen sizes that were 
indistinguishable from naïve mice (Figure 8-2E). We next evaluated innate immune cell 
populations in the spleen and found that while neither drug effectively reduced monocyte 
numbers (Figure 8-2F), JAK inhibition reduced numbers of neutrophils, and this effect was 
significantly enhanced upon combined exposure to DEX (Figure 8-2G). Concordantly, the area 
of liver tissue infiltrated by neutrophils in infected mice was also significantly improved with 
combination treatment (Supplemental Figure 8-3A).  
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The combination of DEX and RUX targets activated CD8 T cells  
The GC DEX is primarily used in HLH due to its lymphotoxic effects, so we next 
analyzed vehicle- and drug-treated mice for disease parameters associated with CD8 T cells, 
which are known to be important drivers of disease (336). Consistent with this, splenic CD4 T 
cells are not elevated in this model, though numbers were reduced upon drug exposure 
(Supplemental Figure 8-3B). Overall numbers of splenic CD8 T cells were significantly reduced 
in treated mice, with the greatest reduction observed in animals treated with the combination of 
DEX and RUX (Figure 8-3A). Examination of the liver by immunohistochemistry (IHC) also 
revealed a significant reduction in CD8 T cell infiltration in the mice treated with both DEX and 
RUX (Figure 8-3B). In order to better understand the activation status of these T cells, we 
further quantified the numbers of CD8 T cells expressing known activation markers in vehicle- 
and drug-treated LCMV-infected Prf1-/- mice. With respect to effector-like CD8 T cells (CD44hi, 
CD62Llo), combination treatment reduced cell numbers to nearly half those of vehicle-treated 
mice, while neither agent alone produced such a dramatic effect (Figure 8-3C). Similarly, 
numbers of CD8 T cells expressing both the costimulatory molecules CD28 and ICOS were 
significantly reduced with RUX treatment, and even more so when RUX was combined with 
DEX (Figure 8-3D). Interestingly, this reduction in the number of activated CD8 T cells was 
associated with a reduction in the number of these cells expressing the IL-2 receptor CD25 and 
in the levels of soluble CD25 in the serum (Figures 8-3E-F).  
 
Activation of STAT5 confers DEX resistance in CD8 T cells in vitro 
We next sought to understand the mechanistic basis for the cooperative effects of DEX 
and RUX in this model. Since severe hypercytokinemia is a hallmark feature of HLH, and 
because it has been previously demonstrated that cytokine receptor signaling via the 
JAK/STAT5 pathway interferes with DEX-induced apoptosis in primary human T-ALL cells and 
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in populations of murine thymocytes (254), we hypothesized that the cooperative effect of DEX 
and RUX on CD8 T cells in vivo may be due to enhanced DEX sensitivity as a result of RUX-
mediated inhibition of cytokine receptor signaling. To facilitate further mechanistic investigation, 
we returned to an ex vivo system using isolated, activated murine CD8 T cells. We first 
confirmed that these murine CD8 T cells recapitulate the DEX resistance phenotype that we 
observed in human CD8 T cells, in which the cg chain cytokines IL-2, -7, and -15 induce a 
significant increase in pSTAT5 but not in pSTAT1 or pSTAT3 (Supplemental Figure 8-4A), 
consistent with reports that STAT5 is the predominant downstream effector of these cytokine 
receptors (25). Similarly, we confirmed that all three of these cytokines confer resistance to DEX 
in murine CD8 T cells (Figure 8-4A). Additionally, we established that this resistance phenotype 
is independent of an underlying genetic defect in cytotoxic function, as we observed equivalent 
IL-2-induced DEX resistance in CD8 T cells isolated from both wild-type and Prf1-/- mice 
(Supplemental Figure 8-4B). As a result, all subsequent mechanistic analyses were performed 
using CD8 T cells from wild-type mice.  
In addition to the cg cytokines, cytokines from many other families are elevated in the 
plasma of patients with HLH (Supplemental Figure 8-1) and in the serum of LCMV-infected  
Prf1-/- mice (Supplemental Figure 8-2A), so we assessed the effect of a number of these other 
cytokines on DEX sensitivity in CD8 T cells. We observed that, in addition to the cg cytokine IL-
2, only IL-12 conferred any resistance to DEX, while TNF-a, IFN-g, IL-6, IL-1b, and IL-10 did not 
(Figure 8-4B). Furthermore, the effects of IL-2 and IL-12 on drug sensitivity were specific to 
DEX, as we did not detect any IL-2- or IL-12-induced resistance to etoposide, another 
lymphotoxic agent used in frontline treatment for HLH (Figure 8-4C). Consistent with the pattern 
of DEX resistance and pSTAT5 activation observed in human CD8 T cells, only IL-2 and IL-12 
induced a significant increase in pSTAT5 in murine CD8 T cells, while neither IL-6 nor IFN-g, 
two other cytokines that signal through pSTAT5 in other cell types, activated STAT5 under 
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these conditions (Figure 8-4D and Supplemental Figure 8-4C). Due to the significant DEX 
resistance observed upon IL-2 exposure, we used IL-2 as a tool in subsequent experiments to 
evaluate the mechanistic basis for this resistance phenotype. We found that IL-2 induces DEX 
resistance in a dose-dependent manner, with significant IL-2-induced resistance observed even 
at very low concentrations of IL-2 (Supplemental Figure 8-4D). To further confirm that this 
resistance is mediated by JAK/STAT signaling, we asked whether RUX could overcome the IL-
2-mediated induction of pSTAT5 and restore DEX sensitivity. CD8 T cells were pre-treated with 
varying concentrations of RUX for one hour and stimulated with IL-2. RUX abrogated the 
cytokine-induced increase in pSTAT5 (Figure 8-4E) and completely overcame the associated 
DEX resistance (Figure 8-4F) in a manner that was both dose-dependent (Figures 8-4E-F) and 
synergistic with DEX (Figure 8-4G). This was consistent with the RUX-induced reduction in 
pSTAT5 observed following in vivo drug exposure (Supplemental Figure 8-4D). Thus, cytokines 
that activate STAT5 in CD8 T cells, including those that are known to be pathologically relevant 
in HLH such as IL-12 and especially cg cytokines such as IL-2, result in resistance to DEX that 
is effectively overcome upon concomitant treatment with RUX.  
  
IL-2 inhibits DEX-induced apoptosis of CD8 T cells by altering the balance of BH3 proteins  
 To further understand the mechanistic basis for IL-2-induced DEX resistance in CD8 T-
cells, we first asked whether IL-2 directly interferes with GR signaling. To determine whether IL-
2 receptor (IL-2R) signaling and the resulting activation of pSTAT5 impairs nuclear translocation 
of ligand-activated GR, we assessed GR nuclear localization in CD8 T cells treated with DEX in 
the presence or absence of IL-2. We observed that both total and S211 phosphorylated GR, 
which represents a transcriptionally active modification, effectively co-localized to the nucleus 
with pSTAT5, suggesting that IL-2R signaling does not impair nuclear translocation of ligand-
activated GR (Figure 8-5A). Similarly, IL-2R signaling did not interfere with the capacity for GR 
to activate gene transcription, as revealed by transcript expression of known direct GR target 
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genes following treatment with DEX in the presence or absence of IL-2 (Figure 8-5B). Since IL-2 
had no effect on GR localization or transcriptional activation, these data suggest that GR 
signaling remains intact in the presence of IL-2.  
DEX has well-established effects on modulation of the intrinsic apoptotic pathway in 
lymphocytes (18,49), and STAT5 has been shown to directly regulate anti-apoptotic 
components of this pathway in T-cells (299). We therefore hypothesized that IL-2R signaling 
may alter the apoptotic potential of CD8 T-cells, making them refractory to the pro-apoptotic 
effects of DEX. To test this, we first measured expression of anti-apoptotic BCL-2 family 
members, all of which are STAT5 target genes (299), following exposure to IL-2. CD8 T cells 
exposed to IL-2 upregulated protein expression of BCL-2, BCL-xL, and MCL-1. Importantly, 
RUX treatment restored expression of all three anti-apoptotic proteins to basal levels, confirming 
that these proteins are induced downstream of the IL-2R/JAK/STAT pathway (Figure 8-5C).   
In order to determine the functional significance of these changes in protein expression, 
we utilized BH3 profiling to assess the apoptotic potential of CD8 T-cells treated under these 
various conditions. In an analysis of CD8 T cells cultured ex vivo with DEX with or without IL-2, 
DEX alone induced a significant increase in priming with respect to BCL-2, BCL-XL, and MCL-1 
activity. Consistent with the finding that IL-2 confers DEX resistance, we found that the apoptotic 
potential of CD8 T cells was significantly reduced in the presence of IL-2, such that DEX was no 
longer able to increase apoptotic priming. Exposing the cells to RUX, however, blocked IL-2R 
signaling and was sufficient to restore the basal apoptotic potential of CD8 T-cells. Furthermore, 
with the addition of RUX, DEX was again capable of increasing apoptotic priming, consistent 
with the finding that RUX synergizes with DEX in the presence of IL-2 (Figure 8-6A). Finally, to 
test the relevance of these findings in vivo, we performed BH3 profiling on CD8 T cells 
harvested from naïve and vehicle- and drug-treated LCMV-infected Prf1-/- mice. As with the ex 
vivo findings, cells from vehicle-treated LCMV-infected mice showed a reduction in apoptotic 
potential relative to naïve mice, and this reduction was effectively overcome upon exposure to 
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DEX and RUX (Figure 8-6B). Taken together, these results support a model in which the 
hypercytokinemia of HLH, and in particular the elevated levels of cg cytokines, signal through 
STAT5 to upregulate anti-apoptotic proteins that protect CD8 T cells from DEX-induced cell 
death. This effect is inhibited by the JAK1/2 inhibitor RUX, which re-sensitizes cytokine-exposed 
CD8 T cells to apoptosis and synergizes with DEX to effect cell death.  
 
8.4: Discussion 
 
 Survival rates for patients diagnosed with HLH remain at 61% (38), owing to the fact that 
many patients are refractory to current frontline therapy and many more who experience an 
initial therapeutic response ultimately relapse. Therefore, there is a considerable need for the 
development of novel therapeutic strategies to enhance the efficacy of frontline therapy. 
Hypercytokinemia is a hallmark feature of HLH, and many disease-associated cytokines signal 
via the JAK/STAT pathway. CD8 T cells both secrete and respond to these cytokines, making 
them an important cellular target of HLH therapy (336). DEX is therefore a central component of 
frontline therapy for HLH due to its potent lymphotoxic effects. However, cytokine receptor 
signaling has been shown to mediate DEX resistance in a number of disease contexts, including 
asthma (341–344) and T cell leukemia (132,254). We therefore hypothesized that the cytokines 
associated with HLH may induce relative DEX resistance in CD8 T cells, thereby contributing to 
these poor clinical outcomes.   
In the current study, we found that cytokines from nearly all cytokine classes were 
elevated in the plasma from HLH patients. In particular, this analysis revealed a previously 
under-appreciated elevation in the cg cytokines IL-7 and IL-15, which exert a multitude of critical, 
well-described effects on T-cell biology (43). Importantly, we showed that plasma from these 
patients uniformly attenuated DEX sensitivity in CD8 T cells. Using recombinant cytokines to 
test the sufficiency of cytokine receptor activation for DEX resistance, we found that only those 
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cytokines that significantly activate STAT5 in CD8 T cells impaired DEX sensitivity. We went on 
to demonstrate the feasibility and efficacy of a combined therapeutic strategy involving DEX and 
the JAK1/2 inhibitor RUX in an in vivo model of HLH. Here, we found that DEX and RUX 
cooperatively attenuated many disease manifestations, and in particular showed strong 
cooperativity with respect to reducing both the absolute numbers of CD8 T cells as well as the 
numbers of activated CD8 T cells. Mechanistically, we demonstrated that cytokine exposure 
results in a significant reduction in the apoptotic potential of CD8 T cells, rendering them 
refractory to the pro-apoptotic effects of DEX. Both in vivo and ex vivo, we showed that RUX-
mediated restoration of this apoptotic potential underlies the synergistic interaction between 
DEX and RUX.  
While we observed improvement in many disease parameters upon combined treatment 
with DEX and RUX in vivo, our mechanistic findings suggest that this combination may be 
particularly effective due in large part to combinatorial effects on CD8 T cells. Importantly, 
compelling data demonstrate the necessity of CD8 T cells to the pathogenesis of HLH. In 
healthy immune responses, immune homeostasis is restored upon clearance of the initiating 
trigger and subsequent termination of the immune response. CD8 T cells are critical effectors of 
this process, as they function to target infected or malignant cells directly and to inhibit both the 
antigen presenting cells (APCs) that promote further T cell activation as well as other T cells 
themselves through a process known as fratricide (345). Consistent with this critical homeostatic 
function, mice engineered to produce T cells with impaired perforin- or Fas-dependent killing of 
APCs have exacerbated HLH-like disease, and depletion of CD8 T cells in this model is 
protective against HLH (36,346). Mechanistically, this protective effect can be attributed to 
continued expansion and activation of immune cells in the absence of CD8 T cell cytolytic 
activity, a process that both requires and results in the production of cytokines, particularly cg 
cytokines (347). This central role for CD8 T cells in disease pathogenesis underlies the utility of 
DEX as a lymphotoxic agent in the treatment of this disease. However, as demonstrated in the 
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current study, the cg cytokines IL-2, -7, and -15 potently antagonize DEX-induced apoptosis. 
Our findings, in conjunction with the established role for CD8 T cells and cg cytokines in the 
pathogenesis of HLH, therefore suggest that a therapeutic strategy combining DEX and RUX 
has the potential to both enhance CD8 T cell killing and attenuate cytokine-mediated 
contributions to disease progression.  
In addition to HLH, DEX is widely used for its immunosuppressive properties in a 
multitude of other clinical contexts. While our study centered on a model of primary HLH, this 
paradigm of cytokine-induced DEX resistance has been observed in many other DEX-treated 
diseases, suggesting that our mechanistic findings have relevance and implications beyond the 
treatment of HLH. The mechanisms by which T cells become resistant to DEX are not fully 
elucidated, but it is clear that cytokine signaling plays an important role. Treatment of mouse 
thymocytes with IL-2 induces expression of pro-survival transcription factors such as c-Fos, AP-
1, and c-Myc, and increases NFkB activity (348). Additionally, many cytokines induce 
expression of the pro-survival protein BCL-2, which directly antagonizes the pro-apoptotic 
molecule BIM. Consistent with these findings, treatment of human leukemic T cells with 
cytokines such as IL-2, IL-4, and IL-7 induces resistance to DEX-induced cell death, with IL-7 
increasing expression of BCL-2 (132,248,249). Altogether, cytokine-induced DEX resistance is 
often mediated by the modulation of the levels of the BH3 proteins BCL-2 and BIM, effectors of 
apoptosis (18,349). Here, we see that cg cytokines and other cytokines that activate STAT5 in 
CD8 T cells, such as IL-12, confer DEX resistance in a manner proportional to their degree of 
STAT5 activation. This likely depends on the induction of expression of a variety of anti-
apoptotic molecules downstream of pSTAT5 activity. While we observe increases in the 
expression of and functional relevance of BCL-2, BCL-xL, and MCL-1, the most relevant 
survival protein for DEX resistance may be cell and disease context-dependent. Because of this 
variability and redundancy in pro-survival protein function, our findings indicate that targeting the 
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upstream JAK/STAT signaling is more therapeutically attractive than targeting these proteins 
themselves.  
 While our findings provide compelling evidence for a therapeutic strategy combining 
DEX and RUX for the treatment of HLH, there are also several important limitations of this work. 
First, as demonstrated in our own patient cohort, cytokine profiles in the plasma from patients 
with HLH are highly variable, including with respect to the cg cytokines. This heterogeneity likely 
reflects the considerable diversity in the underlying etiology of disease amongst patients 
meeting the diagnostic criteria for HLH (37). Importantly, our study relies upon a genetic model 
of primary HLH, a disease entity known to be driven in large part by excessive CD8 T cell 
activity. Other related hyperinflammatory diseases, such as macrophage activation syndrome 
(MAS), are known to be significantly less T cell-dependent and may therefore have a distinct 
plasma cytokine composition (350). Our findings suggest that synergistic effects on T cells 
underlie the efficacy of this combined strategy, and further studies are needed to elucidate the 
clinical potential for combining DEX and RUX in other hyperinflammatory conditions. However, 
as RUX inhibits signaling downstream of all JAK1/2-activating cytokine receptors regardless of 
the initiating ligand and cytokine receptor, the use of RUX in combination with DEX likely has 
broader applicability to these other conditions.    
Importantly, a therapeutic strategy combining DEX and RUX has the potential for 
imminent clinical translation. DEX is already a component of frontline therapy for HLH (38). Due 
to relatively poor clinical outcomes on currently established treatment protocols, the ethical 
introduction of novel therapeutic agents into future protocols will require combination with 
existing standard of care. The safety and efficacy of RUX has already been established, 
including in pediatric populations (351), suggesting the feasibility of adding RUX to existing 
treatment protocols for HLH. Furthermore, although HLH is a rare immunological disorder, 
hyperinflammation is a shared feature of many diseases for which DEX is a critical component 
of therapy. We believe that the findings presented here support a role for combining DEX and 
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RUX as a means of more effectively controlling inflammation and reducing the associated 
immunopathology in HLH and related cytokine storm syndromes.  
 
8.5: Methods 
 
Study Design 
 For the preclinical trial experiments in this study, sample sizes were selected based on 
previous experience with this model (42), which demonstrated that the chosen sample sizes 
were sufficient to identify differences between treatment groups. Sample sizes were not altered 
during the course of the study. In vivo treatment was terminated on day 8, which was defined 
prior to the initiation of the experiment and was consistent with previous applications of this 
model (42). For all experiments, endpoints were prospectively selected and were based on the 
peak of the CD8 T cell response to LCMV or humanely defined in protocols approved by the 
Institutional Animal Care and Use Committees of St. Jude Children’s Research Hospital. 
Outliers were removed using one-way ANOVA with Grubb’s test. All experiments presented in 
this study were performed on a minimum of four biological replicates, and when indicated in the 
corresponding figure legends, data are presented as the combined analysis from two 
independent experiments. 
 The objective of this study was to assess the utility of combining the JAK inhibitor RUX 
with the GC DEX, as we hypothesized that the hypercytokinemia associated with HLH may 
impair DEX sensitivity. This study utilized plasma samples from patients with HLH, an in vivo 
genetic model of primary HLH, and ex vivo analysis of human and murine CD8 T cells. The 
preclinical trial constituted a controlled laboratory experiment in which mice were randomized to 
receive vehicle control, DEX alone, RUX alone, or the combination of DEX and RUX. Due to the 
nature of drug administration, researchers were not blinded to treatment groups.  
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Patient Samples 
 Pre-treatment plasma samples were obtained from 15 pediatric patients with confirmed 
primary or secondary HLH who were treated at Texas Children’s Hospital. Control plasma was 
obtained from pediatric patients of a similar age and gender distribution who were treated at 
Texas Children’s Hospital for non-inflammatory conditions. Studies were performed according to 
protocols approved by the Institutional Review Board of Baylor College of Medicine. 
 
Mice 
Perforin-deficient (C57BL/6 Prf1tm1Sdz/J) and WT (C57BL/6-J) mice were purchased 
from the Jackson Laboratory and subsequently bred and maintained in specific pathogen-free 
facilities at St. Jude Children’s Research Hospital or the University of California, San Francisco. 
Experimental animals were age- and sex-matched and were used at 6 to 12 weeks of age. All 
animal experiments were conducted following protocols that were approved by the Institutional 
Animal Care and Use Committees of St. Jude Children’s Research Hospital or the University of 
California, San Francisco. 
 
Primary HLH model and in vivo treatment 
LCMV-Armstrong was originally provided by John Wherry (University of Pennsylvania) 
and propagated in BHK (CL-13) cells as previously described (ref). Prf1-/- mice were infected 
with 2 x 105 plaque forming units (pfu) of LCMV via intraperitoneal injection. Beginning on day 4 
post-injection, mice were treated with vehicle control, DEX alone, RUX alone, or the 
combination of DEX and RUX. DEX was administered at 1.5mg/kg/day by intraperitoneal 
injection, with the exception of the survival study (Supplemental Figure 8-2B), where DEX was 
administered ad lib in drinking water containing 7.5µg/mL of DEX. RUX was administered ad lib 
in modified rodent chow (Incyte) containing 2g RUX per 1kg of chow, resulting in a dose of 
approximately 60mg/kg/day. For most experiments, treatment continued through day 8 post-
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infection, and animals were sacrificed for analysis the following morning. For the survival study, 
treatment extended from day 7 to 17, and mice were sacrificed when moribund or at the 
termination of the study on day 17. For analysis of pSTAT5 in CD8 T cells following in vivo drug 
treatment, mice received one dose of 1.5 mg/kg DEX, 60mg/kg RUX, or both via intraperitoneal 
injection on day 4 p.i., and animals were sacrificed 12 hours later. 
 
T cell activation and expansion 
 For isolation of human CD8 T cells, TRIMA residuals enriched for peripheral blood 
mononuclear cells (PBMCs) were obtained from the Vitalant blood bank. PBMCs were isolated 
using a Ficoll (GE Healthcare) density gradient in a SepMate PBMC Isolation Tube (STEMCELL 
Technologies). 5 x 107 cells were labeled with biotinylated antibodies against CD4 (clone 
A161A1; BioLegend), CD19 (clone HIB19; BioLegend), CD11b (clone ICRF44; BioLegend), 
CD24 (clone ML5; BioLegend), and B220 (clone RA3-6B2; Biolegend). Negative selection was 
performed by depleting biotin-labeled cells with Biotin Binder Dynabeads (Life Technologies). 
The remaining cells were cultured in RPMI (Mediatech) supplemented with 10% fetal bovine 
serum (VWR), glutamine, antibiotics, and 20ng/mL recombinant human IL-2 (Peprotech). Cells 
were activated by the addition of Human T-Activator CD3/CD28 Dynabeads (Life Technologies). 
 Murine CD8 T cells were isolated from the spleens of WT or Prf1-/- C57BL/6 mice. Red 
blood cell lysis was performed and CD8 T cells were isolated using negative selection with 
Biotin Binder Dynabeads following staining of 5 x 107 cells with biotinylated antibodies against 
CD4 (clone GK1.5; Biolegend), CD19 (clone 6D5; BioLegend), CD11b (clone M1/70; 
BioLegend), CD24 (M1/69; BioLegend), and B220 (RA3-6B2; BioLegend). The remaining cells 
were cultured in DMEM (Mediatech) supplemented with 20% fetal bovine serum, glutamine, 
non-essential amino acids, sodium pyruvate, HEPES, antibiotics, 2-mercaptoethanol, and 
20ng/mL recombinant murine IL-2 (Peprotech). Cells were activated by the addition of Mouse T-
Activator CD3/CD28 Dynabeads (Life Technologies). 
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Flow Cytometry  
For the analysis of murine cell populations from the spleens of vehicle- and drug-treated 
mice, splenocytes were stained with the following fluorescently-labeled antibodies: TCRb (clone 
H57-597), F4/80 (clone BM8.1), NK1.1 (clone PK136), Ly6C (clone HK1.4), CD11c (clone 
N418), CD11b (clone M1/70), CD8 (clone 53-6.7), CD19 (clone 1D3), Ly6G- (clone 1A8), CD4 
(clone GK1.5), CD44 (clone IM7), CD62L (clone MEL-14), and CD25 (PC61.5.3) (eBioscience, 
Biolegend, Tonbo Biosciences, and R&D Systems). For the analysis of pSTAT5, intracellular IL-
2, and for BH3 profiling, CD8 T cells were identified by gating on the TCRb/CD8 double positive 
population. All flow cytometry data were acquired with a BD LSRII Fortessa or a BD FACSVerse 
and analyzed using FlowJo software. 
Phosphoflow cytometry for measurement of STAT proteins following cytokine stimulation 
was performed as previously described (132). Briefly, human or murine CD8 T cells were 
allowed to rest for one hour in serum free media and were stimulated with recombinant murine 
or human cytokines (Peprotech) at a concentration of 100ng/mL for 15 minutes unless 
otherwise indicated. Cells were subsequently fixed with 2% paraformaldehyde and 
permeabilized with methanol. For analysis of pSTAT5 in CD8 T cells from vehicle- and drug-
treated mice, cells were immediately fixed and permeabilized following harvesting from mice. 
STAT protein  staining was performed with antibodies against pSTAT1 pY701 (BD Biosciences), 
pSTAT3 pY705 (BD Biosciences), and pSTAT5 pY694 (BD Biosciences) and data were 
recorded as the median fluorescent intensity (MFI). 
For the analysis of BCL-2, BCL-XL, and MCL-1 protein expression, murine CD8 T cells 
were fixed and permeabilized as described above. They were then stained with an anti-cleaved 
caspase 3 antibody (clone C92-605; BD Biosciences) and with antibodies against BCL-2 (clone 
BCL/10C4; BioLegend), BCL-XL (clone 54H6; Cell Signaling Technology) or MCL-1 (clone 
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D2W9E; Cell Signaling Technology) and data were recorded as the MFI in the cleaved caspase 
3-negative gate. 
 
T cell viability assays 
 Human T cell viability assays were performed by culturing human CD8 T cells in plasma 
obtained from the Vitalant blood bank or from control or HLH patients treated at Texas 
Children’s Hospital. Plasma was supplemented with RPMI 1640 Amino Acids Solution (Sigma-
Aldrich), RPMI 1640 Vitamins Solution (Sigma-Aldrich), and D-(+)-Glucose Solution (Sigma-
Aldrich). Murine CD8 T cells were cultured in supplemented DMEM, as described above. Cells 
were aliquoted into a round bottom 96-well plate at 105 cells per well and treated with vehicle 
control (DMSO), DEX (Sigma-Aldrich), and/or RUX (Selleck Chemicals) with or without 
supplementation with recombinant cytokine for 48 hours for human T cells and 24 hours for 
murine T cells. To assess viability, cells were stained with Hoechst 33258 (Molecular Probes) 
and analyzed by flow cytometry. Data were recorded as the percentage of Hoechst-negative 
cells and all viability data were normalized to the viability of the relevant vehicle control 
condition. 
 
Complete Blood Counts (CBCs), Histology, and Plasma Protein Quantification 
All CBCs and histologic analyses were performed by the veterinary pathology core 
facilities at St. Jude Children’s Research Hospital. For CBCs, heparinized blood samples were 
analyzed on a Forecyte multi-species hematology system (Oxford Science). For histology and 
immunohistochemistry (IHC), tissues were fixed in 10% neutral buffered formalin and embedded 
in paraffin. De-paraffinized sections were stained with hematoxylin and eosin (Richard-Allan 
Scientific) and labeled with biotinylated antibodies against CD3 (M20, Santa Cruz) or Ly6B.2 
(Neut 7/4, Novus Biologicals), which were detected with HRP-labeled streptavidin (Thermo 
Fisher) and counterstained with hematoxylin. Images were acquired on a ScanScope XT 
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scanner and digitized to scalable images up to a 20X objective (Leica Biosystems). The area 
encompassed by inflammatory foci was determined using FIJI image analysis in a blinded 
fashion.  
Plasma protein quantification from human plasma samples was performed using the 
Milliplex MAP Human Cytokine Panel I (Millipore) for the MagPix instrument. For quantification 
of proteins from mouse serum, a Milliplex mouse cytokine/chemokine magnetic bead panel 
(EMD Millipore) was used according to the manufacturer’s instructions, and results were 
collected and analyzed with BIO-Plex 200 System (Bio-Rad) and xPONENT software. Ferritin 
and sCD25 were measured with ELISA kits (ALPCO and R&D Systems, respectively). 
 
Western blotting 
 To assess cytoplasmic and nuclear localization of STAT5 and GR, murine CD8 T cells 
were pre-treated with vehicle control or 10ng/mL IL-2 for one hour prior to treatment with vehicle 
control or 1µM DEX for 30 minutes. Cytoplasmic and nuclear protein lysates were generated 
using the NE-PER kit (ThermoFisher). Immunoblotting was performed with the following 
antibodies: pSTAT5 pY694 (Cell Signaling Technology), total STAT5 (clone D2O6Y; Cell 
Signaling Technology), GR pS211 (Cell Signaling Technology), total GR (clone D6H2L; Cell 
Signaling Technology), b-actin (clone 8H10D10; Cell Signaling Technology), and p84 
(Genetex). Donkey anti-rabbit IRDye800 and donkey anti-mouse IRDye680 secondary 
antibodies (LI-COR Biosciences) were used for detection and imaging was performed using the 
Odyssey Imaging System (LI-COR Biosciences). 
 
Quantitative PCR (qPCR) 
 For analysis of GR target gene expression, murine CD8 T cells were pre-treated with 
vehicle control or 10ng/mL IL-2 for one hour prior to treatment with vehicle control or 1µM DEX 
for four hours. RNA was isolated using the RNeasy Mini Kit (Qiagen) and cDNA was generated 
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using the Superscript III kit (ThermoFisher). Taqman quantitative PCR probes (Applied 
Biosystems) were used in conjunction with Taqman Master Mix (Applied Biosystems) to assess 
transcript levels of the following genes: Gapdh (Mm99999915_g1; VIC-MGB), Bcl2l11 
(Mm00437796_m1; FAM-MGB), Gilz (Mm00726417_s1; FAM-MGB), and Fkbp5 
(Mm00487406_m1; FAM-MGB). Experiments were performed in technical triplicate and were 
run on a QuantStudio 5 Real-Time PCR Instrument (Applied Biosystems).The fold change in 
transcript expression was calculated relative to cells cultured without DEX using the delta-delta 
Ct method, with the use of Gapdh transcript for normalization. 
 
BH3 Profiling 
 BH3 profiling was performed according to established methods (13). Briefly, ex vivo 
activated and expanded murine CD8 T cells were cultured in the presence or absence of 
10ng/mL IL-2, 1µM DEX, and 500nM RUX for 16 hours prior to analysis and were subsequently 
stained with LIVE/DEAD Fixable Violet Dead Cell Stain (Life Technologies) to facilitate gating on 
the live cell population. For analysis of apoptotic potential in CD8 T cells following in vivo 
treatment, analysis was performed immediately after harvesting cells from mice. Cells were 
permeabilized with digitonin (Sigma-Aldrich) and exposed to ABT-199 (ApexBio), WEHI-539 
(ApexBio), S63845 (Selleck Chemicals), or NOXA peptide (New England Peptide) at the 
indicated concentrations for 90 minutes prior to fixation with paraformaldehyde. Cells were then 
stained with an anti-cytochrome c antibody (clone 6H2.B4; BioLegend) and analyzed by flow 
cytometry. Cells exposed to alamethicin (Alfa Aesar) or DMSO were used as positive and 
negative controls and percent priming was calculated based on the relative cytochrome c 
release in cells exposed to BH3 mimetics or NOXA peptide relative to these controls. 
 
 
 
 189 
Statistical Analyses 
Statistical analyses were performed using Prism 8 (GraphPad). All tests were two-sided 
and the threshold for significance was p≤0.05. Comparisons between groups were made using 
t-tests, with one-way ANOVA and Tukey’s method for multiple comparisons adjustment used for 
comparisons of three or more groups. For in vivo survival analysis, the log-rank test was used to 
perform pairwise comparisons between survival curves. Interactions between drugs were 
assessed using Bliss independence analysis (281). Error bars represent the standard error of 
the mean. Outliers were removed using one-way ANOVA with Grubb’s test.  
 
8.6: Acknowledgements 
 
This work was supported by grants from the National Institutes of Health, National Institute of 
Allergy and Infectious Diseases (K.E.N.), Histiocytosis Association of America (K.E.N.), 
American Lebanese Syrian Associated Charities (K.E.N.), a Buster Posey Family Pediatric 
Cancer Pilot Award (M.L.H.), the Campini Family Foundation (M.L.H.), the Pepp Family 
Foundation (M.L.H.), a St. Baldrick’s Innovation Award (C.E.A.), a Genentech Foundation 
Research Fellowship (L.K.M.), and the National Institutes of Health Medical Scientist Training 
Program grant T32GM007618 (L.K.M.). Additionally, this work was facilitated by the UCSF 
Helen Diller Family Comprehensive Cancer Center National Institutes of Health grant 
P30CA082103, which supports the shared resource facilities that were used to conduct the flow 
cytometry work at UCSF.   
 190 
8.7: Figures 
 
 
Figure 8-1: The cytokine composition of plasma from patients with HLH confers DEX 
resistance in CD8 T cells. (A) Viability relative to vehicle control in human CD8 T cells cultured 
in plasma from control patients or patients with HLH and treated with 1µM DEX for 48 hours. (B) 
Levels of common gamma chain cytokines in plasma from control patients versus patients with 
HLH. (C) Viability relative to vehicle control of human CD8 T cells following exposure to 1µM 
DEX for 48 hours in the presence or absence of 10ng/mL of the indicated cytokine in technical 
triplicate. Statistical significance is relative to the no cytokine condition. (D) MFI and 
representative histograms of pSTAT5 in human CD8 T cells following stimulation with 100ng/mL 
of the indicated cytokine for 15 minutes in technical triplicate. Statistical significance is relative 
to the basal condition. Statistical significance was assessed using two-sample t-tests (A and B) 
or one-way ANOVA with Tukey’s method for multiple comparisons adjustment (C and D). The 
data in panels C and D are representative of three independent experiments. ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05. 
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Figure 8-2: The combination of DEX and RUX cooperatively attenuates disease 
manifestations in an in vivo model of HLH. (A) Bodyweight over time relative to baseline 
bodyweight of naïve mice and vehicle- and drug-treated LCMV-infected mice. Statistical 
significance is relative to the naïve condition. (B) Survival of naïve mice and vehicle- and drug-
treated LCMV-infected mice. (C) Hematocrit values in naïve mice and vehicle- and drug-treated 
LCMV-infected mice on day 9 post-infection. (D) Platelet count in naïve mice and vehicle- and 
drug-treated LCMV-infected mice on day 9 post-infection. (E) Spleen weight as percentage of 
initial bodyweight and representative spleen images from naïve and vehicle- and drug-treated 
LCMV-injected mice on day 9 post-infection. (F) Number of monocytes in spleens from naïve 
and vehicle- and drug-treated LCMV-infected mice on day 9 post-infection. (G) Number of 
neutrophils in spleens from naïve and vehicle- and drug-treated LCMV-infected mice on day 9 
post-infection. Statistical significance was assessed using one-way ANOVA with Tukey’s 
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method for multiple comparisons adjustment (A, C-H). With the exception of panel B, all data 
represent a combined analysis of two independent experiments.  ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05, N.S. – not significant. 
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Figure 8-3: The combination of DEX and RUX cooperatively attenuates CD8 T cell number 
and markers of CD8 T cell activation in an in vivo model of HLH. (A) Number of splenic 
CD8 T cells in naïve and vehicle- and drug-treated LCMV-infected mice on day 9 post-infection. 
(B) Representative histologic images and number of CD3+ cells in livers from naïve and 
vehicle- and drug-treated LCMV-infected mice on day 9 post-infection. (C) Number CD44 
high/CD62L low cells in spleens from naïve and vehicle- and drug-treated LCMV-infected mice 
on day 9 post-infection. (D) Number of CD28 and ICOS double positive cells in spleens from 
naïve and vehicle- and drug-treated LCMV-infected mice on day 9 post-infection. (E) Number of 
CD25 positive CD8 T cells in spleens from naïve and vehicle- and drug-treated LCMV-infected 
mice on day 9 post-infection. (F) Levels of soluble CD25 in plasma from naïve and vehicle- and 
drug-treated LCMV-infected mice on day 9 post-infection. Statistical significance was assessed 
using one-way ANOVA with Tukey’s method for multiple comparisons adjustment (A-F). The 
data in panels A and F represent a combined analysis of two independent experiments. 
****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
 
  
 195 
 
 
 196 
Figure 8-4: Common gamma chain cytokines activate STAT5 and confer DEX resistance 
in murine CD8 T cells. (A) Viability relative to vehicle control of murine CD8 T cells treated with 
increasing concentrations of DEX in the absence or presence of 10ng/mL of the indicated 
common gamma chain cytokine for 24 hours in technical triplicate. (B) Viability relative to 
vehicle control of murine CD8 T cells treated with increasing concentrations of DEX in the 
absence or presence of 10ng/mL of the indicated cytokine for 24 hours in technical triplicate. (C) 
Viability relative to vehicle control of murine CD8 T cells treated with increasing concentrations 
of etoposide in the absence or presence of 10ng/mL of the indicated cytokine for 24 hours in 
technical triplicate. (D) Fold change in the MFI of pSTAT5 in murine CD8 T cells stimulated with 
100ng/mL of the indicated cytokine for the indicated period of time in technical triplicate. 
Statistical significance is indicated for the difference between the basal condition and the peak 
pSTAT5 value for each cytokine.  (E) Fold change and representative histograms of pSTAT5 in 
murine CD8 T cells in the basal condition or after one-hour pre-treatment with the indicated 
concentration of RUX followed by a 15-minute stimulation with 100ng/mL IL-2 in technical 
triplicate. Statistical significance is relative to the vehicle-treated IL-2-stimulated condition. (F) 
Viability relative to vehicle control of murine CD8 T cells treated with increasing concentrations 
of DEX in the presence of 10ng/mL IL-2 and the indicated concentration of RUX for 24 hours in 
technical triplicate. (G) Heatmap of Bliss independence scores calculated as the average of 
technical triplicates of cell viability in murine CD8 T cells treated with the indicated 
concentrations of DEX and RUX in the presence of 10ng/mL IL2 for 24 hours. Positive values, 
indicated in red, are indicative of a synergistic interaction. Statistical significance was assessed 
using two-sample t-tests (D) or one-way ANOVA with Tukey’s method for multiple comparisons 
adjustment (E). All data are representative of three independent experiments. ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05, N.S. – not significant.  
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Figure 8-5: IL-2 upregulates anti-apoptotic proteins. (A) Western blot of cytoplasmic and 
nuclear total and phosphorylated STAT5 and GR in murine CD8 T cells pre-treated or not with 
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10ng/mL IL-2 followed by treatment with vehicle control or 1µM DEX for 30 minutes. b-actin is 
used as a cytoplasmic loading control and p84 is used as a nuclear loading control. (B) Fold 
change in transcript expression of the direct GR target genes Bcl2l11, Gilz, and Fkbp5 in murine 
CD8 T cells pre-treated or not with 10ng/mL IL-2 for one hour followed by treatment with vehicle 
control or 1µM DEX for four hours in technical triplicate. Fold change values are relative to 
untreated or IL-2 treated cells, respectively. (C) MFIs and representative histograms of BCL-2, 
BCL-XL, and MCL-1 protein expression in murine CD8 T cells in the basal state or following 
exposure to 10ng/mL IL-2 with or without 500nM RUX for 24 hours in technical triplicate. 
Statistical significance was assessed using two-sample t-tests (B) or one-way ANOVA with 
Tukey’s method for multiple comparisons adjustment (C). All data are representative of three 
independent experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
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Figure 8-6: Cytokine exposure decreases the apoptotic potential of CD8 T cells and this 
apoptotic potential is restored upon RUX exposure. (A) Percent priming values generated 
from BH3 profiling of murine CD8 T cells treated ex vivo with or without 10ng/mL IL-2, 1µM 
DEX, and/or 500nM RUX for 16 hours in technical triplicate prior to BH3 profiling with 1µM ABT-
199 to measure BCL-2 activity, 10µM WEHI-539 to measure BCL-XL activity, or 10µM synthetic 
NOXA peptide to measure MCL-1 activity. (B) Percent priming values generated from BH3 
profiling of murine CD8 T cells harvested on day 9 post-infection from naïve or vehicle- or drug-
treated LCMV-infected mice prior to BH3 profiling with 10µM ABT-199 to measure BCL-2 
activity, 10µM WEHI-539 to measure BCL-XL activity, or 10µM S63845 to measure MCL-1 
activity. Statistical significance was assessed using one-way ANOVA with Tukey’s method for 
multiple comparisons adjustment. The data in panel A are representative of three independent 
experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N.S. – not significant. 
 
  
 201 
 
 
Supplemental Figure 8-1: Disease-associated proteins are elevated in the plasma from 
patients with HLH. Levels of HLH-associated plasma proteins in plasma from control patients 
versus patients with HLH. Statistical significance was assessed using two-sample t-tests. 
****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Supplemental Figure 8-2: HLH-like disease in Prf1-/- mice recapitulates key features of 
human disease. (A) Levels of HLH-associated plasma proteins in plasma from naïve mice or 
LCMV-infected vehicle-treated mice on day 9 post-infection. (B) Levels of common gamma 
chain cytokines in plasma from naïve mice or LCMV-infected vehicle-treated mice on day 9 
post-infection. (C) Bodyweight on day 9 post-infection relative to baseline bodyweight in naïve 
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and vehicle- or DEX-treated mice. Statistical significance is relative to the vehicle-treated 
condition. (D) Number of CD8 T cells in spleens from naïve and vehicle- and drug-treated 
LCMV-infected mice on day 9 post-infection. Statistical significance is relative to the vehicle-
treated condition. (E) Hematocrit values in naïve mice and vehicle- and drug-treated LCMV-
infected mice on day 9 post-infection. Statistical significance is relative to the vehicle-treated 
condition. Statistical significance was assessed using two-sample t-tests (A and B) or one-way 
ANOVA with Tukey’s method for multiple comparisons adjustment (C-E). ****p<0.0001, 
***p<0.001, **p<0.01, *p<0.05. 
 
  
 204 
 
 
Supplemental Figure 8-3: Neutrophils and CD4 T cells are affected by drug exposure in 
vivo. (A) Representative histologic images and number of  Ly5B.2+ cells in livers from naïve 
and vehicle- and drug-treated LCMV-infected mice on day 9 post-infection. (B) Number of CD4 
T cells in spleens from naïve and vehicle- and drug-treated LCMV-infected mice on day 9 post-
infection. Statistical significance was assessed using one-way ANOVA with Tukey’s method for 
multiple comparisons adjustment. The data in panel B represent a combined analysis of two 
independent experiments. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. 
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Supplemental Figure 8-4: STAT5-activating cytokines confer DEX resistance in murine 
CD8 T-cells. (A) Representative histograms of pSTAT1, pSTAT3, and pSTAT5 in murine CD8 
T cells in the basal state or following stimulation with 10ng/mL of the indicated cytokine for 15 
minutes. (B) Viability relative to vehicle control of WT or Prf1-/- murine CD8 T cells treated with 
increasing concentrations of DEX in the absence or presence of 10ng/mL IL-2 for 24 hours in 
technical triplicate. (C) Representative histograms of pSTAT5 in murine CD8 T cells following 
stimulation with 10ng/mL of the indicated cytokine for the indicated period of time. (D) Viability 
relative to vehicle control of murine CD8 T cells treated with increasing concentrations of DEX in 
the presence or absence of the indicated concentration of IL-2 for 24 hours in technical 
triplicate. (E) Fold change in pSTAT5 MFI from murine CD8 T cells harvested from naïve and 
vehicle- and drug-treated LCMV-infected mice on day four post-injection 12 hours after a single 
dose of 1.5mg/kg DEX and/or 60mg/kg RUX. Statistical significance was assessed using one-
way ANOVA with Tukey’s method for multiple comparisons adjustment (E). The data in panels 
A-D are representative of three independent experiments. ****p<0.0001, ***p<0.001, **p<0.01, 
*p<0.05. 
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Chapter 9: Conclusions and Future Directions 
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 Glucocorticoid (GC) resistance is an important barrier to successful therapy in lymphoid-
driven diseases. The overarching objective of this work was to identify novel concepts and to 
contribute mechanistic insights into existing concepts regarding the ways in which lymphoid 
cells resist the pro-apoptotic effects of GCs. In contrast to many studies in the field of cancer 
biology that focus on understanding mechanisms of drug resistance that are acquired during 
exposure to therapy, the studies presented here focus instead on elucidating intrinsic drivers of 
GC resistance that pose therapeutic challenges beginning at the time of disease diagnosis. 
Specifically, these studies utilized a developmental lens to consider the unique fact that, in 
addition to their pharmacologic use, GCs are endogenous hormones that engage in extensive 
interactions with the immune system. The physiologic co-existence of GCs and immune cells 
necessitates intrinsic resistance mechanisms to protect lymphoid cell populations from GC-
induced cell death at distinct stages of development and under certain environmental 
conditions. Through the use of multiple disease models, this work highlights a number of 
unifying themes that contribute to our understanding of this unique and complex interplay 
between GCs and the immune system and the ways in which intrinsic GC resistance 
mechanisms may be co-opted to interfere with GC therapy in lymphoid-driven diseases. 
 Beginning with Philadelphia chromosome-like acute lymphoblastic leukemia (ALL), we 
established the relationship between aberrant cytokine receptor activity and GC resistance. In 
Ph-like ALL, cytokine receptor signaling is dysregulated due to frequent chromosomal 
translocations involving the cytokine receptor gene CRLF2, which are often accompanied by 
activating mutations in downstream signal transduction effectors such as JAK2. Using a cohort 
of primary patient Ph-like ALL samples, we demonstrated that the presence of these genomic 
lesions was uniformly associated with GC resistance. In the context of these genomic 
alterations, signal transduction inhibitors effectively induced GC sensitivity. 
 We then turned our attention to T-cell ALL (T-ALL), a disease complicated by a lack of 
clinically relevant biomarkers, impeding efforts to risk stratify patients and implement precision 
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medicine-based approaches to treatment. This work expanded upon our previous findings that 
the cytokine interleukin-7 (IL7) mediates GC resistance in a subset of T-ALLs. In contrast to Ph-
like ALL, where our findings supported the idea that genotype is an important driver of 
phenotype, we found that IL7-induced GC resistance most commonly occurred in the absence 
of activating mutations in the IL7 receptor (IL7R) signaling pathway. We therefore sought to 
understand both how IL7 confers GC resistance and why this occurs only in a subset of T-ALLs. 
Mechanistically, we encountered an intriguing paradox in which GCs induce their own 
resistance by augmenting IL7 receptor (IL7R) pathway signaling, contributing to an anti-
apoptotic state that is refractory to the pro-apoptotic effects of GCs. We demonstrated that this 
mechanism also conferred GC resistance in early populations of developing thymocytes but not 
in later populations, suggesting that it plays a role in protecting those early populations from 
apoptosis in the presence of endogenous GCs. Using RNA-seq to analyze primary patient T-
ALLs, we showed that T-ALLs arising from those same stages of thymocyte development 
tended to retain this pattern of resistance. When considered in light of the processes that occur 
during normal thymopoiesis, these data were consistent with the idea that GC-induced 
apoptosis of thymocytes prior to T-cell receptor (TCR) selection would be maladaptive, as it 
would dramatically reduce the pool of thymocytes generating potentially productive TCR 
rearrangements. Similarly, our data supported previous findings that the later double positive 
thymocytes are highly sensitive to GCs, which act endogenously to induce apoptosis in 
thymocytes lacking functional TCRs. Taken together, these data highlight the utility of 
considering drug sensitivity in the context of developmental processes, as we have shown that 
these are tightly linked with respect to GC sensitivity. 
 To expand upon key elements of these findings, we pursued two additional studies in T-
ALL, one focused on the identification of a gene expression-based biomarker for therapeutic 
response and another on evaluating the efficacy of a novel therapeutic strategy for overcoming 
IL7-induced GC resistance. In the first study, we analyzed RNA-seq data from two cohorts of T-
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ALL patients enrolled on Children’s Oncology Group trials to discover that diagnostic samples 
from patients who went on to have detectable residual disease at the end of induction therapy 
had gene expression patterns that differed significantly from those of patients without detectable 
disease at the end of induction. In addition to providing the first steps towards a clinically 
tractable assay for predicting responses to induction therapy, this study identified further 
insights into the relationship between T-cell development and therapeutic response, particularly 
given the fact that induction therapy relies heavily on the use of GCs. Specifically, this analysis 
demonstrated that T-ALLs with immunophenotypic features characteristic of a later stage of 
development but with positive minimal residual disease (MRD) at the end of induction had a 
gene expression signature that looked identical to that of T-ALLs arising earlier in T-cell 
development. Though identified through entirely independent methods, these data accurately 
recapitulate the findings discussed above regarding the relationship between developmental 
stage and GC sensitivity, and suggest that assessing the developmental stage of a T-ALL 
through gene expression profiling may have prognostic and therapeutic relevance.  
 Drawing on the precedent for the incorporation of the LDA card into the clinical 
management of patients with Ph-like ALL, ongoing efforts are focused on generating an 
analogous targeted gene expression assay for the prediction of MRD in newly-diagnosed T-ALL 
patients, with the intention of validating the prognostic significance of such an assay in 
independent patient cohorts. In addition to its potential clinical utility, future applications of these 
gene expression data may also include establishing the feasibility of a precision medicine-based 
approach to the treatment of T-ALL. Specifically, our preliminary data regarding the association 
between gene expression signatures and BCL-2 expression suggest that a subset of T-ALL 
patients may benefit from targeted inhibition of BCL-2 as a therapeutic strategy. Further analysis 
of these data for other potential therapeutic targets, in conjunction with preclinical trials 
conducted in clinically-relevant PDX model systems, is likely to be a powerful approach to 
identifying rational therapeutic strategies for the treatment of this highly heterogeneous disease. 
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Finally, one important caveat of this work is that, while MRD status remains an important 
prognostic indicator, the primary goal in the treatment of T-ALL is the prevention of relapse. 
Despite the clinical significance of this endpoint, the patient cohorts utilized in this study were 
too small to provide sufficient power for addressing this important question. Future studies in 
larger datasets may be more adequately powered to assess the relationship between gene 
expression patterns and risk of relapse, potentially facilitating the development of a similar 
sample score metric for prediction of these outcomes. 
 As an alternative to JAK/STAT pathway inhibition, we also took advantage of our 
mechanistic understanding of IL7-induced GC resistance to hypothesize that preventing 
localization of IL7R to the cell surface would effectively restore GC sensitivity in the presence of 
IL7. Using KZR-508445, an inhibitor of the Sec61 translocon, we demonstrated the utility of 
inhibiting the cellular secretory pathway to enhance GC sensitivity in T-ALL. Furthermore, we 
demonstrated that this compound is well-tolerated in mice, and showed preliminary data to 
suggest that it may act effectively in conjunction with GCs in an in vivo model of T-ALL. Future 
studies are needed to further establish the in vivo utility of this compound in a patient-derived 
xenograft model established from T-ALLs that demonstrate IL7-induced GC resistance.  
 Finally, we extended our analysis of the interaction between cytokines and GCs to a 
model of hemophagocytic lymphohistiocytosis (HLH), a rare and complicated hyperinflammatory 
condition in which CD8 T-cells are a well-established driver of disease. As with T-ALL, GCs are 
a central component of therapy for HLH, and we hypothesized that the rampant 
hypercytokinemia that classically occurs in this disease may confound the use of GCs in this 
context and contribute to poor clinical outcomes. Consistent with our hypothesis, we found that 
the cytokine composition of patient plasma was sufficient to confer GC resistance in CD8 T-
cells. Using an in vivo model of HLH, we demonstrated that inhibiting cytokine receptor signaling 
with ruxolitinib profoundly attenuated many disease parameters, but was particularly effective 
for augmenting GC sensitivity in CD8 T-cells, both with respect to reducing their abundance and 
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their activation status. We went on to show in a series of ex vivo mechanistic studies using 
murine T-cells that, just as was observed in T-ALL, cytokine-induced GC resistance occurs due 
to the altered apoptotic potential of T-cells in the presence of cytokine, which is effectively 
reduced with ruxolitinib, thereby facilitating GC-induced apoptosis.   
 While these mechanistic studies focused on the effects of combining dexamethasone 
and ruxolitinib on CD8 T-cells, it is important to note that our evaluation of disease parameters 
in the in vivo model demonstrated profound effects of ruxolitinib, both alone and in combination 
with dexamethasone, on other cell lineages, including monocytes and neutrophils. While CD8 T-
cells are a well-established driver of disease in primary HLH, these other lineages likely play a 
more central role in related hyperinflammatory conditions, including macrophage activation 
syndrome (MAS). Further studies focused on elucidating the mechanistic basis for the efficacy 
of this therapeutic strategy in those other lineages therefore have the potential to increase the 
clinical utility of this drug combination for the treatment of a wider spectrum of 
hyperinflammatory conditions. 
  In conclusion, the extension of our work from T-ALL to HLH serves to increase the 
generalizability of our findings and contribute to our conceptual understanding of intrinsic 
mechanisms of GC resistance. Specifically, this work suggests that cytokines are ubiquitous 
drivers of GC resistance across the spectrum of T-cell development, and that local and systemic 
regulation of cytokine production as well as developmentally-regulated patterns of cytokine 
receptor expression likely underlie the differential sensitivity of healthy T-cell populations to 
endogenous GCs. Our findings suggest that these patterns of sensitivity can be extrapolated to 
a number of disease contexts, where they in turn contribute to poor therapeutic efficacy. Taken 
together, our work highlights the importance of considering GCs not just as therapeutic agents, 
but as endogenous hormones that have complex physiologic interactions with immune cells, 
which in turn have important therapeutic implications that are amenable to the inclusion of signal 
transduction inhibitors as a means of enhancing the efficacy of GC therapy.    
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